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ABSTRACT 
 
STRUCTURE AND FUNCTION OF METALLOHYDROLASES IN THE ARGINASE-
DEACETYLASE FAMILY 
 
Yang Hai 
David W. Christianson 
 
Arginases and deacetylases are metallohydrolases that catalyze two distinct chemical 
transformations. The arginases catalyze the hydrolysis of the guanidinium group of arginine by 
using a hydroxide ion bridging the binuclear manganese cluster (Mn
2+
A-Mn
2+
B) for nucleophilic 
attack. The deacetylases catalyze the hydrolysis of amide bonds by using a mononuclear Zn
2+
-
ion activated water molecule as the nucleophile. Despite the diverse functions, metallohydrolases 
of the arginase-deacetylase superfamily share the same characteristic α/β hydrolase core fold 
and a conserved metal binding site (the Mn
2+
B site in arginase corresponds to the catalytic Zn
2+
 
site in deacetylase) which is essential for catalysis in both enzymes.  
We report crystal structure of formiminoglutamase from the parasitic protozoan 
Trypanosoma cruzi and confirm that formiminoglutamase is a Mn
2+
-requiring hydrolase that 
belongs to the arginase-deacetylase superfamily. We also report the crystal structure of an 
arginase-like protein from Trypanosoma brucei (TbARG) with unknown function. Although its 
biological role remains enigmatic, the evolutionarily more conserved Mn
2+
B site can be readily 
restored in TbARG through side-directed mutagenesis. We also report crystal structure of an 
arginase from the parasite Schistosoma mansoni (SmARG). Structural comparison of SmARG 
complexed with second-generation arginase inhibitors (α,α-disubstituted boronic acid inhibitors) 
with another parasitic arginase from Leishmania mexicana and human arginases reveal 
interesting differences in the binding modes of the additional α-substituents.  
 iv 
 
Reversible lysine acetylation rivals phosphorylation in the regulation of protein structure 
and function, and inhibition of the “eraser” histone deacetylase (HDAC) is a validated approach 
for cancer chemotherapy. HDAC6, the sole HDAC that harbors a full duplication of catalytic 
domain (CD1 and CD2), is a cytosolic lysine deacetylase known to deacetylate α-tubulin, heat-
shock protein 90, etc. Here, we report HDAC6 structures that provide new insights about 
mechanism, catalysis, and inhibitor binding. In light of biochemical studies, we reveal a “gate 
constriction” mechanism responsible for the strict substrate specificity of CD1 versus broad 
substrate specificity of CD2. Analysis of other isozymes indicates that the closest relative 
HDAC10 contains an alternative gatekeeper that favors catalysis with acetylpolyamines. Indeed, 
we provide structural evidence that HDAC10 is the long-sought mammalian N
8
-acetylspermidine 
deacetylase whose identity has remained elusive for 30 years. 
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Chapter 1: Introduction 
1.1 Arginase-Deacetylase Superfamily 
Arginase family, also known as ureohydrolase, or amidinohydrolase family, embraces 
enzymes involved in L-arginine catabolism, such as arginase (Christianson, 2005), agmatinase 
(Ahn et al., 2004), guanidinobutyrase (Romagnoli et al., 2014), and guanidinopropionase (Lee 
and Kim et al., 2011); enzymes in L-histidine catabolism, such as formiminoglutamase (Lund and 
Magasanik, 1965); as well as enzymes involved in certain secondary metabolism, such as 
proclavaminate amidinohydrolase in clavulanic acid biosynthesis (Elkins et al., 2002) and 
amidinohydrolases involved in many antifungal macrocyclic polyketide biosynthesis including 
Desertomycin, Primycin A1, and Kanchanamycin C (Hong et al., 2016). All arginase family 
members catalyze similar chemical reactions: hydrolysis of a guanidinium group (or formiminium 
group) to yield a primary amine and the byproduct urea (or formamide) (Figure 1.1). The 
chemistry of all these enzymes involves nucleophilic attack at the guanidinium (or formiminium) 
carbon by a hydroxide ion bridging the characteristic binuclear manganese cluster.   
Zinc-dependent histone/polyamine deacetylase family consists of polyamine deacetylase 
(PDAC, also referred as acetylpolyamine amidohydrolase, APAH) involved in polyamine 
metabolism, histone deacetylase (HDAC, also referred as lysine deacetylase, KDAC) involved in 
protein lysine acetylome (Yang and Seto, 2008; Choudhary et al., 2009), and acetoin utilization 
protein (AcuC) whose exact function and substrates remains unclear (Leipe and Landsman, 
1997). Both HDACs and PDACs catalyze similar chemical reactions: hydrolysis of an amide bond 
liberating a primary amino group and byproduct acetate (Figure 1.1). Again, the chemistry of all 
Zinc-dependent histone/polyamine deacetylase involves nucleophilic attack at the amide carbon 
by a mononuclear Zn
2+
-activated water molecule.  
The seemingly unrelated diverse functions and low sequence identities (~15%) between 
arginase family and histone/polyamine deacetylase family precluded any homology prediction  
 2 
 
 
 3 
 
Figure 1.1: Arginase-Deacetylase Superfamily. Arginase family includes enzymes involved in 
both primary and secondary metabolism. Deacetylase family includes enzymes in protein post-
translational modification as well as polyamine metabolism. Abbreviations: GbuA, guanidine-
butyrase; GpuA, guanidinopropionase; FIGase, formiminoglutamase involved in histidine 
utilization pathway; PAH, proclavaminate amidinohydrolase; DstH, desertomycin 
amidinohydrolase; HDAC, histone deacetylase; PDAC, polyamine deacetylase.  
 4 
 
 
Figure 1.2: Arginase-deacetylase fold. (a) Topology diagrams of arginase, HDAC8, and APAH 
(b) The Mn
2+
B site of arginase is conserved in HDAC8, APAH, and related metalloenzymes 
as D(A,V,L,F)HX∼100D (boldface indicates metal ligands). The Mn
2+
A site of arginase is not 
conserved in deacetylases. Reprinted from Current Opinion in Structural Biology, Vol 21, 
Lombardi et al., Structure, mechanism, and inhibition of histone deacetylases and related 
metalloenzymes, 735-743, Copyright (2011), with permission from Elsevier.    
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and evolutionary connection, until the first structure determination of a member from 
histone/polyamine deacetylase family, histone deacetylase-like protein (HDLP) from Aquifex 
aeolicus (Finnin et al., 1999). HDLP structure reveals an α/β hydrolase fold: a central 8-stranded 
parallel β-sheet (strand order 2-1-3-8-7-4-5-6) sandwiched between α-helices. Surprisingly, the 
same fold was actually first observed three years earlier in the rat liver arginase structure (Kanyo 
et al., 1996). This characteristic α/β fold now is known as the arginase-deacetylase fold (Dowling 
and Di Costanzo, et al., 2008; Lombardi and Cole, et al., 2011). In addition, the metal binding 
sequence motif initially identified in arginase family is also partially retained in the 
histone/polyamine deacetylate family. In arginase family, residues from loops L3, L4, and L7 
coordinate to 2 Mn
2+
 ions (Mn
2+
A–Mn
2+
B), while conserved residues from L4 and L7 coordinate to 
a single Zn
2+
 ion in histone/polyamine deacetylase. Consequently, the catalytic Zn
2+
 binding site 
in HDAC/PDAC corresponds to the Mn
2+
B site in arginase family (Figure 1.2). Therefore, in spite 
of the distinct chemical transformations catalyzed by these two metallohydrolase, it is 
unequivocally accepted that arginase and deacetylase divergently evolved from a common 
primordial ancestral metal-requiring hydrolase.  
1.1  Structure and Function of Arginase Family 
Arginase is the prototypical member of this family and has been very well characterized 
both structurally and functionally. Arginase deficiency in human leads to accumulation of either L-
arginine in blood known as hyperarginemia, or accumulation of nitrogen in the form of ammonia, 
known as hyperammonemia (Morris, 2002). Mn
2+
 is the physiologic activator of arginase, and it 
has been reported that Co
2+
, Ni
2+
, Fe
2+
, VO
2+
, and Cd
2+
 can satisfy activity as well (Hellerman and 
Perkins, 1935; Mora et al., 1965; Brown, 1966; Anderson, 1945). The first crystal structure of an 
arginase enzyme was that of rat liver arginase (Kanyo et al., 1996), which for the first time not 
only revealed the overall arginase-deacetylase fold, but also provided the first view of the spin-
coupled binuclear manganese cluster originally studied by electron-paramagnetic resonance 
spectroscopy (Reczkowski and Ash, 1992). The binuclear manganese cluster (Mn
2+
A–Mn
2+
B) 
 6 
 
resides at the bottom of a ∼15 Å-deep active site cavity with internuclear separation as 3.3 Å, 
consistent with the zero-field splitting of the quintet state observed in the early EPR spectrum 
(Khangulov et al., 1995). Subsequent structural studies of bacterial and human arginase (Bewley 
et al., 1999; Di Costanzo et al., 2005; Cama et al., 2003), parasitic arginases from Plasmodium 
falciparum (Dowling et al., 2010) and Leishmania mexicana (D'Antonio et al., 2013), as well as 
other members in the arginase family all reveal identical tertiary structure and the conserved 
binuclear manganese site. Mn
2+
A is positioned deep in the active site, whereas Mn
2+
B is closer to 
the surface. Each Mn
2+
 ion is coordinated in a distorted octahedral geometry. Two histidine, four 
aspartate residues, and two water molecules play as ligands to complete the metal coordination 
polyhedral. The nucleophile water molecule simultaneous coordinates to both metal ions 
facilitates ionization to form a metal-bridging hydroxide ion. The Mn
2+
A-bound only water 
molecule, was not always observed in some arginase structure (Kanyo et al., 1996), or was 
observed to weakly interact with Mn
2+
A since the distance (>2.6 Å) is too long to be considered 
innersphere coordination interaction (Di Costanzo et al., 2007). Nevertheless, the Mn
2+
A-bound 
only water molecule is suggested to be displaced by the upcoming substrates and may function 
as a proton wire to facilitate proton transfer in catalysis, whereas the Mn
2+
A-Mn
2+
B bridging 
hydroxide ion plays as the key nucleophile in catalysis.   
  Mechanistic insights of arginase family have been gained from the structures of enzyme-
substrate complex (B. caldovelox arginase inactivated by metal depletion in complex with L-
arginine) (Bewley, et al., 1999); enzyme-product complex (the structure of H141C arginase-urea-
L-ornithine ternary complex) (Cox et al., 2001); and structure of arginase complexed with the 
boronic acid substrate analogue 2(S)-amino-6-boronohexanoic acid (ABH) (Cox et al., 1999), 
which binds to arginase as the tetrahedral boronate anion and thus mimics the tetrahedral 
intermediate and its flanking transition states in the arginase reaction). The current widely 
accepted catalytic mechanism of arginase family is summarized in Figure 1.3.   
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Figure 1.3: General catalytic mechanism proposed for arginase family. This mechanism is 
mainly based on the study of arginases.   
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Figure 1.4: Substrate specificity determinants of arginase family. (a) Arginase I complexation 
with substrate analogue ABH (X=CH2) and S-(2-boronoethyl)-L-cysteine, BEC (X=S) illustrates 
the constellation of hydrogen bond interactions recognizing the amino acid moiety of the 
substrate L-arginine. (b) Stereo-view of specificity loops of arginase family: human arginase I 
(blue), E. coli agmatinase (yellow), S. clavuligerus proclavaminate amidinohydrolase (red). 
Reprinted with permission from Shishova et al., Probing the specificity determinants of amino acid 
recognition by arginase, Biochemistry 2009, 48 (1), 121-131. Copyright (2009) American 
Chemical Society  
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The substrate specificity determinants of arginase family were also illuminated by the 
above X-ray crystal structures, which all revealed similar constellation of direct and water-
mediated hydrogen bond interactions between conserved active site residues and the non-
electrophilic region of the bound substrate. For arginase, the precise geometries and bond 
distances of these interactions were confirmed by the high resolution crystal structures of human 
arginase I complexed with ABH and the related inhibitor BEC (Di Costanzo et al., 2005). The 
molecular recognition of the α-substituents (amino acid moiety) of L-arginine result in the maximal 
number of hydrogen bond interactions (direct or water-mediated) formed between α-
carboxylate/amino group and the substrate specificity determining residues from loops (L1, L2, 
L4, and L5). Comparison of the structures in the arginase family confirmed this notion that the 
evolution of substrate recognition is achieved by mutation in the “specificity loops” flanking the 
active site mouth so that diverse guanidino group-containing substrates can be accommodated 
by keeping the same fold (Figure 1.4) (Shishova et al., 2009).   
1.2  Remaining Questions in Arginase Family 
1.3.1 Formiminoglutamase 
Formiminoglutamase (FIGase), is the least-understood member of arginase family. It 
catalyzes the final step in histidine utilization pathway I by catalyzing the hydrolysis of the 
formimino group of N-formimino-L-glutamate to form L-glutamate and formamide (Figure 1.1). 
Although early studies of formiminoglutamases from Aerobacter aerogenes and Bacillus subtilis 
have shown that the maximal activity of formimino-glutamase does require the presence of Mn
2+ 
(Lund and Magasanik, 1965; Kaminskas, 1970), which is a signature of arginase family, the 
chemistry of formiminoglutamase is distinct from the other arginase family members and has not 
been characterized mechanistically: it involves nucleophilic attack of manganese-activated water 
(or hydroxide ion) at the electrophilic formimino carbon rather than the guanidino carbon in other 
arginase family members. Presumably, the reaction undergoes through a similar tetrahedral 
intermediate after nucleophilic attack, and then the intermediate collapses into formamide and L-
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glutamate rather than ammonia and N-formyl-L-glutamate that are seen in the reaction catalyzed 
by HutF, N-formiminoglutamate iminohydrolase, involved in histidine utilization pathway II. 
Furthermore, although two crystal structures have been determined by structural genomics 
consortia and these structures confirm the conserved arginase fold and active site, surprisingly 
neither of these structures appears to be that of a functional metalloenzyme. The structure of 
FIGase from Vibrio cholerae (PDB entry 1XFK) does not contain bound metal ions, while the 
structure of FIGase from Bacillus subtilis (PDB entry 3M1R) contains a binuclear calcium cluster 
instead of the binuclear manganese cluster. In addition, an arginase-like protein 
fromTrypanosoma cruzi (PDB entry 2A0M), which is presumably a formiminoglutamase based on 
the sequence homology as well as its structural similarity with the FIGase from V. cholerae and B. 
subtilis, does not contain metal ions in the structure either. We chose to study this putative T. 
cruzi FIGase: 1) to test whether it is indeed a formiminoglutamase; 2) to characterize FIGase 
structure and confirm Mn
2+
 ion binding; 3) to understand the evolutionary relationship between 
formiminoglutamase (iminohydrolase) and other arginase family members (amidinohydrolases). 
FIGase may represent an intriguing case, i.e. a "snapshot" of an intermediate evolutionary state 
for the metal binding site between arginases and deacetylases, since sequence alignment of 
different FIGases suggests that the Mn
2+
A site is more variable than the Mn
2+
B site: specifically, 
the histidine ligand to Mn
2+
A is substituted by asparagine in both the putative T. cruzi FIGase and 
B. subtilis FIGase. The bridging aspartate ligand D228 of the putative T. cruzi FIGase appears as 
cysteine in the FIGases from S. aereus, P. aeruginosa, M. caseolyticus and R. solanacearum. 
The greater evolutionary potential of Mn
2+
A site ligands is indeed consistent with the fact that only 
the Mn
2+
B site is conserved among members of the greater arginase/deacetylase superfamily.  
1.3.2 Putative arginase proteins evolved without manganese cluster 
A number of arginase-like proteins lacking the signature manganese cluster binding 
motifs but sharing modest sequence homology with arginase/agmatinase (~25%) are widely 
conserved, and are only found in the family of Trypanosomatidae, including Angomonas, 
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Leptomonas, Phytomonas, Strigomonas, Herpetomonas, as well as the well-known 
trypanosomatids that can cause human tropical diseases, such as Trypanosoma and Leishmaina. 
Although these protein sequences are annotated as arginase-like, agmatinase-like, or putative 
arginase proteins in the current protein sequence database, they should not exhibit arginase-like 
activity simply due to the loss of the metal-binding residues as suggested by sequence analysis. 
Additionally, except the genus Leishmania which harbors a bona fide arginase responsible for de 
novo biosynthesis of ornithine in vivo, most of these trypanosomatids lack intrinsic 
arginase/agmatinase activity as well as a functional urea cycle and appear to be ornithine 
auxotrophs (Berriman et al., 2005). As a result, the exact biological function of these arginase-like 
proteins in these trypanosomatids, especially those human parasites, remains enigmatic. Gene 
knockout of this arginase-like protein from the T. brucei genome demonstrates that this protein is 
nonessential for bloodstream-form T. brucei growth; and accompanied metabolomics analysis 
confirmed that this protein has no role in the conversion of L-arginine to L-ornithine in these cells. 
It is unprecedented for a naturally existed, relatively well-conserved arginase family protein with 
complete loss of metal-binding function and thus it is difficult to decipher the molecular function of 
this protein solely based on its modest homology with arginase family. The current hypothesis is 
that important clues to the function of this arginase-like protein might be obtained from its 3D 
structure, as structure is much more conserved than sequence during evolution, and can reveal 
unforeseeable functional and evolutionary relationships (Bunker et al., 2015).  
1.3.3 Arginase in Parasitic Disease 
Parasites have employed a variety of strategies to escape the host immune system 
during invasion, and to take advantage of host metabolites as growth factors. A common 
mechanism of the various strategies is the activation of arginase (Vincendeau et al., 2003). 
Activation of arginase expression would lead to local depletion of L-arginine pool, which is the 
substrate of nitric oxide synthase, and thus lower the level of nitric oxide production; meanwhile, 
increased arginase activity would result in increased production of ornithine and the subsequent 
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downstream polyamine production, which is necessary for parasite growth and differentiation. 
Therefore, arginase may represent a promising drug target for the treatment of parasitic diseases, 
such as some neglected tropical diseases: malaria, leishmaniases, and schistosomiasis (Das et 
al., 2010).    
Disruption of arginase in Plasmodium falciparum was shown to compromise the in vivo 
viability of sporozoites during liver infection stage (Dowling et al., 2010). Studies of arginase-
knockout mutants in Leishmania parasites confirm that arginase activity is essential for parasite 
viability and infectivity (Roberts et al., 2004; Reguera et al., 2009; da Silva and Zampieri et al., 
2012). The arginase inhibitors N
ω
-hydroxy-L-arginine (NOHA) and nor-N
ω
-hydroxy-L-arginine 
(nor-NOHA) were shown to reduce the growth of L. infantum and L. major in macrophages and 
mice (Iniesta et al., 2001, 2005; Kropf et al., 2005). Furthermore, natural flavonoids which have 
demonstrated antileishmanial activity are found to be inhibitors of Leishmania arginase and 
arginase II from mammals (da Silva and Maquiaveli et al., 2012). Recently, verbascoside, a 
natural phenylethanoid glycoside extracted from many different plants in Latin America was 
shown to be leishmanicidal (EC50 =19 µM and 14 µM for L. amazonensis promastigoates and L. 
donovani amastigoates, respectively) and prove to be competitive inhibitor of Leishmania 
arginase with Ki of 0.7 µM against L. amazonensis arginase (Figure 1.5) (Maquiaveli et al., 
2016).  
Christianson and his colleagues recently determined crystal structures of P. falciparum 
arginase and L. mexicana arginase both in complex with some of the first-generation L-amino-
acid inhibitors such as ABH (Dowling et al., 2010; D’Antonio et al., 2013). These structures 
revealed the molecular basis of affinity and inhibitory activity of parasitic arginases, and suggest 
that although the active sites are highly conserved, the surface residues at the active site rim are 
not; thereby setting the stage for the design and evaluation of second-generation inhibitors, such 
as the recently reported α,α-disubstitued boronic acid inhibitors (Van Zandt et al., 2013).  
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Figure 1.5: Chemical structure of verbascoside and docking of verbascoside into Leishma-
nia arginase active site. Reprinted with permission from Maquiaveli et al., Verbasco-side inhibits 
promastigote growth and arginase activity of Leishmania amazonensis, J. Nat. Prod. 2016, 
Article ASAP. Copyright (2016) American Chemical Society 
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1.4 Histone/Polyamine Deacetylase 
1.4.1 Lysine acetylome and HDAC 
Reversible protein acetylation in living systems is a ubiquitous posttranslational 
modification (Kouzarides, 2000; Norvell and McMahon, 2000; Choudhary, 2000; Choudhary et 
al., 2014). The cellular functions of nuclear and cytoplasmic proteins can be regulated by lysine 
acetylation-deacetylation cycles in a diver range of cellular events, such as epigenetics (Berger et 
al., 2009), cell signaling (Choudhary et al., 2014), and metabolism (Zhao et al., 2010; Wang et al., 
2010). The prevalence of lysine acetylation rivals the well-known phosphorylation to some extent. 
Three classes of proteins are involved in the chemical biology of the acetylome: "writers", or 
lysine acetyltransferases (KATs); "readers", i.e., bromodomain-containing proteins that 
specifically recognize the acetyllysine moiety; and "erasers", or histone deacetylases (HDACs, 
also known as lysine deacetylases, KDACs) (Verdin et al., 2015). The HDACs are particularly 
noteworthy in that upregulated activity is often associated with tumorigenesis, and four HDAC 
inhibitors (Romidepsin, Vorinostat, Belinostat, and Panobinostat) are currently approved for 
clinical use for the treatment of different cancers, and many others are under clinical trials 
(Minucci and Pellici, 2006; Dokmanovic et al., 2007). HDACs may also serve as therapeutic 
targets for other diseases, including neurodegenerative diseases and immune disorders 
(Haberland et al., 2009; Arrowsmith et al., 2012; Falkenberg et al., 2014). 
The first mammlian HDAC, HDAC1, was identified by Schreiber and his colleagues using 
a trapoxin-based affinity resin (Taunton et al., 1996). Since then, 18 histone deacetylases in total 
have been identified so far and they are grouped into 4 classes based on the sequence homology 
with yeast prototypes Rpd3/Hda1 and Sirtuins: class I HDACs 1, 2, 3, and 8; class IIa HDACs 4, 
5, and 7, and class IIb HDACs 6 and 10; class III HDACs, designated sirtuins 1-7; and the class 
IV enzyme HDAC11 (Gregoretti et al., 2004; Yang and Seto, 2008). Class I, II, and IV HDACs are 
Zn
2+
-dependent enzymes that adopt the arginase-deacetylase fold and are often referred as 
classical HDACs (Figure 1.6), whereas class III HDACs (sirtuins 1-7) are NAD
+
-dependent 
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Figure 1.6: Domain organization of classical HDACs from yeast and humans. The 
percentage amino acid sequence identity/similarity to that of Rpd3 (for class I) or Hda1 (class 
II/IV) is shown. The sequence identity/similarity of Hda1 and HDAC11 to Rpd3 is given in 
brackets. The C-terminal domains (shaded rectangles) of Hda1 and Clr3 are homologous 
(identity/similarity, 26/57%). Dark bars represent similar N-terminal domains and C-terminal tails 
of class IIa histone deacetylases (HDACs). Myocyte enhancer factor 2 (MEF2)-binding motifs are 
depicted as small green boxes, whereas 14-3-3 binding motifs are indicated by small boxes 
labelled with the letter “S” (for serine). SE14, Ser-Glu-containing tetradecapeptide repeats; ZnF, 
ubiquitin-binding zinc finger. Reprinted with permission from Macmillan Publishers Ltd: Nature: 
Yang, X.-J., & Seto, E., Nat. Rev. Mol. Cell Biol. 2008, 9 (3), 206-218, Copyright 2016. 
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enzymes that adopt an unrelated fold (Yuan and Marmorstein, 2012).  
The first crystal structure of classical HDACs was HDLP from Aquifex aeolicus, which not 
only provided the molecular insights into lysine deacetylation (Figure 1.7), but also established 
the evolutionary relationship with arginase family (Finnin et al., 1999). Subsequently, crystal 
structures of both class I HDACs and catalytic domains of class IIa HDACs were determined, 
such as human HDAC8 (Somoza et al., 2004; Vannini et al., 2004), HDAC-like protein (HDAH) 
from Bordetella/Alcaligenes strain FB188 (Nielsen et al., 2005), human HDAC4 catalytic domain 
(Bottomley et al., 2008), human HDAC7 catalytic domain (Schuetz et al., 2008), human HDAC2 
(Bressi et al., 2010; Lauffer et al., 2013), human HDAC3-corepressor complex (Watson et al., 
2012), human HDAC1 in complex with the dimeric ELM2-SANT domain of MTA1 from the NuRD 
complex (Millard et al., 2013), S. mansoni HDAC8 (Marek et al., 2013), and S. pombe class II 
HDAC Clr3 (Job et al., 2016). The structural insights from these studies, along with the detailed 
biochemical studies carried on human HDAC8 (Gantt et al., 2006, 2010, 2016) have provided a 
comprehensive picture of catalysis (Figure 1.7) and inhibitor binding of HDACs (López et al., 
2016). The details about HDAC structure, metal ion specificity, substrate binding, and mechanism 
have been reviewed by Christianson and his colleagues (Lombardi and Cole, et al., 2011).  
1.4.2 Polyamine acetylation and PDAC 
Polyamines such as spermidine and spermine, and their diamine precursor putrescine, 
are ubiquitous and essential in all living systems (Tabor, C.W. and Tabor, H., 1984). These 
polycations present at millimoloar concentration intracellularly and their concentration increases 
in rapidly proliferating cells. Polyamines play fundamental roles in diverse biological processes, 
including replication, transcription, and translation, and these roles can involve noncovalent 
(commonly interacting with nucleic acids, such as RNA) as well as covalent interactions. For 
example, the aminobutyl group of spermidine is utilized for hypusination of a lysine residue in the 
eukaryotic translation initiation factor 5A (elf5A), and this modification is required for the viability,  
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(a) 
 
(b) 
Figure 1.7: HDAC catalytic mechanism. (a) Original catalytic mechanism proposed by Finnin et 
al. based on the crystal structure of HDLP. Reprinted with permission from Macmillan Publishers 
Ltd: Nature: Finnin et al., Structures of a histone deacetylase homologue bound to the TSA and 
SAHA inhibitors. Nature, 1999, 401(6749), 188-193, Copyright 1999. (b) Revised catalytic 
mechanism based on the study of human HDAC8. Reprinted with permission from López et al., 
Metal-dependent deacetylases: cancer and epigenetic regulators, ACS Chem. Biol. 2016, 11 (3), 
706-716. Copyright (2016) American Chemical Society 
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Figure 1.8: Polyamine metabolism in prokaryotes and eukaryotic cells. Enzymes: 1, 
arginase; 2, ornithine decarboxylase; 3, spermidine synthase; 4, spermidine/spermine 
acetyltransferase; 5, polyamine oxidase; 6, acetylpolyamine amidohydrolase; 7, spermine 
synthetase; 8, spermidine N
8
-acetyltransferase; 9, N
8
-acetylspermidine deacetylase. Reprinted 
with permission from Lombardi et al., Structure of prokaryotic acetylpolyamine deacetylase 
reveals evolutionary functional relationships with eukaryotic histone deacetylases, Biochemistry 
2011, 50 (11), 1808-1817. Copyright (2011) American Chemical Society  
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growth, and proliferation of eukaryotic cells
 
(Saini et al., 2009). In order to coordinate intracellular 
polyamine metabolism with the needs of the cell, polyamine metabolism is an elaborately 
orchestrated balance of cellular uptake, transport, biosynthesis, and catabolism (Figure 1.8), e.g., 
polyamine metabolism is tightly controlled by feed-back loops that function at both transcription 
and translational levels (Coffino, 2001; Ivanov et al., 2010). Dysregulation of polyamine 
metabolism is frequently associated with cancer and other hyperproliferative diseases, so 
enzymes of polyamine metabolism are emerging drug targets for chemothereaputic strategies 
(Gerner, 2004; Casero and Marton, 2007).  
In prokaryotes, a critical strategy for the regulation of polyamine function is reversible 
acetylation. Bacterial acetylpolyamine amidohydrolase (APAH), also known as polyamine 
deacetylase (PDAC), is responsible for making acetylated polyamines accessible for cell growth 
under lack of other carbon sources (Krämer et al., 2016). Biochemical and structural studies of 
APAH from Mycoplana ramosa reveals that like Zn
2+
-dependent HDACs, PDAC uses the similar 
catalytic machinery for polyamine deacetylation (Sakurada et al., 1996; Lombardi and Angell et 
al., 2011). Interestingly, the substrate binding site of PDAC is distinct from those of HDACs. 
PDAC uses an 18 Å-long “L”-shaped active site tunnel at the dimer interface, accessible only to 
narrow and flexible substrates, such as acetylpolyamines, which explains why PDAC can 
selectively recognize acetylpolyamines versus acetyllysine.  
   This strategy is analogous to the regulation of protein function by reversible acetylation 
of lysine side chains by histone acetyltransferases and histone deacetylases. However, reversible 
polyamine acetylation in eukaryotes is poorly understood. It has been known that reversible 
polyamine acetylation is initiated in the nucleus in mammalian cells, where spermidine is 
acetylated at the aminobutyl position (Libby, 1980). It is then exported to cytosol and deacetylated 
by a metal-dependent cytosolic N
8
-acetylspermidine deacetylase (PDAC) (Blankenship, 1978; 
Dredar et al., 1989). Notably, PDAC does not deacetylate N
1
-acetyl-spermidine or N
1
-
acetylspermine, which are also present in the cytosol (Marchant et al., 1986). Thus, the catalytic 
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specificity of PDAC is very strict with regard to the length of the substrate as well as the location 
of the secondary amino group within the substrate (Figure 1.8). Unfortunately, the exact role of 
reversible polyamine acetylation in eukaryotes is unknown, and the identity of the cytosolic PDAC 
in eukaryotes has remained elusive. 
1.5 Unanswered Questions about Histone/Polyamine Deacetylase 
In spite of the explosion of acetylome studies implicating many roles of HDACs, it is still 
not clear which specific HDAC isoform is involved in a specific (de)acetylation event and how 
HDAC selects its substrate. Besides, regardless of the success of clinical use of HDAC inhibitors, 
only few isoform-specific HDACis have been developed. One of the hurdles is the lack of 
thorough understanding of HDAC functions at molecular level, in particular for class IIb and class 
IV HDACs.  
Class IIb HDACs (HDAC6 and HDAC10) are well distinguished from the other 9 HDACs 
due to their unique multidomain architecture (Figure 1.6). HDAC6 harbors tandem catalytic 
domains and a zinc finger domain at its C-terminus (Grozinger et al., 1999), whereas HDAC10 
contains an N-terminal catalytic domain and a C-terminal Leu-rich α/β domain (Tong et al., 2002; 
Fischer et al., 2002; Kao et al., 2002; Guardiola and Yao et al., 2002). The function of HDAC10 
Leu-rich domain remains unknown, and even the function of HDAC10 itself has been poorly 
characterized. HDAC10 was implicated in autophagy through interaction with Hsc70/Hsp70 
(Oehme et al., 2013), and recently it was shown that HDAC10 can regulate the cell cycle G2/M 
phase transition through Let-7-HMGA2-Cyclin A2 pathway by deacetylating histone H3 (Li et al., 
2015); and also regulate DNA mismatch repair and may involve the deacetylation of MutS 
homolog 2 (MSH2) (Radhakrishnan et al., 2015). Studies of HDAC10 at molecular level have 
been missing, which hinders us from understanding its biological function.  
In contrast, HDAC6 has been better characterized since its discovery. Its C-terminal zinc-
finger domain was shown to bind unanchored ubiquitin and recruit polyubiquitinated misfolded 
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protein cargo to dynein motors for transport to aggresomes (Ouyang et al., 2012; Kawaguchi et 
al., 2003). Anchored in the cytoplasm by serine/glutamate-rich repeat motifs (Bertos et al., 2004), 
HDAC6 catalyzes the deacetylation of K40 in the α-tubulin subunit of the microtubule (Hubbert et 
al., 2002), thereby regulating microtubule dynamics: HDAC6 inhibition leads to hyperacetylation 
of α-tubulin and suppression of microtubule dynamics, while overexpression of HDAC6 reduces 
tubulin acetylation levels and increases cell motility (Szyk et al., 2014).  
  However, a fundamental question about HDAC6 has not been resolved yet: it is not 
completely clear whether both CD1 and CD2 domains of HDAC6 are fully functional. Early 
studies indicated that both catalytic domains are active toward histone substrates, with only CD2 
exhibiting tubulin deacetylase activity (Grozinger et al., 1999; Haggarty et al., 2003), whereas 
subsequent studies suggested that only CD2 is catalytically active (Zou et al., 2006), or both 
domains may be required for activity (Zhang et al, 2006). Schreiber and his colleagues also 
proposed that CD1 could serve as a microtubule binding domain (Schreiber and Bernstein, 2002).  
1.6 Focus of thesis 
The crystal structure of formiminoglutamase from Trypanosoma cruzi (TcFIGase) bound 
with Mn
2+
 ions is reported at 1.85 Å resolution. We show that reconstitution of this protein with 
Mn²⁺ confers maximal catalytic activity in the hydrolysis of formiminoglutamate to yield glutamate 
and formamide. Equilibration of TcFIGase crystals with MnCl₂ at higher pH yields a binuclear 
manganese cluster similar to that observed in arginase, except that the histidine ligand to the 
Mn
2+
A of arginase is an asparagine ligand Mn
2+
A to the Mn²⁺(A) ion of TcFIGase. The crystal 
structure of N114H TcFIGase reveals a binuclear manganese cluster essentially identical to that 
of arginase, but the mutant exhibits a modest 35% loss of catalytic efficiency.   
The X-ray crystal structure of an arginase-like protein from the parasitic protozoan 
Trypanosoma brucei, designated TbARG, is reported at 1.80 Å resolution. Intriguingly, TbARG 
does not contain metal ions in its putative active site, and amino acid sequence comparisons 
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indicate that all but one of the residues required for coordination to the catalytically obligatory 
binuclear manganese cluster in other arginases are substituted here with residues incapable of 
metal ion coordination. Therefore, the structure of TbARG is the first of a member of the arginase 
family that is not a metalloprotein. Although we show that metal binding activity is easily 
reconstituted in TbARG by site-directed mutagenesis and confirmed in X-ray crystal structures, it 
is curious that this protein and its parasitic orthologues evolved away from metal binding function. 
The molecular function of TbARG remains enigmatic.   
The X-ray crystal structure of arginase from Schistosoma mansoni (SmARG) and the 
structures of its complexes with several amino acid inhibitors have been determined at atomic 
resolution. This enzyme is upregulated in all forms of the parasite that interact with the human 
host. Current hypotheses suggest that parasitic arginases could play a role in host immune 
evasion by depleting pools of substrate l-arginine that would otherwise be utilized for NO 
biosynthesis and NO-dependent processes in the immune response. Although the amino acid 
sequence of SmARG is only 42% identical with that of human arginase I, residues important for 
substrate binding and catalysis are strictly conserved. In general, classical amino acid inhibitors 
such as ABH tend to bind more weakly to SmARG than to human arginase I despite identical 
inhibitor binding modes in each enzyme active site. The identification of a patch on the enzyme 
surface capable of accommodating the additional Cα substitutent of an α,α-disubstituted amino 
acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The 
structures of SmARG complexed with two different α,α-disubstituted derivatives of ABH are 
presented. Additionally, two X-ray crystal structures of L. mexicana arginase complexed with the 
same α,α-disubstituted derivatives are reported. Structural comparison between human and 
parasitic arginase complexes reveal interesting differences in the binding modes of the additional 
α-substituents, i.e. the D-side chains, of these inhibitors. Subtle differences in the three-
dimensional contours of the outer active-site rims among arginases from different species lead to 
different conformations of the D-side chains and thus different inhibitor-affinity trends. The 
 23 
 
structures suggest that it is possible to maintain affinity while fine-tuning intermolecular 
interactions of the D-side chains of α,α-disubstituted boronic amino-acid inhibitors in the search 
for isozyme-specific and species-specific arginase inhibitors. 
Histone deacetylase 6 (HDAC6) is a critical target for drug design due to its role in 
oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases 
in that it contains tandem catalytic domains designated CD1 and CD2. We now report the crystal 
structures of CD2 from Homo sapiens and CD1 and CD2 from Danio rerio HDAC6, and we 
correlate these structures with activity measurements using a panel of 13 different substrates. 
The catalytic activity of CD2 from both species exhibits broad substrate specificity, whereas that 
of CD1 is highly specific for substrates bearing C-terminal acetyllysine residues. Crystal 
structures of substrate complexes yield unprecedented snapshots of the catalytic mechanism. 
Additionally, crystal structures of complexes with 8 different inhibitors, including Belinostat and 
Panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, 
and the HDAC6-specific inhibitor N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-
oxoethyl)benzamide, reveal surprising new insight regarding changes in Zn
2+
 coordination and 
isozyme-specific inhibition. 
Polyamines such as spermidine and spermine are polycationic small molecules that bind 
to nucleic acids and influence gene expression in all forms of life. Intracellular polyamine 
metabolism is regulated by reversible acetylation, and dysregulated polyamine metabolism is 
observed in many diseases such as colon cancer, prostate cancer, and neuroblastoma. Although 
the reversible acetylation of spermidine was first observed in rat liver more than 30 years ago, the 
identity of the vertebrate N
8
-acetylspermidine deacetylase (PDAC) has remained elusive until 
now. Here, we show that HDAC10, a cytosolic class IIb histone deacetylase, exhibits robust 
catalytic activity in vitro against acetylpolyamines such as acetylputrescine, acetylcadaverine, and 
N
8
-acetylspermidine, but not N
1
-acetylspermidine or N
1
-acetylspermine; furthermore, HDAC10 
exhibited minimal or no activity against a panel of acetyllysine-containing peptides. Therefore, we 
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conclude that HDAC10 is the long-sought cytoslic PDAC in vertebrate polyamine metabolism. 
The crystal structure of HDAC10/PDAC from Danio rerio (zebrafish) reveals two active site 
features conserved in HDAC10/PDAC enzymes from different vertebrate species that contribute 
to selectivity for polyamine substrates: (1) a 310-helix insertion in active site loop L1 that constricts 
the mouth of the active site, effectively lengthening the active site tunnel to favor the binding of 
long, narrow polyamine substrates and disfavor the binding of shorter acetyllysine substrates; and 
(2) a glutamate "gatekeeper" that can make favorable electrostatic interactions with cationic 
polyamine substrates. The crystal structure of HDAC10 further reveals the Leu-rich domain 
shares the arginase-deacetylase fold with the PDAC domain, yet contains no active site. 
Accordingly, this pseudo-deacetylase domain is designated "ΨDAC". The ΨDAC domain appears 
to be important for stabilizing and solubilizing the PDAC domain for catalytic function.  
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Chapter 2:  Structural and Inhibition Study of Schistosoma mansoni 
Arginase and Leishmania mexicana Arginase 
This work is published in Hai, Y., Edwards, J. E., Van Zandt, M. C., Hoffmann, K. F., & 
Christianson, D. W. Biochemistry, 2014, 53 (28), 4671-4684; Hai, Y., & Christianson, D. W. Acta 
Cryst. 2016, F72, 300-306. 
2.1 Introduction 
Leishmaniasis is a neglected tropical disease caused by more than 20 different 
Leishmania species prevalent in nearly 100 countries, with 1.3 million new cases diagnosed 
annually (World Health Organization, 2013). It is estimated that 20,000–40,000 people die from 
visceral leishmaniasis annually (Alvar et al., 2012). The occurrence of leishmaniasis is on the rise 
in western countries due to travel to and from endemic regions by military and civilian personnel 
(Antinori et al., 2005), so this neglected tropical disease comprises an increasingly prominent 
threat to the public health. Treatment options for patients diagnosed with leishmaniasis vary 
depending upon the parasite species involved, the organs and tissues affected, and the quality of 
health care available (Desjeaux, 1996, 2001). For example, many cases of cutaneous 
leishmaniasis can resolve spontaneously, and those that do not generally respond to treatment 
with pentavalent antimony-based drugs. Other drugs currently in use for the treatment of 
cutaneous or visceral leishmaniasis include amphotericin B, pentamidine, and miltefosine. 
Unfortunately, no single leishmaniasis treatment option is ideal due to financial expense 
(especially for patients in developing countries), long drug treatment regimens, and side effects. 
Moreover, the emergence of resistance to currently existing drugs suggests that there is an 
urgent need for new pharmacological targets for leishmaniasis therapy (Sundar, 2001; Perez-
Victoria et al., 2002). Leishmania mexicana arginase (LmARG) has been considered as an 
attractive drug target in the exploration of new therapeutic approaches. Crystal structures of 
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LmARG complexed with first-generation L-amino acid inhibitors such as 2-(S)-amino-6-
boronohexanoic acid (ABH) reveal the molecular basis of affinity and inhibitory activity (D’Antonio 
et al., 2013), thereby setting the stage for the design and evaluation of second-generation 
inhibitors, novel α,α-disubstituted boronic acid inhibitors based on ABH (Ilies et al., 2011; 
Golebiowski et al., 2013; Van Zandt et al., 2013).  
Schistosomiasis, also known as bilharzia or snail fever, is a neglected tropical disease 
caused by parasitic schistosomes (also known as blood flukes) indigenous to tropical and 
subtropical regions of the developing world (Hotez et al., 2012; Pavlin et al., 2012). Biomphalaria 
fresh-water snails serve as intermediate hosts for Schistosoma mansoni and release infectious 
larvae (cercariae), which burrow into human skin upon contact with contaminated water sources. 
After definitive host penetration, the parasite transforms into a schistosomulum that enters the 
circulation and migrates to the hepatic portal and mesenteric veins surrounding the liver. Here, 
schistosomula develop into sexually mature adults (male and female forms) that can evade 
immunity and thrive for many years. Intravascular adult females produce hundreds of eggs daily 
during this time, which either cross the intestinal lumen to continue the lifecycle or circulate to the 
liver where they induce a robust host immunological response (Pearce and MacDonald, 2002). 
Chronic inflammation of the liver ultimately results, leading to portal vein hypertension and severe 
hepatic fibrosis. Although schistosomiasis is usually treated effectively with praziquantel, currently 
believed to target schistosomal voltage-gated Ca
2+
 channels (Greenberg, 2005), the continuous 
threat of praziquantel-resistant schistosomes portends an urgent need for alternative drug targets 
(Pica-Mattoccia et al., 2009; Wang et al., 2012). Arginase may comprise just such an alternative. 
Although arginase activity was first discovered in S. mansoni fifty years ago (Senft, 1963) and 
implicated in L-proline biosynthesis (Senft, 1966), S. mansoni arginase (SmARG) was not 
enzymatically characterized until recently (Fitzpatrick et al., 2009). The full-length mRNA for 
SmARG encodes a 364-residue protein exhibiting 42% and 40% amino acid sequence identity 
with human arginases I and II, respectively. All residues important for catalysis by the human 
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isozymes, including two histidine and four aspartate ligands to the binuclear manganese cluster, 
are strictly conserved in SmARG. SmARG is expressed in all life stages of the parasite that 
interact with the human host and is hypothesized to play a role in immune evasion: by depleting 
the L-arginine substrate otherwise utilized for nitric oxide (NO) biosynthesis, SmARG can 
attenuate the anti-schistosomula NO-mediated immune response of classically activated 
macrophages (James and Glaven, 1989). A similar strategy of arginase-facilitated immune 
evasion is exploited by Leishmania parasites in leishmaniasis (Kropf et al., 2003), Helicobacter 
pylori in peptic ulcer disease (Zabaleta et al., 2004), and certain cancer tumor cells (Raber et al., 
2012). Accordingly, inhibition of SmARG might render the parasite more susceptible to the 
immune response. If so, then SmARG may comprise a new target for structure-based drug 
design in the treatment of schistosomiasis.
 
As the first step in exploring the “druggability” of SmARG, we determined the X-ray 
crystal structures of the unliganded enzyme and its complexes with selected inhibitors, including 
the classical boronic acid amino acid inhibitors ABH and S-(boronoethyl)-L-cysteine (BEC). 
Additionally, we report the crystal structures of SmARG complexes with the N-
hydroxyguanidinium amino acids N-hydroxy-L-arginine (NOHA)
 
and nor-N-hydroxy-L-arginine 
(nor-NOHA), and the simple amino acids L-ornithine (the catalytic product), L-lysine, and L-valine. 
(Figure 2.1). Finally, to advance beyond classical amino acid inhibitor designs, we report the 
crystal structures of SmARG complexed with two novel α,α-disubstituted amino acid derivatives 
of ABH: (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid (ABHPE) and (R)-2-amino-
6-borono-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)hexanoic acid (ABHDP). In comparison, we also 
determined crystal structures of LmARG in complex with ABHPE and ABHDP. Structural 
comparisons with human and parasitic arginase complexes reveal interesting differences in the 
binding modes of the D-side chains of these inhibitors. Even though the active site clefts of these 
enzymes are highly conserved, the outer rims are not. Accordingly, different conformations are 
observed for the D-side chains. As proof-of-concept, our structures suggest that it is possible to 
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maintain affinity while fine-tuning intermolecular interactions of the D-side chain of α,α-
disubstituted boronic acid amino acid inhibitors in the search for isozyme- and species-specific 
arginase inhibitors.   
2.2 Materials and Methods 
2.2.1 Materials.  
Manganese(II) chloride tetrahydrate (≥99%), L-arginine, and α-isonitrosopropiophenone 
were purchased from Sigma. Tris(2-carboxyethyl)phosphine hydrochloride (98%, TCEP) was 
purchased from Gold Biotechnology. 2(S)-amino-6-boronohexanoic acid (ABH) was purchased 
from Enzo Life Sciences (Farmingdale, NY). NOHA, nor-NOHA, and BEC were purchased from 
Cayman Chemical Company (Ann Arbor, MI). ABHPE and ABHDP were the generous gift of New 
England Discovery Partners (Figure 3.1). 30% (w/v) PEG 20,000 solution, 50% (w/v) PEG 3350 
solution, 50% (w/v) PEG 10,000 solution, and 100% Tacsimate (pH 7.0) solution were purchased 
from Hampton Research.  
2.2.2 SmARG Construct Design.  
A silent mutation was introduced in the gene encoding wild-type SmARG prepared in a 
TOPO vector to eliminate a native NdeI site by using the QuickChange method (Stratagene) with 
the following oligonucleotide primers (sense: 5’-GGT AAT ATG AGT CGG GCG GCA CAC ATG 
CAG CAG ACA AAA CAA TAA TCG-3’, antisense: 5’-CGA TTA TTG TTT TGT CTG CAT GTG 
TGC CGC CCG ACT CAT AAT ACC-3’; underlined bases indicate the silent mutation). The 
coding sequence for SmARG was then amplified by PCR using oligonucleotide primers (sense: 
5’-GCA GCA CAT ATG ATG TTG AAA TCA GTC GCG ACC-3’, antisense: 5’-GCA GCA CTC 
GAG TTA TTG TTT TGT CTG CAT GTG TGC-3’; underlined bases represent the restriction 
enzyme recognition sites). The PCR product was subcloned into NdeI and XhoI sites of the pET-
28a vector (Novagen Inc.) yielding an N-terminal hexahistidine tag, a thrombin cleavage site, and 
a linker (MGSSHHHHHHSSGLVPRGSHM). 
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2.2.3 Expression and Purification.  
Recombinant LmARG was expressed and purified as previously reported (D’Antonio et 
al., 2013). SmARG was overexpressed in Escherichia coli BL21(DE3) cells. Transformed cell 
cultures were grown in Lysogeny-Broth (LB) media supplemented with 50 µg/L kanamycin. 
Expression was induced by 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Carbosynth) for 
16 h at 20 °C when OD600 reached 0.6-0.7. Cells were harvested by centrifugation at 6000 g for 
10 min. The cell pellet was resuspended in buffer A (50 mM K2HPO4 (pH 8.0), 300 mM NaCl, 
10% (v/v) glycerol, 1 mM TCEP). Cells were lysed by sonication on ice using a Sonifer 450 
(Branson), and cell lysate was clarified by centrifugation at 26,895 g for 1 h. Proteins were 
isolated from lysate by affinity chromatography with a Talon column (Clontech Laboratories, 
Mountain View, CA). After washing with 10 column-volumes of 20 mM imidazole in buffer A, 
SmARG was eluted with a 200 mL gradient of 20–300 mM imidazole. Pooled fractions were 
concentrated and applied to a Superdex 200 preparative grade 26/60 size exclusion column (GE 
Healthcare) with buffer B (50 mM bicine (pH 8.5), 100 μM MnCl2). The estimated purity of 
SmARG was >95% based on SDS-PAGE. Although the N-terminal hexahistidine tag and linker 
segment contained a thrombin cleavage site, the recombinant enzyme was not treated with 
thrombin and hence contained a full-length N-terminus. Enzyme was concentrated to 40 mg/mL, 
flash frozen by liquid nitrogen and stored at -80 °C.  
2.2.4 Activity Assay.  
Arginase activity was assayed by a colorimetric assay developed by (Archibald et al., 
1945)
 
with slight modification . Briefly, 0.5-50 mM L-arginine was added to a solution of 50 mM 4-
(2-hydroxyethyl)piperazine-1-propanesulfonic acid (EPPS), 100 μM MnCl2, and the reaction was 
initiated by adding 1 µM SmARG in a total volume of 200 µL at 21 °C. The reaction was 
terminated after 1 min using 30 µL of a 3:1 (v/v) concentrated acid/dye solution 
[H2SO4:H3PO4:H2O (1:3:1 v/v/v)/245 mM α-isonitrosopropiophenone in ethanol]. Samples were 
heated to 90 °C for 1 h in a thermocycler to ensure complete reaction of urea with the dye. To 
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quantify urea formation, the absorbance of each sample was assessed at λ = 550 nm using a 
Tecan Infinite M1000 Pro Microplate Reader. Kinetic parameters were determined with Graphpad 
Prism (2008). The Ki values for ABH and NOHA were calculated using the modified Michaelis-
Menten equation for competitive inhibition. For IC50 determinations, 30 mM L-arginine was used 
and the Ki values for ABHPE and ABHDP were calculated based on the Cheng-Prusoff equation [Ki 
= IC50 / (1 + [S]/KM)] (Cheng and Prusoff, 1973). All measurements were performed in triplicate at 
room temperature.  
2.2.6 Crystallography.   
Unliganded SmARG crystals were prepared by the sitting drop vapor diffusion method at 
4 °C. Typically, a 4 μL drop of protein solution [10 mg/mL SmARG, 50 mM bicine (pH 8.5), 100 
μM MnCl2] was mixed with a 4 μL drop of precipitant solution [12% (w/v) PEG 20,000, 0.1 M 
imidazole (pH 7.0)] and equilibrated against a 500 μL reservoir of precipitant solution. Cubic 
crystals first appeared after two days, and grew to maximal size in three days. To obtain crystals 
of the SmARG-L-ornithine, SmARG-L-valine and SmARG-L-lysine complexes, unliganded 
SmARG crystals were soaked with 50 mM concentrations of each ligand in a 20 μL drop of 
soaking solution [14% PEG 20000, 0.1 M imidazole (pH 7.0)] equilibrated against a 500 μL 
reservoir of soaking solution for 24 hours. To co-crystallize SmARG with the higher-affinity 
arginase inhibitors ABH, BEC, NOHA, and nor-NOHA, as well as the α,α-disubstituted amino acid 
inhibitors ABHPE and ABHDP, SmARG was incubated with each inhibitor (10 mM) on ice for 1 hour 
before the crystallization experiment. Typically, 1 μL drop of protein solution [9 mg/mL SmARG, 
45 mM bicine, 90 μM MnCl2, 10 mM inhibitor] was added to 1 μL drop of precipitant solution [4% 
(v/v) Tacsimate (pH 7.0), 12% (w/v) PEG 3350 for SmARG-ABH and SmARG-BEC complexes; 
0.2 M potassium sodium tartrate tetrahydrate, 0.1 M Bis-Tris (pH 6.5), 10% w/v PEG 10,000 for 
the SmARG-NOHA complex; 0.2 M L-proline, 0.1 M HEPES (pH 7.5), 10% (w/v) PEG 3350 for 
the SmARG-norNOHA complex; 0.1 M HEPES (pH 7.4), 12% (w/v) PEG 3350 for the SmARG-
ABHPE complex; 0.15 M CsCl, 13% (w/v) PEG 3350 for the SmARG-ABHDP complex] and 
 31 
 
equilibrated against a 100 μL reservoir of precipitant solution. Cubic crystals appeared overnight 
and grew to maximal size in three days. The LmARG-ABHPE complex was crystallized using the 
sitting drop vapor diffusion method at 21 
o
C by mixing 1 µL of LmARG [6 mg/mL protein 
preincubated with 10 mM ABHPE in 50 mM Bicine (pH 8.5), 100 µM MnCl2, 1 mM TCEP, 5% 
glycerol, 2.5% DMSO] on ice with 1 µL precipitant solution [0.1 M HEPES (pH 7.5), 25% PEG 
3350]. The LmARG-ABHDP complex was crystallized in similar fashion by mixing 1 µL of LmARG 
[6 mg/mL protein preincubated with 10 mM ABHDP in 50 mM Bicine (pH 8.5), 100 µM MnCl2, 1 
mM TCEP, 5% glycerol, 2.5% DMSO] on ice with 1 µL precipitant solution [0.1 M HEPES (pH 
7.2), 22% PEG 3350] at 21 
o
C. Crystals appeared in three days and were soaked in a 
cryoprotectant solution comprised of precipitant solution supplemented with 25-30% glycerol prior 
to flash-freezing in liquid nitrogen.  
X-ray diffraction data were collected on beamline X29 at the National Synchrotron Light 
Source (NSLS, Brookhaven National Laboratory, New York). Diffraction data were integrated and 
scaled with HKL2000 (Otwinowski and Minor, 1997). The structure was determined by molecular 
replacement using the program PHASER (McCoy et al., 2007) as implemented in the CCP4 suite 
of programs. For LmARG structure, the atomic coordinates of unliganded LmARG (PDB 
accession code: 4ITY) was utilized as a search probe for rotation and translation function 
calculations. For SmARG structure determination, the atomic coordinates of unliganded human 
arginase I (PDB accession code: 2ZAV)
 
was used. Iterative cycles of refinement and model 
building were performed using PHENIX (Adams et al., 2010) and COOT (Emsley et al., 2010), 
respectively. For LmARG, the hemihedral twinning operator h, -h-k, -l was included in the 
refinement strategy as previously described (D’Antonio et al., 2013). Solvent molecules and 
inhibitors were added in the final stages of refinement for each structure. The quality of each final 
model was verified with Molprobity (Chen et al., 2010). Refinement statistics are reported in 
Tables 2.1–2.3.  
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2.2.5 Isothermal Titration Calorimetry (ITC).   
A MicroCal iTC200 calorimeter (GE Healthcare) was used to measure the dissociation 
constants of SmARG-inhibitor complexes. Briefly, SmARG was exhaustively dialyzed against 50 
mM Bicine (pH 8.5), 100 μM MnCl2, and 1.0 mM TCEP (5% (v/v) DMSO was included in the 
dialysis buffer when SmARG was titrated with ABHPE and ABHDP). The inhibitor (ABH, 0.547 mM; 
NOHA, 1.097 mM; nor-NOHA, 0.443 mM; ABHPE, 0.410 mM; ABHDP, 0.436 mM) was dissolved in 
dialysis buffer. The inhibitor was titrated into the sample cell (0.2 mL) overfilled with SmARG 
(typically 20-40 μM) with sequential injections. An initial 0.2 μL injection was not used in the data 
analysis. Data analysis was performed using Origin 7.0. For SmARG complexes with nor-NOHA, 
ABH, ABHPE, and ABHDP, data were best fit assuming a single binding site. For the SmARG-
NOHA complex, data were best fit with the equation describing two sets of independent sites, i.e., 
a model in which binding to one site (association constant K1) has higher affinity than binding to 
the second site (association constant K2):  
 
(Q is the heat evolved during the course of the reaction, [E]t is the total enzyme concentration, V 
is the cell volume, n1 is the number of inhibitor equivalents required to saturate the first binding 
site, n2 is the number of equivalents to saturate the second site, ∆H1 and ∆H2 are the binding 
enthalpy per mole of ligand to the first site and to the second site, respectively, and [L] is inhibitor 
concentration). Note that dissociation constants Kd1 = 1/K1 and Kd2 = 1/K2. 
2.3 Results  
2.3.1 Enzyme kinetics and inhibition 
Wild-type SmARG exhibits a turnover number (kcat) of 330 ± 60 s
-1
 and a Km value of 12 ± 
5 mM at pH 8.5. These values are in reasonable agreement with previously reported values of 
537 s
-1
 and 17 mM, respectively, for a slightly different SmARG construct at pH 9.7 containing the 
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remnant of an N-terminal GST fusion tag (Fitzpatrick et al., 2009) instead of the hexahistidine tag 
and linker utilized herein. These values are also comparable to those measured for human 
arginase I, although the Km values of SmARG are slightly larger (4-6–fold) than the Km value 
reported for the human enzyme (Table 2.4). Steady-state kinetic analysis yields an inhibition 
constant (Ki) of 1.8 ± 0.6 µM for the SmARG-ABH complex, which is consistent with the ITC 
measurement of 1.3 ± 0.2 µM for the dissociation constant (Kd) of this complex (Figure 2.2). 
Interestingly, ITC measurements indicate Kd values of 0.26 ± 0.02 µM and 0.54 ± 0.08 µM for 
SmARG complexes with ABHPE and ABHDP, respectively, suggesting the additional α-substituent 
of these α,α-disubstituted amino acid inhibitors provides 2-5-fold enhancement of affinity 
compared with the parent SmARG-ABH complex. ITC measurements indicate that Kd = 0.36 ± 
0.08 µM for the SmARG-nor-NOHA complex.  
The binding of NOHA is slightly more complex, and ITC data are best fit by a model in 
which the binding affinity to the first site is higher (Kd = 0.33 ± 0.09 µM) than the binding affinity to 
the second site (Kd = 13 ± 4 µM). The location of the weaker binding site is unknown, since only 
the higher-affinity binding site is occupied in the crystal structure of the SmARG-NOHA complex 
(vide infra). Taken together, these data suggest that the N-hydroxyguanidinium moiety of nor-
NOHA is ca. 4-fold more effective as an inhibitor functional group targeting metal ion coordination 
than the tetrahedral boronate anion of ABH in binding to SmARG. This contrasts with human 
arginase I, which is preferentially inhibited (at least 10-fold) by ABH compared with nor-NOHA  
(Di Costanzo et al., 2006, 2010). Possibly, these selectivity differences could be exploited in 
developing inhibitors that preferentially block the parasitic enzyme. Finally, ITC measurements 
indicate Kd values of 0.26 ± 0.02 µM and 0.54 ± 0.08 µM for SmARG complexes with ABHPE and 
ABHDP, respectively. Notably, the additional α-substituent of these α,α-disubstituted amino acid 
inhibitors provides 2-5-fold enhancement of affinity compared with the parent SmARG-ABH 
complex, which is similar to the recently reported modestly improved inhibitory potency against 
human arginase II (3.8-fold and 7.4-fold, respectively) (Golebiowski et al., 2013). However,  
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Figure 2.1: (a) Reaction catalyzed by SmARG. (b) Arginase inhibitors 2(S)-amino-6-
boronohexanoic acid (ABH), S-(boronoethyl)-L-cysteine (BEC), N-hydroxy-L-arginine (NOHA), 
nor-N-hydroxy-L-arginine (nor-NOHA), (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic 
acid (ABHPE), and (R)-2-amino-6-borono-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)hexanoic acid 
(ABHDP). Although ABHDP is shown as the single stereoisomer that binds to SmARG and 
LmARG, the racemic mixture was utilized for the experiments described herein. 
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Table 2.1: Data collection and refinement statistics of SmARG 
 unliganded 
SmARG 
SmARG-
ABH 
SmARG-
ABHPE 
SmARG-
ABHDP 
SmARG- 
norNOHA 
SmARG-
NOHA 
Data Collection       
Space group  P213 P213 P213 P213 P213 P213 
Resolution (Å) 2.50 2.00 2.11 2.17 2.50 2.14 
Total (unique)   
reflections measured 
468739 
(65315) 
1358593 
(126488) 
993349 
(106363) 
1704963 
(96325) 
382879 
(61714) 
599891 
(102397) 
Unit cell parameters   
(a = b = c; Å) 
178.4 178.2 178.2 177.5 178.3 177.8 
Completeness (%) 99.9 (99.6) 100 (99.9) 98.5 
(96.1) 
98.3 
(92.5) 
94.4(87.0) 99.9 (99.6) 
I/σI
  
13.7 (2.1) 13.5 (3.1) 14.7 (2.0) 16.5 (2.0) 18.2 (2.1) 12.0 (2.0) 
Rsym
 
0.167  
(0.834) 
0.153 
0.831) 
0.106 
(0.757) 
0.165 
(1.190) 
0.118 
(0.712) 
0.150  
(0.883) 
Rpim
c 
0.066  
(0.350) 
0.045 
(0.262) 
0.031 
(0.342) 
0.041 
(0.376) 
0.047 
(0.412) 
0.066  
(0.420) 
Redundancy 7.2 (6.4) 10.7 (9.8) 9.3 (5.3) 17.7 
(10.1) 
6.3(3.6) 5.9 (5.2) 
Refinement       
No. of reflections, 
refinement/test set 
65276 
(3303) 
118487 
(5927) 
106337 
(5301) 
96490 
(4812) 
61299 
(3100) 
102353 
(5117) 
Rwork/Rfree (%) 
d 
 
17.7/21.4 
(24.7/30.4) 
16.8/20.2 
(20.1/24.5) 
17.3/20.6 
(23.2/25.8) 
17.4/20.6 
(24.9/29.4) 
17.4/22.5 
(21.7/29.0) 
17.6/20.9 
(24.8/29.2) 
Protein atoms
e 
10271 10241 10270 10120 10182 10243 
Solvent atoms 495 895 849 627 390 607 
Ligand atoms 36 88 132 173 84 127 
Mn
2+ 
ions 8 8 8 8 8 8 
R.m.s. deviations     
bonds (Å) 0.005 0.010 0.006 0.009 0.009 0.006 
angles (deg) 0.9 1.2 1.0 1.1 1.2 1.0 
Average B factors (Å
2
)     
main chain 36 30 30 32 44 29 
side chain 37 34 33 34 45 32 
solvent 29 34 33 30 38 30 
Mn
2+ 
ions 29 21 23 24 37 24 
ligands 37 34 34 45 43 42 
Ramachandran 
favored (%) 
97.4 98.0 98.2 97.4 96.5 98.0 
Ramachandran 
outliers (%)
 
0.1 0.0 0.0 0.2 0.6 0.1 
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Table 2.2: Data collection and refinement statistics of SmARG 
 SmARG-BEC SmARG- 
L-ornithine 
SmARG- 
L-valine 
SmARG- 
L-lysine 
Data Collection     
Space group  P213 P213 P213 P213 
Resolution (Å) 2.50 2.00 2.11 2.17 
Total (unique)   
reflections measured 
468739 
(65315) 
1358593 
(126488) 
993349 
(106363) 
1704963 
(96325) 
Unit cell parameters   
(a = b = c; Å) 
178.4 178.2 178.2 177.5 
Completeness (%) 99.9 (99.6) 100 (99.9) 98.5 (96.1) 98.3 (92.5) 
I/σI
  
13.7 (2.1) 13.5 (3.1) 14.7 (2.0) 16.5 (2.0) 
Rsym
 
0.167  
(0.834) 
0.153 
0.831) 
0.106 
(0.757) 
0.165 
(1.190) 
Rpim
c 
0.066  
(0.350) 
0.045 
(0.262) 
0.031 
(0.342) 
0.041 
(0.376) 
Redundancy 7.2 (6.4) 10.7 (9.8) 9.3 (5.3) 17.7 (10.1) 
Refinement     
No. of reflections, 
refinement/test set 
65276 
(3303) 
118487 
(5927) 
106337 
(5301) 
96490 
(4812) 
Rwork/Rfree (%) 
d 
 
17.7/21.4 
(24.7/30.4) 
16.8/20.2 
(20.1/24.5) 
17.3/20.6 
(23.2/25.8) 
17.4/20.6 
(24.9/29.4) 
Protein atoms
e 
10271 10241 10270 10120 
Solvent atoms 495 895 849 627 
Ligand atoms 36 88 132 173 
Mn
2+ 
ions 8 8 8 8 
R.m.s. deviations    
bonds (Å) 0.005 0.010 0.006 0.009 
angles (deg) 0.9 1.2 1.0 1.1 
Average B factors (Å
2
)    
main chain 36 30 30 32 
side chain 37 34 33 34 
solvent 29 34 33 30 
Mn
2+ 
ions 29 21 23 24 
ligands 37 34 34 45 
Ramachandran favored 
(%)
 
97.4 98.0 98.2 97.4 
Ramachandran outliers 
(%)
 
0.1 0.1 0.1 0.2 
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Table 2.3: Data collection and refinement statistics of LmARG 
 LmARG-ABHPE LmARG-ABHDP 
Data Collection   
Space group  R3:H R3:H 
Resolution (Å) 1.28 1.65 
Total (unique) reflections 
measured 
1041671 
(86060) 
281614 
(40479) 
Unit cell parameters   
(a = b,  c; Å) 
89.1, 113.6 88.9, 113.9 
Completeness (%) 99.4 (94.6) 99.5 (95.3) 
I/σI
  
29.3 (1.2)
 
22.4 (2.1) 
Rsym
 
0.091 (1.202) 0.089 (0.730) 
Rpim
c 
0.029 (0.509) 0.035 (0.316) 
Redundancy 12.1 (8.5) 7.0 (5.7) 
CC1/2
 
0.956 (0.510) 0.987 (0.817) 
Overall B factor from 
Wilson plot (Å2) 
16 24 
Twin fraction 0.15 0.08 
Refinement   
No. of reflections, 
refinement/test set 
77901/8159 36600/3879 
Twin Law h, -h-k, -l h, -h-k, -l 
Rwork (%)
e 
14.6 (30.1) 18.7 (31.8) 
Rfree (%)
e 
15.9 (31.0) 21.2 (34.5) 
Protein atoms
e 
2425 2326 
Solvent atoms 200 146 
Ligand atoms 67 36 
Mn
2+ 
ions 2 2 
R.m.s. deviations   
bonds (Å) 0.012 0.004 
angles (deg) 1.3 0.8 
Average B factors (Å
2
)   
protein 25 35 
solvent 35 40 
Mn
2+ 
ions 14 25 
inhibitor 30 55  
other ligands 32 28 
Ramachandran favored (%)
 
97.3 96.6 
Ramachandran outliers (%)
 
0.6 0.33 
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Table 2.4: Enzyme kinetics and inhibitor binding affinities of SmARG 
 SmARG
 a
 SmARG 
b
 Human arginase I 
Km (mM) 12 ± 5 17 3 ± 1 
c
 
kcat (s
-1
) 330 ± 60 537 340 ± 160 
c
 
kcat/Km (M
-1
s
-1
) (3.0 ± 0.9) × 10
4
 3.2 × 10
4
 (11 ± 2) × 10
4 c
 
Ki (ABH) (μM) 1.8 ± 0.6 n.d. 3.5 
d
 
Kd (ABH) (μM) 1.3 ± 0.2 n.d. 0.005 
e
 
Ki (NOHA) (μM) 3.7 ± 0.8 n.d. n.d. 
Kd (NOHA) (μM) 0.33 ± 0.09, 
13 ± 4 
n.d. 3.6 
f
 
Kd (nor-NOHA) (μM) 0.36 ± 0.08 n.d. 0.517 
g
 
Kd (ABHPE) (μM 0.26 ± 0.02 n.d. n.d. 
Kd (ABHDP) (μM) 0.54 ± 0.08 n.d. n.d. 
a 
This study, 
 
determined by enzyme assay at pH 8.5. 
b 
From ref. (Fitzpatrick et al., 2009), determined by enzyme assay at pH 9.7. 
c 
From ref. (D'Antonio et al., 2012), determined by enzyme assay at pH 8.5. 
d 
From ref. (Riley et al., 2011), determined by enzyme assay at pH 9.5. 
e 
From ref. (Di Costanzo and et al., 2005), Kd was determined at pH 8.5 by ITC. 
f 
From ref. (Di Costanzo and Ilies et al., 2010), Kd was determined at pH 8.5 by surface plasmon 
resonance.  
g 
From ref. (Di Costanzo and Ilies et al., 2010), Kd was determined at pH 8.5 by surface plasmon 
resonance; however, isothermal titration calorimetry yielded Kd ~ 50 nM. 
 
 
 
 
 
Table 2.5: Inhibitory activity of ABH derivatives against LmARG. 
Inhibitor IC50 (µM) Ki (µM) 
ABH, S-isomer (L) 1.3 ± 0.2 0.9 ± 0.1 
ABHPE, S-isomer (L) 2.1 ± 0.3 1.4 ± 0.2 
ABHDP, racemic (DL) 1.7 ± 0.4 1.1 ± 0.3 
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neither ABHPE nor ABHDP exhibit improved inhibitory potency against LmARG (Table 2.4, Figure 
2.2). Even so, since the ABHDP sample is a racemic mixture, the effective IC50 of the L-boronic 
acid side chain enantiomer should be two-fold lower than that measured for the racemic mixture, 
since only the L-boronic acid side chain enantiomer binds to the enzyme. In comparison, ABHPE 
and ABHDP also exhibit modestly improved inhibitory potency (IC50) against human arginase I 
(6.5-fold and 7.4-fold, respectively) (Van Zandt et al., 2013), and human arginase II (3.8-fold and 
7.4-fold, respectively) (Golebiowski et al., 2013). However, neither ABHPE nor ABHDP exhibit 
improved inhibitory potency against LmARG (Table 2.5, Figure 2.3). Even so, since the ABHDP 
sample is a racemic mixture, the effective IC50 of the L-boronic acid side chain enantiomer should 
be two-fold lower than that measured for the racemic mixture, since only the L-boronic acid side 
chain enantiomer binds to the enzyme.  
2.3.2 SmARG structure 
The overall fold of the SmARG monomer is generally similar to that of unliganded human 
arginase I (PDB entry 2ZAV) with an r.m.s. deviation of 1.1 Å for 271 Cα atoms, which is 
consistent with the modest amino acid sequence identity of 42% between SmARG and human 
arginase I. SmARG oligomerizes to form a homotrimer (Figure 2.4) with total buried surface area 
of 10,980 Å
2
 (31% of total solvent-accessible surface area) as determined by PISA. As indicated 
by the sequence alignment with human arginase I, SmARG contains a 20-residue extension at 
the N-terminus and a 13-residue extension at the C-terminus, plus a 12-residue insertion in the 
loop connecting α-helix B and β-strand 3. The N-terminal extension (17 residues plus the 
hexahistidine tag and its linker segment) and the inserted loop lack clearly-defined electron 
density and are presumed to be disordered. Most of the C-terminal extension is fully ordered and 
contains two additional short α-helices previously unobserved in the crystal structures of 
arginases from other species. The S-shaped C-terminus is suggested to be important for 
oligomerization and mediates 54% of the intermonomer contact surface area in rat arginase I,  
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Figure 2.2: Isothermal titration calorimetry (a)–(e): (a) SmARG-ABH complex; fitted line indicates 
stoichiometry n = 0.84 ± 0.01, ΔH = –11.4 ± 0.3 kcal/mol, and dissociation constant Kd = 1.3 ± 0.2 
μM. (b) SmARG-nor-NOHA complex; fitted line indicates stoichiometry n = 0.85 ± 0.01, ΔH = –
16.0 ± 0.3 kcal/mol, and dissociation constant Kd = 0.36 ± 0.08 μM. (c) SmARG-NOHA complex; 
data were best fit with the equation describing two sets of independent binding sites. The fitted 
curve indicates stoichiometry n = 0.77 ± 0.03, ΔH = –8.6 ± 0.3 kcal/mol, and dissociation constant 
Kd = 0.33 ± 0.09 μM for the first binding site, and n = 2.8 ± 0.2, ΔH = 2.4 ± 0.3 kcal/mol, and Kd = 
13 ± 4 μM for the second binding site. (d) SmARG-ABHPE complex; fitted line indicates 
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stoichiometry n = 0.908 ± 0.003, ΔH = –26.5 ± 0.1 kcal/mol, and dissociation constant Kd = 0.26 ± 
0.02 μM. (e) SmARG-ABHDP complex (racemic mixture); fitted line indicates stoichiometry n = 
2.29 ± 0.02, ΔH = –7.7 ± 0.1 kcal/mol, and dissociation constant Kd = 0.54 ± 0.08  
 
 
 
 
 
 
 
μM.  
Figure 2.3: (a) Steady-state kinetics of LmARG yield kcat = 4.1 ± 0.2 s
-1
 and KM = 61 ± 6 mM. (b) 
Inhibitory activity assays of LmARG.  
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although mutagenesis studies suggest that mutations in the C-terminus destabilize but do not 
necessarily prevent trimerization of rat arginase I or human arginase I. The unusually long C-
terminal tail of SmARG is similarly responsible for the majority of subunit-subunit interactions; the 
13-residue extension alone contributes ~3,900 Å
2 
total buried surface area (36% of total buried 
surface area) to trimer assembly. The structure of the binuclear manganese cluster (Figure 2.4) 
is essentially identical to that observed in unliganded arginases from other species, such as 
human arginase I.
  
Each Mn
2+
 ion is coordinated in octahedral or distorted octahedral fashion by 
two non-protein ligands and conserved metal-binding residues. The metal-bridging non-protein 
ligand is expected to be a hydroxide ion in the catalytically active state, and the Mn
2+
A-bound non-
protein ligand is interpreted as a water molecule. This is similar to the identification of non-protein 
metal ligands in unliganded human arginase I, B. caldovelox arginase, and L. mexicana arginase. 
Most other inner active site residues are conserved in SmARG, except that T135 in human 
arginase I is conserved as S165 in SmARG (Figure 2.4).  
2.3.3 Structure of SmARG-inhibitor complexes 
The overall structure of SmARG in each complex with the amino acid L-ornithine, L-
valine, and L-lysine is essentially identical to the structure of unliganded SmARG; the r.m.s. 
deviations between liganded and unliganded structures are 0.17 Å for 322 Cα atoms in the 
SmARG-L- ornithine complex, 0.17 Å for 319 Cα atoms in the SmARG-L-valine complex, and 0.30 
Å for 316 Cα atoms in the SmARG-L-lysine complex. As evident in Figure 2.5, the molecular 
recognition of the catalytic product L-ornithine, the product analogue L-lysine, and the weak 
inhibitor L-valine is dominated by three direct and four water-mediated hydrogen bonds that 
selectively accommodate the α-amino and α-carboxyl group of an amino acid with L-
stereochemistry. This hydrogen bond network comprises the L-amino acid recognition motif, as 
first observed in the rat arginase I-ABH complex. The overall structure of the SmARG-NOHA 
complex is essentially identical to that of unliganded SmARG, with an r.m.s. deviation of 0.23 Å 
for 316 Cα atoms. The α-amino and α-carboxyl groups of NOHA hydrogen bond with the L-amino 
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Figure 2.4: (a) Structure of the SmARG homotrimer; the disordered K111-S119 loop appears as 
a yellow dotted line. (b) Simulated annealing omit map contoured at 4.0σ of the metal-bound 
solvent molecules in unliganded SmARG. Metal coordination and hydrogen bond interactions are 
represented by red and green dashed lines, respectively. (c) Superposition of unliganded 
SmARG (color-coded as in (b), with black residue labels) and human arginase I (PDB entry 
2ZAV; C = yellow, N = blue, O = red, Mn
2+
 ion = pink spheres, solvent molecules = yellow 
spheres, with red residue labels). 
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acid recognition motif, and the Nη-OH group interacts with the binuclear manganese cluster 
(Figure 2.6). Intriguingly, however, the electron density map indicates that the N-
hydroxyguanidinium group binds with two alternative conformations. In the major conformation 
(refined with 75% occupancy), the Nη-OH group of NOHA displaces the metal-bridging hydroxide 
ion and symmetrically bridges the binuclear manganese cluster with an average Mn
2+
•••O 
coordination distance of 1.8 Å, and the Mn
2+
A-Mn
2+
B separation increases from 3.1 Å to 3.3 Å. 
The η-NH2 group of NOHA is oriented toward Mn
2+
A (but does not coordinate) and donates a 
hydrogen bond to E307. This conformation is similar to that observed in the 2.9 Å resolution 
crystal structure of the rat arginase I-NOHA complex (PDB entry 1HQF) (Cox et al., 2001). In the 
minor conformation (refined with 25% occupancy), the Nη-OH group of NOHA displaces the 
Mn
2+
A bound water molecule with an average Mn
2+
A•••O coordination distance of 2.0 Å. The 
metal-bridging hydroxide ion must also be displaced to accommodate NOHA binding in this 
conformation, so both Mn
2+
A and Mn
2+
B exhibit square bipyramidal coordination geometry. Two 
hydrogen bonds are observed between SmARG and NOHA in its minor conformation: the Nη-H 
group of NOHA donates a hydrogen bond to D158, and the η-NH2 group donates a hydrogen 
bond to T276. These interactions are similar to those observed in the 2.04 Å resolution crystal 
structure of the human arginase I-NOHA complex (PDB entry 3LP7).  
Finally, the overall structure of SmARG in its complex with nor-NOHA is essentially 
identical to that of unliganded SmARG, with an r.m.s. deviation of 0.19 Å for 331 Cα atoms. The 
amino acid moiety of nor-NOHA is accommodated by the L-amino acid recognition motif, as 
observed for NOHA. However, in contrast with the binding of NOHA, the N-hydroxyguanidinium 
group of nor-NOHA binds with just a single conformation in which the Nζ-OH group displaces the 
metal-bridging hydroxide ion and bridges the binuclear manganese cluster with average 
MnA
2+
•••O and MnB
2+
•••O coordination distances of 1.9 Å and 2.2 Å, respectively (Figure 2.6). 
The ζ-NH group of nor-NOHA donates a hydrogen bond to D158, and the ζ-NH2 group is oriented 
toward Mn
2+
B (but does not coordinate) and donates a hydrogen bond to T276. 
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Figure 2.5: Simulated annealing omit maps of amino acids bound in the active site of SmARG: 
(a) L-ornithine, contoured at 3.0σ; (b) L-valine, contoured at 3.0σ; and (c) L-lysine, contoured at 
5.5σ. Metal coordination and hydrogen bond interactions are represented by red and green 
dashed lines, respectively. The α-amino and α-carboxyl group of each amino acid makes an array 
of direct and water-mediated hydrogen bonds with conserved protein residues D213, E216, 
N160, S165, S167, N169, and H171. These residues comprise the L-amino acid recognition motif. 
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Figure 2.6: (a) Simulated annealing omit map (contoured at 3.0σ) of the inhibitor NOHA reveals 
that the hydroxyguanidinium group adopts two alternate conformations. Atoms are color-coded as 
in Figure 4. Metal coordination and hydrogen bond interactions are represented by red and green 
dashed lines, respectively. Note that residue D213 adopts two alternate conformations. (b) 
Simulated annealing omit map (contoured at 3.0σ) of the inhibitor nor-NOHA. Metal coordination 
and hydrogen bond interactions are represented by red and green dashed lines, respectively. 
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The crystal structure of the SmARG-ABH complex reveals that no significant 
conformational changes are triggered upon inhibitor binding, and the r.m.s. deviation is 0.15 Å for 
318 Cα atoms in comparison with the unliganded enzyme. The simulated annealing omit map in 
Figure 2.7 reveals that the boronic acid group of ABH undergoes nucleophilic attack, presumably 
by the metal-bridging hydroxide ion of the native enzyme, to form the tetrahedral boronate anion, 
which mimics the tetrahedral intermediate and its flanking transition states in the arginase 
reaction (Baggio et el., 1997). The α-carboxylate group and α-amino group of ABH hydrogen 
bond with the L-amino acid recognition motif, as first observed in the crystal structure of the rat 
arginase I-ABH complex. This structure serves as a starting point for understanding structure-
activity relationships for α,α-disubstituted ABH derivatives described below. The crystal structure 
of the SmARG-BEC complex, although determined at a lower resolution of 2.7 Å, similarly reveals 
the binding of the tetrahedral boronate anion and an array of hydrogen bonds with the α-amino 
acid moiety (Figure 2.7). No significant conformational changes are triggered upon inhibitor 
binding, and the r.m.s. deviation is 0.26 Å for 320 Cα atoms in comparison with the unliganded 
enzyme. Although fewer water molecules are observed in the active site due to the modest 
resolution, the structure of the SmARG-BEC complex is similar to that first observed in the rat 
arginase I-BEC complex (Kim et al., 2001). The structure of the SmARG-ABH complex reveals 
that the Cα-H group of ABH can be substituted with an additional side chain capable of making 
additional interactions on the protein surface.  
To demonstrate proof-of-concept, we have determined the crystal structures of SmARG 
complexes with the novel α,α-disubstituted amino acid inhibitors ABHPE and ABHDP. The overall 
structures of SmARG complexed with ABHPE and ABHDP are essentially identical to the structure 
of unliganded SmARG, with r.m.s deviations of 0.19 Å for 332 Cα atoms and 0.17 Å for 330 Cα 
atoms, respectively. Although racemic ABHDP was used in crystallization experiment with 
SmARG, the electron density map clearly shows that the stereoisoimer corresponding to L-ABH  
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Figure 2.7: (Top) Simulated annealing omit map (contoured at 3.0σ) of the boronic acid inhibitor 
ABH. Metal coordination and hydrogen bond interactions are represented by red and green 
dashed lines, respectively. (Bottom) Simulated annealing omit map (contoured at 3.0σ) of the 
boronic acid inhibitor BEC. Metal coordination and hydrogen bond interactions are represented by 
red and green dashed lines, respectively. 
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binds exclusively in the active site. As shown in Figure 2.8, the boronic acid moiety of each 
inhibitor undergoes nucleophilic attack by the metal-bridging hydroxide ion to form a tetrahedral 
boronate anion, as observed in the crystal structure of the parent SmARG-ABH complex. 
However, in contrast with the SmARG-ABH complex, the additional α-substituents of ABHPE and 
ABHDP block the binding of water molecule W4; this water molecule ordinarily mediates a 
hydrogen bond between the inhibitor α-amino group and D213 (Figure 2.8). Therefore, the L-
amino acid recognition motif in the active site of SmARG is slightly compromised by the binding of 
α,α-disubstituted amino acid inhibitors.  
Regardless, the additional α-substituents of both ABHPE and ABHDP make additional 
interactions in the active site of SmARG, which presumably accounts for the higher affinity 
binding of these inhibitors relative to ABH. In each enzyme-inhibitor complex, the piperidine ring 
exclusively adopts a chair conformation and its protonated tertiary amino group donates a 
hydrogen bond to D213 (purple dashed lines in Figures 2.8; average N---O separation = 2.7 Å in 
the SmARG-ABHPE complex and 2.9 Å in the SmARG-ABHDP complex). Additionally, the 
dichlorobenzyl group of ABHDP interacts with E58 from an adjacent monomer. Incomplete 
electron density for the dichlorobenzyl group of ABHDP and a higher average temperature factor 
(~55 Å
2
) compared with that of the piperidine ring (~30 Å
2
) suggests increased flexibility. 
Structural comparison of the SmARG-ABHPE complex with the human arginase I-ABHPE complex 
(PDB entry: 4HWW) reveals striking differences in the conformation of the piperidine α- 
substituent of ABHPE, even though the parent ABH scaffold retains the same conformation in both 
structures (Figure 2.9). Van Zandt and colleagues note that the piperidine ring of ABHPE adopts 
two alternate conformations in the human arginase I-ABHPE complex: distorted boat (66%) and 
chair (33%).
 
With the piperidine ring of ABHPE shifted further away from D183 in the human 
arginase I-ABHPE complex (D183 of human arginase I corresponds to D213 of SmARG), it makes 
water-mediated hydrogen bonds with D183 and D181 through water molecules W1 and W4, 
instead of making a direct hydrogen bond as observed in the SmARG-ABHPE complex. More  
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Figure 2.8: Simulated annealing omit maps of α,α-disubstituted amino acid inhibitors: (a) ABHPE, 
contoured at 5.0σ; and (b) ABHDP, contoured at 3.0σ. Atoms are color-coded as in Figure 4 (Cl = 
dark green). Metal coordination and hydrogen bond interactions are represented by red and 
green dashed lines, respectively. Note that residue E58 from an adjacent monomer of the 
homotrimer adopts two alternate conformations (highlighted in cyan). (c) Superposition of the 
SmARG-ABH complex (C, Mn
2+
 = white), the SmARG-ABHPE complex (C, Mn
2+
 = salmon), and 
the SmARG-ABHDP complex (C, Mn
2+
 = yellow). 
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Figure 2.9: (a) Superposition of the SmARG-ABHPE complex (C = white (protein) or yellow 
(inhibitor)) with the human arginase I-ABHPE complex (C = cyan; PDB entry 4HWW). (b) 
Superposition of the SmARG-ABHDP complex (C = white (protein) or yellow (inhibitor)) with the 
human arginase II-ABHDP1 complex (C = cyan; PDB entry 4IXV). Selected hydrogen bonds are 
shown as purple dashed lines (SmARG) or black dashed lines (human arginases). Solvent 
molecules are shown as small red spheres; Mn
2+
 ions are shown as purple or orange spheres in 
SmARG and human arginases, respectively. Black residue labels correspond to SmARG, and red 
labels correspond to the human arginases. 
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importantly, due to the conservation of water molecule W4, the L-amino acid recognition motif is 
intact in the human arginase I-ABHPE complex. 
Structural differences in the binding of an α,α-disubstituted amino acid are also revealed 
in the comparison of the SmARG-ABHDP complex with the complex between human arginase II 
and (R)-2-amino-6-borono-2-(1-(4-chlorobenzyl)piperidin-4-yl)hexanoate (ABHDP1, which differs 
from ABHDP by one chlorine atom on the pendant aromatic ring; PDB entry: 4IXV) (Figure 2.9). 
Here, too, the parent ABH structures adopt similar conformations; however, significant 
conformational differences are observed for the additional α-substituents of ABHDP and ABHDP1. 
The piperidine ring of ABHDP1 in the human arginase II-ABHDP1 complex adopts a distorted boat 
conformation, with the piperidine amino group forming a water-mediated hydrogen bond with 
S155 (equivalent to T136 in human arginases I and II), instead of hydrogen bonding with D213, 
as observed in the SmARG-ABHDP1 complex.  Additionally, the chlorobenzyl ring of ABHDP1 
makes no interactions with the protein. Active site comparisons reveal that A166 (equivalent to 
T136 in human arginase I and S155 in human arginase II) is another nonconserved residue in 
SmARG (besides S165) that can interact with α,α-disubstituted amino acid inhibitors (Figure 2.9). 
Interestingly, the corresponding residue is similarly nonpolar in two other parasitic arginases: 
P228 in Plasmodium falciparum arginase and V149 in Leishmania mexicana arginase. 
Differences in polarity and size at this position in parasitic arginases compared with human 
arginases may be a contributing factor to the alternative binding modes of α,α-disubstituted amino 
acid inhibitors.  
2.3.4 Structure of LmArg in complex with α,α-disubstituted boronic acid inhibitors 
The overall structures of LmARG complexed with ABHPE and ABHDP (Figure 2.10) are 
essentially identical to the structure of the LmARG-ABH complex (PDB entry 4IU0), with r.m.s. 
deviations of 0.26 Å (ABHPE) and 0.17 Å (ABHDP) for 289 and 286 Cα atoms, respectively. 
Although racemic ABHDP was used in the crystallization experiment, the electron density map 
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unambiguously shows that the L-stereoisomer binds exclusively in the active site, as also 
observed for binding to S. mansoni arginase. The α-carboxylate and α-amino groups are 
recognized by the conserved L-amino acid recognition motifs, which saturate the hydrogen 
bonding potential and ensure strict molecular recognition of the proper amino acid stereoisomer. 
The α-carboxylate group of ABHPE accepts hydrogen bonds from N143, S150, and two water 
molecules, and the α-amino group donates hydrogen bonds to D194 and two water molecules. It 
is interesting that the stereoselectivity for L-amino acid binding is maintained by four water-
mediated and three direct hydrogen bonds with the protein. In the LmARG-ABHDP complex, 
however, the D-side chain blocks a water molecule mediating the hydrogen bond between D194 
and the α-amino group (the direct hydrogen bond between D194 and the α-amino group is 
maintained). Nevertheless, a superposition of the LmARG complexes with ABH, ABHPE, and 
ABHDP shows that the binding modes of the parent ABH backbones are essentially identical 
(Figure 2.11). 
 Despite similar binding modes for the L-amino acid portion of each inhibitor, the 
additional D-side chains adopt different conformations. In the LmARG-ABHPE complex, the 
piperidine ring is unambiguously assigned as chair conformation based on high resolution 
electron density (Figure 2.10). Remarkably, the D-side chain of ABHPE makes no direct 
interaction with LmARG – the protonated tertiary amino group of the piperidine ring is oriented 
away from D194 forms a hydrogen bond with a water molecule. The binding mode of ABHPE with 
LmARG contrasts with that observed in S. mansoni arginase, where the piperidine amino group 
donates a hydrogen bond to D213 (which corresponds to D194 in LmARG). The binding mode of 
ABHPE in SmARG is unique, since only this particular enzyme has a groove that accommodates 
the piperidine ring of ABHPE (Figure 2.12). Notably, the piperidine ring of ABHPE does not interact 
directly with active site residues in human arginases I and II, although a water-mediated 
interaction is observed in the human arginase I-ABHPE complex. In the LmARG-ABHDP complex, 
the D-side chain of LmARG-ABHDP is characterized by weak and broken electron density,  
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Figure 2.10: (a) Simulated annealing omit map of ABHPE bound to LmARG contoured at 2.5σ. 
Mn
2+
 ions are shown as purple spheres. Ligand atoms are color coded as follows: C, orange; N, 
blue; O, red; Cl, dark green; B, green. Metal coordination and hydrogen bond interactions are 
shown as red and black dashed lines, respectively. (b) Simulated annealing omit map of ABHDP 
bound to LmARG contoured at 2.5σ, color-coded as in (a). 
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Figure 2.11: Stereo image of superposition of the LmARG-ABH complex (C atoms, blue), the 
LmARG-ABHPE complex (C atoms, magenta), and the LmARG-ABHDP complex (C atoms, 
orange) reveals similar overall binding modes of the ABH-based scaffold of each inhibitor, but 
different binding conformations for the D-side chains of ABHPE and ABHDP. 
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suggesting that it is largely disordered. Regardless, the piperidine ring is best modeled in a chair 
conformation with the protonated tertiary amino group donating a hydrogen bond to D194 (Figure 
3b). Interestingly, the dichlorobenzyl group packs against the A192 region. This conformation is 
unique to LmARG, since A192 is conserved as aspartate in human arginase I, human arginase II, 
and SmARG. The bulky, charged aspartate at this position in SmARG causes the D-side chain of 
ABHDP to adopt an alternative conformation (Figure 2.12). 
2.4 Discussion 
Although the affinities of the classical arginase inhibitors ABH, NOHA, and nor-NOHA are 
in the low micromolar range (Table 2.4), it is somewhat surprising that these affinities fall short of 
the nanomolar binding affinities reported for complexes with human arginase I. The structural 
basis of weaker affinity is not clear based on analysis of the crystal structures, since each 
inhibitor makes essentially identical metal coordination and hydrogen bond interactions in the 
active site of SmARG compared with the active sites of mammalian enzymes. It is clear, however, 
that the best inhibitors of arginase from any species will bear side chains capable of metal ion 
coordination. This accounts for the generally weaker binding affinity of simple amino acids such 
as L-valine, L-ornithine, and L-lysine, which do not interact directly with the active site Mn
2+
 ions 
(Figure 2.5). Parenthetically, we note that this feature facilitates release of the L-ornithine product 
during catalysis. The crystal structures of SmARG complexed with ABH and nor-NOHA reveal 
that the tetrahedral boronate anion and the N-hydroxyguanidinium moiety serve as ideal 
functional groups for metal ion coordination and active site hydrogen bond interactions (Figure 
2.6). The α-carboxylate and α-amino group of each inhibitor also make an array of hydrogen bond 
interactions with the L-amino acid recognition motif, and these hydrogen bonds similarly make an 
important contribution to enzyme-inhibitor affinity (Shishova et al., 2009). Thus, in the quest to 
improve SmARG-inhibitor affinity and selectivity, these conserved features of enzyme-inhibitor 
recognition cannot be perturbed. It is somewhat surprising that the additional D-side chain 
substituents of ABHPE and ABHDP do not confer some degree of affinity enhancement relative to  
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Figure 2.12: Comparison of α,α-disubstituted boronic acid inhibitors bound to arginases 
from different species. (a) LmARG-ABHPE complex. (b) human arginase I-ABHPE complex. (c) 
SmARG-ABHPE complex (4Q3S). (d) LmARG-ABHDP complex. (e) human arginase II-ABHCP 
complex. (f) SmARG-ABHDP complex (4Q3R). The conserved aspartate residues (D194 in 
LmARG) potentially interacting with the piperidine group of the D-side chain are highlighted in 
sticks. Ligand atoms are color coded as follows: C, bright orange; N, blue; O, red; Cl, dark green; 
B, green. Hydrogen bonds are shown as black dashed lines.     
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ABH. Even though the additional side chains do not make any polar interactions with protein 
residues, these side chains bind in the so-called "D-cleft" (Ilies et al., 2011), making van der 
Waals contacts and displacing associated water molecules to bulk solvent. Presumably, the 
entropic gain provided by the release of water to bulk solvent upon enzyme-inhibitor complexation 
is offset by the conformational entropic cost of side chain binding in the D-cleft. Even so, these 
structures will inform the future design of alternative D-substituents for an α,α-disubstituted ABH 
inhibitor. For example, a bulkier side chain substituent might thwart the molecular disorder 
observed for the D-side chain of ABHDP. The three-dimensional contour and chemical nature of 
the D-cleft region can vary in arginases from different species, and it is conceivable that 
interactions of inhibitor substituents in this region could contribute to isozyme- or species-
selectivity.   
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Chapter 3: Structure and Function Study of Trypanosoma cruzi 
Formiminoglutamase 
This work is published in Hai, Y., Dugery, R. J., Healy, D., & Christianson, D. W. Biochemistry 
2013, 52 (51), 9294-9309;  
Adapted with permission from Hai, Y., Dugery, R. J., Healy, D., & Christianson, D. W. 
Biochemistry 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical Society.  
3.1 Introduction 
L-Histidine catabolism in prokaryotes and eukaryotes is achieved through one of six 
histidine utilization pathways as currently outlined in the MetaCyc database (Caspi et al., 2012). 
These pathways are classified by the enzyme that catalyzes the first step, which is either a 
histidase (pathways I-III and VI) or a transaminase (pathways IV and V) (Bender, D.A., 2012). In 
the transaminase pathways, L-histidine is converted into imidazolylpyruvate by either histidine-2-
oxoglutarate aminotransferase in prokaryotes (pathway IV) (Hedegaard et al., 1966), or histidine-
pyruvate aminotransferase in eukaryotes (pathway V) (Emes and Hassall, 1973), which is then 
reduced to imidazolyllactate (Cortese et al., 1968). In the histidase pathways, L-histidine is 
converted into urocanic acid and ammonia (Tabor et al., 1952; Mehler and Tabor, 1953). 
Pathways I-III then proceed in a similar manner through the key intermediate N-formimino-L-
glutamate (also known as L-formiminoglutamic acid), which is subsequently degraded to form L-
glutamate by a different enzyme in each pathway (Figure 3.1). Pathway III is mainly found in 
mammals (Miller and Waelsch, 1957), whereas pathways I and II are widely conserved in 
bacteria and operated by the hut gene (Bender, R.A., 2012).
 
In pathway VI, 4-imidazolone-5-
propionate, the intermediate shared with pathway I-III, is enzymatically oxidized into L-hydantoin-
5-propionate (Brown and Kies, 1959; Hassall and Greenberg, 1968), which is further processed in 
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some bacteria by hydrolysis to form N-carbamyl-L-glutamate and thence L-glutamate (Hassall and 
Greenberg, 1963). 
Formiminoglutamase (FIGase, also known as N-formimino-L-glutamate 
formiminohydrolase), catalyzes the final step in histidine utilization pathway I by catalyzing the 
hydrolysis of the imino group of N-formimino-L-glutamate to form L-glutamate and formamide 
(Figure 3.1). Two formiminoglutamase crystal structures have been determined by structural 
genomics consortia and are currently available in the Protein Data Bank (www.rcsb.org) and 
these structures confirm the conserved arginase fold and active site. Surprisingly, however, 
neither of these structures appears to be that of a functional metalloenzyme. The structure of 
formiminoglutamase from Vibrio cholerae (PDB entry 1XFK) does not contain bound metal ions, 
and the structure of formiminoglutamase from Bacilus subtilis (PDB entry 3M1R) contains a 
binuclear calcium cluster instead of the binuclear manganese cluster expected for members of 
the arginase/ureohydrolase family. Additionally, the crystal structure of a protein of undetermined 
function annotated as "arginase superfamily protein" from Trypanosoma cruzi was determined by 
the Structural Genomics of Pathogenic Protozoa Consortium (PDB entry 2A0M), but this protein 
does not contain bound metal ions either. However, given that (1) this protein adopts the classic 
α/β arginase fold, (2) this protein exhibits 24% sequence identity with formiminoglutamase from 
B. subtilis, and (3) this protein contains conserved residues for Mn
2+
 coordination, we 
hypothesized that this protein is in fact T. cruzi formiminoglutamase (TcFIGase) crystallized in its 
metal-free state at pH 4.0. It should be noted that although atomic coordinates for these 
formiminoglutamase crystal structures are available in the Protein Data Bank, formal research 
papers describing the structure determinations have not been published. 
Intriguingly, while members of the arginase/ureohydrolase family typically contain two 
conserved histidine and four conserved aspartate ligands to the binuclear manganese cluster, 
one of the histidine ligands is substituted by an asparagine ligand in formiminoglutamase from B. 
subtilis and TcFIGase. Although it might not be clear from the available crystal structures whether  
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Figure 3.1: Pathways I-III for L-histidine catabolism. Formiminoglutamase catalyzes the final step 
in histidine utilization pathway I. Adapted with permission from Hai, Y., Dugery, R. J., Healy, D., & 
Christianson, D. W. Biochemistry 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical 
Society.  
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formiminoglutamases are actually Ca
2+
-dependent enzymes, or whether they are 
metalloenzymes at all, formiminoglutamases from Aerobacter aerogenes and B. subtilis exhibit 
maximal activity in the presence of Mn
2+ 
(Lund and Magasanik, 1965; Kaminskas, 1970). Thus, 
despite the substitution of the putative metal ligand in TcFIGase, we hypothesized that it, too, is a 
manganese metalloenzyme.
 
Now we demonstrate that TcFIGase exhibits maximal catalytic activity in the presence of 
Mn
2+
, thereby confirming that it is a manganese metalloenzyme, and we report the crystal 
structure of TcFIGase containing an intact binuclear manganese cluster. We also report the 
crystal structure of N114H TcFIGase, in which the mutation restores a histidine Mn
2+
 ligand as 
found in arginase and related ureohydrolases. Based on comparisons between TcFIGase and 
arginase, we propose a catalytic mechanism for the hydrolysis of formiminoglutamate. Finally, we 
report the crystal structure of TcFIGase in its oxidized form (TcFIGaseox), bearing a disulfide 
linkage between active site residues C35 and C242, and we show that TcFIGaseox exhibits nearly 
full catalytic activity despite structural changes triggered in the active site by disulfide bond 
formation. 
3.2 Materials and Methods 
3.2.1 Materials   
Dipicolinic acid, manganese(II) chloride tetrahydrate (≥99%), cobalt chloride hexahydrate 
(>99%), nickel chloride hexahydrate, L-arginine, α-isonitrosopropiophenone, 3-guanidinopropionic 
acid, 4-guanidinobuytric acid, agmatine sulfate salt, L-2-amino-3-guanidinopropionic acid 
hydrochloride, Nα-acetyl-L-arginine, L-homoarginine hydrochloride, potassium ferricyanide and 
sodium nitroprusside dihydrate were purchased from Sigma. Magnesium chloride hexahydrate 
(99%) was purchased from Acros Organics. Tris(2-carboxyethyl)phosphine hydrochloride (98%, 
TCEP) was purchased from Gold Biotechnology. α-Guanidinoglutaric acid was purchased from 
Cayman Chemical. 50% (w/v) PEG 3350 solution, 100% PEG 300 solution, and 3.4 M sodium 
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malonate solution were purchased from Hampton Research. Chelex 100 resin (molecular biology 
grade) was purchased from Bio-Rad. L-Formiminoglutamic acid was purchased from Dalton 
Pharma Services (Canada). Ethylenediaminetetraacetic acid tetrasodium salt (99.5%), zinc 
chloride (99.1%), ferrous chloride tetrahydrate, and all other chemicals were purchased from 
Fisher Scientific.  
3.2.2 Mutagenesis, expression and purification of TcFIGase  
The pET plasmid encoding wild-type T. cruzi formiminoglutamase (TcFIGase) with an N-
terminal His6-tag was kindly provided by Dr. Ethan Merritt of the Structural Genomics of 
Pathogenic Protozoa Consortium at the University of Washington. Four mutants were generated 
using the QuickChange method (Stratagene) with the wild-type gene as template and the 
following primers (underlined bases indicate mutated codons): N114H, 5΄-CCT TTT GTG ATT 
GGC GGA GGA CAC GAC CAG TCG GC-3΄ (sense), 5΄-GCC GAC TGG TCG TGT CCT CCG 
CCA ATC ACA AAA GG-3΄ (antisense); R144K, 5΄-GGA TGT TAA ACC ACC TCT GTC GG-3΄ 
(sense), 5΄- CCG ACA GAG GTG GTT TAA CAT CC-3΄ (antisense); R144E, 5΄- GGA TGT TGA 
ACC ACC TCT GTC GG-3΄ (sense), 5΄-CCG ACA GAG GTG GTT CAA CAT CC-3΄ (antisense); 
R144A, 5΄-CTC ATT TGG ATG TTG CCC CAC CTC TGT CGG-3΄ (sense), 5΄-CCG ACA GAG 
GTG GGG CAA CAT CCA AAT GAG-3΄ (antisense). Mutations were verified by DNA sequencing. 
TcFIGase was overexpressed in E. coli BL21(DE3) cells in Lysogeny-Broth (LB) media or M9 
minimal media (1x M9 salts, 10% casamino acids, 20 mM D-(+)-glucose, 2 mM MgSO4, 100 μM 
CaCl2) supplemented with 100 mg/L ampicillin. Expression was induced by 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) (Carbosynth) for 16 hours at 22 °C when OD600 reached 0.6-0.7. 
For minimal media growth, 100 μM MnCl2 was added into the culture 30 minutes before induction. 
Cells were harvested by centrifugation at 5000 g for 10 minutes. The cell pellet was suspended in 
50 mL of buffer A (50 mM K2HPO4 (pH 8.0), 300 mM NaCl, 10% (v/v) glycerol, 1 mM TCEP). 
Cells were lysed by sonication on ice using a Sonifer 450 (Branson) and the cell lysate was 
further incubated with 5 μg/mL DNAse I (Sigma) and 6 μg/mL RNAse A (Roche Applied Science) 
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at 4 °C for 30 min. Cellular debris was removed by centrifugation at 26,895 g for 1 hour. The clear 
supernatant was applied to a Talon column (Clontech Laboratories, Mountain View, CA) pre-
equilibrated with buffer A. TcFIGase was purified with a 200 mL gradient from 10 mM imidazole to 
300 mM imidazole. Pooled fractions were dialyzed into buffer B (20 mM K2HPO4 (pH 8.0), 2 mM 
β-mercaptoethanol (BME) and 100 μM MnCl2) and subsequently loaded onto a 10 mL Q-HP 
anion exchange column (GE Healthcare). Protein was eluted with a 500 mL gradient from 0 mM 
NaCl to 800 mM NaCl. Estimated purity of protein samples was > 95% based on SDS-PAGE. 
Fractions containing TcFIGase were combined and concentrated using Amicon ultra filter units 
(Millipore) with 10 kDa molecular weight-cutoff followed by buffer exchange into buffer C (50 mM 
bicine (pH 8.5), 100 μM MnCl2, 1 mM TCEP) using PD-10 columns (GE Healthcare). Mutants 
were expressed in minimal media and purified as described for the wild-type enzyme. Oxidized 
TcFIGase (TcFIGaseox, bearing a disulfide linkage between C35 and C242) was serendipitously 
obtained by purifying the enzyme in the absence of reducing agent.  
Attempts to use metal chelators such as EDTA and dipicolinic acid (DPA) to remove 
metal ions from wild-type enzyme were not successful. Apo-TcFIGase was prepared by gradually 
lowering the pH to 4.2 through stepwise dialysis: 20 mM N-(2-hydroxyethyl)piperazine-N'-(3-
propanesulfonic acid) was used in the pH range 6.5-7.5; 20 mM 2-(N-morpholino)ethanesulfonic 
acid was used in the pH range 5.5-6.5; and 20 mM sodium acetate was used in the pH range 4.2-
5.5. Routinely, 5 mM BME was included in all dialysis buffers to prevent oxidation. Metal-depleted 
TcFIGase was then buffer-exchanged into Chelex resin pretreated buffer D (10 mM Tris-HCl (pH 
8.0), 1 mM TCEP) by dialysis. Apo-TcFIGase was concentrated to 30 mg/mL, flash frozen by 
liquid nitrogen and stored at -80 °C. Enzyme concentrations were determined by Bradford assay. 
Metal content was quantified by inductively coupled plasma-atomic emission spectrometry (ICP-
AES) at the Center for Applied Isotope Studies, University of Georgia (Athens, GA). Samples 
were extensively dialyzed against 10 mM bicine (pH 8.5) to remove free trace metal ions prior to 
analysis by ICP-AES. 
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3.2.3 Activity Assays  
Ureohydrolase activity was monitored spectrophotometrically based on the formation of 
urea. Briefly, 20 mM guanidino substrate was added to a solution of 50 mM 4-(2-
hydroxyethyl)piperazine-1-propanesulfonic acid (pH 8.5), and the reaction was initiated by adding 
100 µM TcFIGase in a total volume of 200 µL. The reaction was terminated after 1 hour using 30 
µL of a 3:1 (v/v) concentrated acid/dye solution [H2SO4:H3PO4:H2O (1:3:1 v/v/v)/245 mM α-
isonitrosopropiophenone in ethanol]. Samples were heated to 90 °C for 1 h in a thermocycler to 
ensure complete reaction of urea with the dye. Absorbance was measured at λ = 550 nm using 
an Agilent HP 8452A Diode Array Spectrophotometer. L-Formiminoglutamase activity was 
monitored colorimetrically at 22 °C based on the protocol developed by Lund and Magasanik. 
Typically, 0.2 mL assay buffer [20 mM 1,3-bis(tris(hydroxymethyl)methylamino)propane, 20 mM 
N-cyclohexyl-3-aminopropanesulfonic acid (pH 9.5)] containing enzyme (5-100 μM) was initiated 
by the addition of substrate L-formiminoglutamic acid (2-20 mM). The reaction was stopped by 
addition of 0.8 mL saturated sodium borate solution, followed by 0.2 mL of the chromophore 
reagent (4 g of sodium nitroprusside, 4 g of potassium ferricyanide, and 4 g of NaOH in 140 mL 
H2O). Absorbance was measured at λ = 485 nm after 30 min. All measurements were made in 
triplicate. Kinetic constants were calculated by fitting initial velocity data to either the Michaelis-
Menton equation or the Hill equation using OriginPro 8.0 and are reported as mean ± standard 
deviation. Metallo-substituted enzyme was prepared by incubating the apoenzyme with metal 
ions (2 mM MgCl2, CaCl2, MnCl2, CoCl2, NiCl2, CuCl2, ZnCl2, FeCl2, or FeCl3) in 50 mM bicine (pH 
8.5) and 2 mM TCEP on ice for at least one hour prior to dilution into assay buffer. All work with 
Fe
2+
 was performed anaerobically under a nitrogen atmosphere in an AtmosBag (Sigma). 
Dissolved oxygen was removed from ddH2O by sparging with N2.    
3.2.4 Crystallography  
Crystals of TcFIGase were prepared by the hanging drop vapor diffusion method at 21 
°C. For TcFIGaseox and N114H TcFIGase, a 4 μL drop of protein solution [10 mg/mL protein, 50 
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mM bicine (pH 8.5), 100 μM MnCl2] was mixed with a 4 μL drop of precipitant solution [25% PEG 
3350, 0.1 M sodium acetate (pH 4.6)] on a siliconized cover slide and equilibrated against a 500 
μL reservoir of precipitant solution. For wild-type TcFIGase, a 4 μL drop of protein solution [10 
mg/mL protein, 50 mM bicine (pH 8.5), 100 μM MnCl2, 1 mM TCEP] was mixed with a 4 μL drop 
of precipitant solution [31% PEG 300, 0.1 M sodium acetate (pH 4.9)] on a siliconized cover slide 
and equilibrated against a 500 μL reservoir of precipitant solution. Crystals first appeared after 
two days and grew to maximum size in one week. To obtain crystalline metal-bound enzyme, 
crystals of the apoenzyme were successively soaked with 5 – 20 mM MnCl2 in the corresponding 
precipitant solution with gradually increasing pH (in the pH range 6.0 – 8.5, 0.1 M sodium acetate 
was replaced by 0.1 M sodium malonate). Crystals were flash-cooled after transfer to a 
cryoprotectant solution consisting of the soaking solution augmented with 15% – 20% glycerol. 
Diffraction data were collected on our home X-ray source (Rigaku IV++ image plate area detector 
mounted on a Rigaku RU200HB rotating anode X-ray generator) and on beamline X29 at the 
National Synchrotron Light Source (NSLS, Brookhaven National Laboratory, New York). 
Diffraction data were integrated and scaled with HKL2000 (Otwinowski and Minor, 1997).  
In comparison with the structure of the arginase superfamily protein deposited in the PDB 
by the Structural Genomics of Pathogenic Protozoa Consortium (PDB entry 2A0M), crystals of 
N114H Mn
2+
2-TcFIGase and Mn
2+
2-TcFIGaseox (pH 6.0) similarly belonged to space group H3 
and exhibited nearly identical unit cell parameters; crystals of Mn
2+
2-TcFIGase were similarly 
isomorphous except for a c-axis doubled in length and crystals of apo-TcFIGaseox and Mn
2+
2-
TcFIGaseox (pH 8.5) were similarly isomorphous except for partial twinning. The doubled unit cell 
volume indicated that the asymmetric unit contained two monomers. A significant off-origin peak 
(84% of the origin peak) in the Patterson function (calculated with phenix.xtriage) (Adams et al., 
2010) suggested that the two monomers were related by pseudotranslational symmetry. 
However, satisfactory solutions were generated for the rotation and translation functions in 
molecular replacement calculations, and structure refinement proceeded smoothly. Data 
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collection and reduction statistics are listed in Table 1. Structures were determined by molecular 
replacement using the program PHASER
 
(McCoy et al., 2005) with the coordinates of wild-type 
apo-TcFIGase less ligand and solvent molecule as a search model. The degree of crystal 
twinning was assessed using the program phenix.xtriage. Iterative cycles of refinement and 
model building were performed using PHENIX and COOT (Emsley et al., 2010). Solvent 
molecules were added in the final stages of refinement for each structure. Disordered segments 
not included in the final models include the N-terminus (M1-T5 in Mn
2+
2-TcFIGase and apo-
TcFIGaseox; M1-R4 in N114H Mn
2+
2-TcFIGase and Mn
2+
2-TcFIGaseox (pH 6.0 and 8.5)), the C-
terminus (K303-N308 in all structures), L147-G155 in apo-TcFIGaseox, P146-S154 in Mn
2+
2-
TcFIGaseox at pH 6.0, and P145-S154 in Mn
2+
2-TcFIGaseox at pH 8.5. The side chain of active 
site residue C242 is disordered such that its Sγ atom occupies two positions in the final models of 
Mn
2+
2-TcFIGase and N114H Mn
2+
2-TcFIGase. Bijvoet difference Fourier maps were calculated 
with PHENIX. The quality of each final model was verified with PROCHECK (Laskowski et al., 
1993) and secondary structure was defined with DSSP (Kabsch and Sander, 1983). Refinement 
statistics are reported in Table 3.1.   
3.3 Results  
3.3.1 Crystal structure of TcFIGase  
As previously found for the protein of undetermined function annotated as "arginase 
superfamily protein" from Trypanosoma cruzi by the Structural Genomics of Pathogenic Protozoa 
Consortium (PDB entry 2A0M), TcFIGase adopts the classic arginase-deacetylase fold (Figure 
3.2a). Helices η2, A1, B, C, D, and E reside on one face and helices η1, A2, η3, F1, F2, η4, G 
and H reside on the other face of the central β-sheet. Two additional β-strands (βA and βB) are 
inserted between helix A2 and strand β2 to form a protruding β-hairpin, which contributes to the 
interface between monomers. The G111-G112 cis-peptide bond, which is contained in the widely- 
conserved GGDH motif in the ureohydrolase family, is also conserved in TcFIGase and lies at the 
edge of strand β3. This cis-peptide bond is believed to be important for positioning active site  
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Table 3.1:  Data Collection and Refinement Statistics of TcFIGase. 
Enzyme Structure Mn
2+
2-TcFIGase 
  (pH 8.0) 
Mn
2+
2-N114H 
TcFIGase 
(pH 7.5) 
Apo-
TcFIGaseox  
(pH 4.6) 
Mn
2+
2-
TcFIGaseox  
(pH 6.0) 
Mn
2+
2-
TcFIGaseox  
(pH 8.5) 
Data Collection 
Wavelength (Å) 1.5418 1.075 1.075 1.5418 1.5418 
Resolution limits (Å) 50.0-1.85 50.0-1.80 50.0-1.53 50.0-1.80 50.0-1.52 
No. total/unique 
reflections 
108650 
/44906  
156011 
/24658 
187951 
/40029 
77546 
/24341 
144418 
/40463 
Space group R3:H R3:H R3:H R3:H R3:H 
a, b, c (Å) 
 
128.9, 128.9, 
85.4  
129.4, 129.4, 
42.5  
129.4, 129.4, 
42.6 
129.5, 129.5,  
42.7 
129.7, 
129.7, 42.5 
Completeness (%) 99.2 (98.8) 100 (100) 99.9 (100) 98.2 (97.3) 98.4 (95.1) 
I/σI
  
14.2 (2.0) 19.0 (2.9) 17.3 (2.7) 10.0 (2.3) 14.4 (2.7) 
Rsym
 
0.059 (0.438) 0.088 (0.754) 0.077 (0.527) 0.117 (0.466) 0.077 
(0.422) 
Redundancy
 
2.5 (2.4) 6.3 (6.1) 4.7 (4.5) 3.2 (3.1) 3.6 (3.2) 
Refinement 
No. of reflections used in 
refinement/test set 
42190 (2123) 23858/1211 39028/1994 23603/1207 39990/2050 
Rwork/Rfree (%) 
 
18.7/21.7 
(24.0/30.8) 
18.8/22.1 
(24.6/28.2) 
13.4/16.1 
(22.6/25.5) 
17.1/21.0 
(21.7/25.6) 
14.6/16.2 
(40.0/46.1) 
Twining fraction
 
0 0 0.25 0 0.42 
Twin law N/A N/A h, -h-k, -l N/A h, -h-k, -l 
No. of atoms
 
     
protein 4571 2288 2231 2235 2212 
solvent 
 
265 93 160 178 122 
Mn
2+ 
4 2 0 2 2 
glycerol  6 0 0 0 0 
Root-mean-square 
deviation 
 
bonds (Å) 0.006 0.009 0.008 0.008 0.008 
angles (deg) 0.9 1.1 1.1 1.1 1.2 
Average B factor (Å
2
)  
main chain 27 35 16 24 21 
side chain 29 37 20 27 23 
solvent 32 38 24 30 24 
metal ions 26 29 N/A 23 19 
Ramachandran plot (%)  
allowed 91.1% 89.8% 91.4% 90.7% 90.2% 
additionally allowed 8.9% 10.2% 8.2% 9.3% 9.3% 
generously allowed 0.0% 0.0% 0.4% 0.0% 0.4% 
disallowed 0.0% 0.0% 0.0% 0.0% 0.0% 
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Figure 3.2: (a) Stereoview of the Mn
2+
2-TcFIGase monomer. Secondary structure elements are 
defined by DSSP;
30
 α-helices are red and β-strands are blue (β strands 1-8) or purple (β-strands 
βA and βB). The Mn
2+
 ions are shown as white spheres. (b) Top view (left) and side view (right) of 
the Mn
2+
2-TcFIGase trimer. Reprinted with permission from Hai, Y., Dugery, R. J., Healy, D., & 
Christianson, D. W. Biochemistry 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical 
Society. 
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residues N114 and E277, known to be important for catalytic function as implicated in other 
ureohydrolases (Dowling and Di Costanzo, et al., 2008). Similar to eukaryotic arginases,
 
TcFIGase adopts a trimeric quaternary structure (Figure 3.2). The buried solvent accessible 
surface area is 1884 Å
2
 between each monomer of the assembled homotrimer as determined by 
PISA.
 
In contrast with the eukaryotic arginases, in which the S-shaped C-terminal polypeptide 
dominates intermonomer contacts in the trimer, the N-terminus of TcFIGase makes significant 
intermonomer interactions, which is more similar to trimer assembly in proclavaminic acid 
amidinohydrolase, agmatinase, guanidinobutyrase, and guanidinopropionase. 
The crystallization of TcFIGase exclusively yields the metal-free apoenzyme due to the 
fact that it crystallizes only at very low pH (pH < 5). This accounts for the complete lack of active 
site metal ions in the 1.6 Å resolution crystal structure determined by the Structural Genomics of 
Pathogenic Protozoa Consortium and the resultant misannotation of the protein (PDB entry 
2A0M). To obtain the crystal structure of the metal-bound enzyme, crystals of wild-type TcFIGase 
were soaked with 5 mM MnCl2 at pH 8.0. The binding of two Mn
2+ 
ions in the active site was 
confirmed by two strong peaks in the Bijvoet difference Fourier map shown in Figure 3.3. Each 
Mn
2+
 ion is coordinated with octahedral or distorted-octahedral geometry: the Mn
2+
A ion is 
coordinated by N114, D138, D142, D228, and two solvent molecules, one of which bridges Mn
2+
A 
and Mn
2+
B and donates a hydrogen bond to D142; the Mn
2+
B ion is coordinated by H140, D228, 
D138, D230, and the metal-bridging solvent molecule. Metal binding does not cause any global 
conformational changes, and the root-mean-square (r.m.s.) deviation between apo-TcFIGase and 
Mn
2+
2-TcFIGase is 0.18 Å for 278 Cα atoms as calculated with MacPymol.
 
However, metal 
binding triggers some local structural changes in the active site, in that metal ligands undergo 
varying degrees of conformational changes to enable inner-sphere coordination of Mn
2+
A and 
Mn
2+
B (Figure 3.3). In contrast, relatively minimal conformational changes accompany metal 
binding to the metal-free ureohydrolases agmatinase from D. radiodurans and human arginase I. 
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It is possible, however, that the alternative conformations observed for metal ligands in apo-
TcFIGase result from the low pH of the apoenzyme crystal structure determination. 
Interestingly, the conformation of N114 in Mn
2+
2-TcFIGase is comparable to that of N101 
in the 2.5 Å resolution crystal structure of H101N rat arginase I (PDB entry 1P8P, which updated 
a previous structure determination (PDB entry 3RLA) in which the metal ligand was not 
characterized by well-defined electron density (Scolnick et al., 1997). The superposition of Mn
2+
2-
TcFIGase and H101N rat arginase I reveals almost identical metal coordination geometries, with 
the exception that in H101N rat arginase I the Mn
2+
A site is only half-occupied and non-protein 
ligands (solvent molecules) are not observed, probably due to the lower resolution of the structure 
determination (Figure 3.3). The Mn
2+
A-Mn
2+
B separation of 3.2 Å in Mn
2+
2-TcFIGase is 
comparable to that observed in H101N rat arginase I (3.1 Å) as well as the Mn
2+
A-Mn
2+
B 
separations generally observed in wild-type ureohydrolases.
 
In Mn
2+
2-TcFIGase, the Mn
2+
A ion is 
coordinated by N114 Oδ with a separation of 2.2 Å; in H101N rat arginase I, the corresponding 
N101 Oδ---Mn
2+
A separation is 2.1 Å. Additionally, "second shell" interactions are similar in both 
enzymes. In TcFIGase, the N114 Nδ-H groups donates hydrogen bonds to the side chain 
hydroxyl group of S117 and a water molecule; in turn, this water molecule hydrogen bonds with 
the side chains of S226 and N136. In H101N rat arginase I, the N101 Nδ-H group donates a 
hydrogen bond to a water molecule, which in turn hydrogen bonds with S230. 
To restore the characteristic metal binding motif found in most binuclear metalloureo-
hydrolases, i.e., to engineer the metal cluster of TcFIGase so as to resemble that of arginase, 
N114H TcFIGase was prepared. The 1.80 Å-resolution X-ray crystal structure of this mutant 
reveals a nearly fully occupied binuclear manganese cluster (Mn
2+
A occupancy = 75%, Mn
2+
B 
occupancy = 100%). The side chain Nδ atom of H114 coordinates to Mn
2+
A with a separation of 
2.2 Å, and the Nε-H group is a bifurcated hydrogen bond donor to the side chain hydroxyl groups 
of S117 and S226. In rat arginase I and human arginase I, a single serine residue, S230, accepts  
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Figure 3.3: (a) Bijvoet difference Fourier map (grey, contoured at 5σ) of Mn
2+
 ions and simulated 
annealing omit map (blue, contoured at 4σ) of Mn
2+
-bound solvent molecules in the active site of 
Mn
2+
2-TcFIGase (pH 8.0). Metal coordination and hydrogen bond interactions are represented by 
blue and green dashed lines, respectively. Note that the side chain thiol group of C242 is 
disordered between two positions. (b) Superposition of N114H Mn
2+
2-TcFIGase (white) and wild-
type Mn
2+
2-TcFIGase (cyan). Reprinted with permission from Hai, Y., Dugery, R. J., Healy, D., & 
Christianson, D. W. Biochemistry, 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical 
Society. 
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 a hydrogen bond from the Nδ-H group of the corresponding Mn
2+
A ligand, H101 (Di Costanzo et 
al., 2007). The manganese coordination polyhedra are otherwise unchanged compared with wild-
type TcFIGase (Figure 3.3) and resemble those observed in other unliganded ureohydrolases. 
When apo-TcFIGase is prepared and crystallized in the absence of reducing agents, the 
1.53 Å-resolution structure reveals the formation of a disulfide linkage between C35 and C242 in 
the active site. The metal-bound form of this oxidized protein, Mn
2+
2-TcFIGaseox, is prepared by 
soaking apoenzyme crystals in a buffer solution containing 20 mM MnCl2. The 1.8 Å-resolution 
crystal structure of metal-bound TcFIGaseox determined at pH 6.0 reveals one strong peak and 
one weak peak in the Bijvoet difference Fourier map – the Mn
2+
B site is fully occupied and the 
Mn
2+
A site is 40% occupied. The overall structure of metal-bound TcFIGaseox is generally similar 
to that of Mn
2+
2-TcFIGase, with an r.m.s. deviation of 0.13 Å for 241 Cα atoms. However, two 
major conformational changes are triggered by disulfide bond formation (Figure 3.4): first, helix 
A1 (E33-R37, which contains C35 in the disulfide linkage) and its flanking loops shift ~4 Å toward 
the active site; second, the surface loop P146-S154 becomes disordered. As a result of these 
conformational changes, the original entrance to the active site is partially blocked by helix A1 
(especially by N38 and the C35-C242 disulfide linkage). However, two possible alternative 
entrances are formed as calculated with the program MOLE (Sehnal et al., 2013): one is adjacent 
to the original entrance and results from the shift of R144, and the second results from the 
disorder of the P146-S154 loop (Figure 3.4). Comparison of the atomic displacement parameters 
of Mn
2+
2-TcFIGase (pH 8.0) and Mn
2+
2-TcFIGaseox (pH 8.5) reveals that loop P146-S154 and 
helix A1 exhibit significant flexibility in both structures. Therefore, disulfide bond formation 
appears to be a fortuitous consequence of this flexibility. Notably, the binuclear metal cluster is 
influenced by disulfide bond formation in TcFIGox (Figure 3.5). Although the Mn
2+
A-Mn
2+
B 
separation remains at 3.1 Å and the N114 Oδ atom remains coordinated to Mn
2+
A, the occupancy 
of Mn
2+
A is reduced to 40%. Additionally, the second water molecule coordinated to Mn
2+
A as the 
sixth ligand in the structure of Mn
2+
2-TcFIGase is sterically displaced by the Nδ-H group of N114, 
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Figure 3.4: (a) Structural changes in active site access triggered by disulfide bond formation in 
Mn
2+
2-TcFIGase. The original active site entrance is indicated by a green surface (left image). 
Following disulfide bond formation in Mn
2+
2-TcFIGaseox, this entrance becomes constricted and 
two new entrances (blue and red surfaces) become accessible (right image). Selected residues 
lining the entrance surface are shown as stick figures and Mn
2+
 ions are shown as pink spheres. 
Active site entrance surfaces were calculated using MOLE. (b) Superposition of the Mn
2+
2-
TcFIGaseox monomer (pH 6.0, purple) and the Mn
2+
2-TcFIGase monomer (white); dotted lines 
indicate disordered polypeptide segments. Major conformational changes occur for helix A1 (dark 
pink (oxidized state), cyan (reduced state)) and the P146-S154 loop in response to disulfide bond 
formation. Reprinted with permission from Hai, Y., Dugery, R. J., Healy, D., & Christianson, D. W. 
Biochemistry 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical Society. 
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which donates a hydrogen bond to the metal-bridging solvent molecule; while the N114 Nδ atom 
is 3.0 Å away from E273, it is poorly oriented for hydrogen bond formation. The Nδ atom of N114 
is also 2.5 Å away from Mn
2+
A, which is too long for an inner-sphere coordination interaction that 
would also require the unlikely ionization of the carboxamide side chain.  
To increase the occupancy of Mn
2+
A, crystals of apo-TcFIGaseox were soaked in a buffer 
solution containing 20 mM MnCl2 at pH 8.5. However, the resulting crystal structure reveals that 
although Mn
2+
B remains fully bound, Mn
2+
A binds with only 30% occupancy. Intriguingly, lower 
Mn
2+
A occupancy is accompanied by the conformational change of former Mn
2+
A ligand D142, 
which swings away from the metal site to accept hydrogen bonds from N38 and R144. 
Consequently, a solvent molecule coordinates to Mn
2+
A at the site formerly occupied by D142. 
The flexibility of D142 could be mediated in part by its proximity to the highly flexible P146-S154 
loop (Figure 3.5). Other changes observed in the structure include a shorter Mn
2+
A-Mn
2+
B 
separation of 2.9 Å, and asymmetric metal coordination by the bridging solvent molecule with 
Mn
2+
A-O and Mn
2+
B-O separations of 2.1 Å and 2.4 Å, respectively. The N114 Oδ---Mn
2+
A 
interaction is weakened with a separation of 2.6 Å, which is too long to be considered inner-
sphere metal coordination. 
3.3.2 Metal content analysis 
The metal ion content of TcFIGase was measured using inductively coupled plasma-
atomic emission spectrometry (ICP-AES) (Table 3.2). Both wild-type TcFIGase and N114H 
TcFIGase as expressed and purified from LB media exhibit heterogeneity in terms of their metal 
ion content – each contains nearly one equivalent Mn
2+
 per monomer, but wild-type TcFIGase is 
contaminated with Fe
2+
 and N114H TcFIGase is contaminated with Co
2+
. To minimize the 
contamination by adventitious divalent metal ions, expression of wild-type TcFIGase from minimal 
media supplemented with MnCl2 results in the incorporation of only one equivalent of Mn
2+
 into 
each monomer. Notably, ICP-AES analysis suggests that only one site in the binuclear metal  
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Figure 3.5: (a) Close-up view of active site from the superposition of Mn
2+
2-TcFIGaseox (C = 
white) with Mn
2+
2-TcFIGase (C = cyan). Metal coordination and hydrogen bond interactions in 
Mn
2+
2-TcFIGaseox are represented by red and green dashed lines, respectively (b) Cartoon 
representation of Mn
2+
2-TcFIGase (pH 8.0, left) and Mn
2+
2-TcFIGaseox (pH 8.5, right) showing the 
atomic displacement parameters coded by thickness of the main chain and a color gradient from 
blue (low disorder) to red (high disorder). The red dotted line indicates the disordered P146-S154 
loop. Reprinted with permission from Hai, Y., Dugery, R. J., Healy, D., & Christianson, D. W. 
Biochemistry, 2013, 52 (51), 9294-9309. Copyright 2013 American Chemical Society. 
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cluster binds Mn
2+
 tightly in solution. Based on the crystallographic studies outlined in the 
previous section, it is likely that this corresponds to the Mn
2+
B ion; it is possible that the Mn
2+
A ion 
is bound more weakly than the Mn
2+
B ion under physiological conditions.  
3.3.3 Enzyme kinetics 
To evaluate the possibility that TcFIGase might exhibit ureohydrolase activity, given its 
structural similarity to arginase and other related ureohydrolases, different guanidinium 
derivatives were tested as potential substrates using the colorimetric ureohydrolase assay 
developed by Archibald. However, no urea formation was detected in assays that would have 
detected 0.4 micromoles of urea formed per minute with the following substrates: L-arginine, 
agmatine, L-acetylarginine, α-guanidinoglutaric acid, L-homoarginine, L-2-amino-3-guanidino-
propionic acid, 3-guanidinopropionic acid, and 4-guanidinobutyric acid. Instead, TcFIGase 
exclusively exhibits formiminoglutamate activity as measured using the colorimetric L-
formiminoglutamate assay developed by Lund and Magasanik (Table 3.3). Wild-type TcFIGase 
expressed and purified from LB media displays the following steady-state kinetic parameters: kcat 
= 200 ± 20 s
-1
,
 
KM = 40 ± 10 mM, and kcat/KM = 5200 ± 200 M
-1
s
-1
. The catalytic efficiency (kcat/KM) 
is approximately 2-fold higher than that of metal-free wild-type TcFIGase reconstituted exclusively 
with Mn
2+
, which exhibits kcat = 110 ± 20 s
-1
,
 
KM = 50 ± 10 mM, and kcat/KM = 2300 ± 300 M
-1
s
-1
. 
While the KM value measured for TcFIGase is somewhat high, it is comparable to that measured 
for the formiminoglutamases from Aerobacter aerogenes (KM = 40 mM at pH 8.5) (Lund and 
Magasanik, 1965) and Bacillus subtilis (KM = 39 mM at pH 7.4) (Kaminskas et al., 1970). These 
values are, however, higher than the KM value of 4.3 mM measured for formiminoglutamase from 
Pseudomonas aeruginosa (Marti-Arbona et al., 2006). Nevertheless, these results confirm that 
the protein of undetermined function annotated as "arginase superfamily protein" from 
Trypanosoma cruzi by the Structural Genomics of Pathogenic Protozoa Consortium (PDB entry 
2A0M) is in fact a formiminoglutamase. The restoration of an authentic, "arginase-like" Mn
2+
A 
coordination polyhedron does not significantly affect catalysis: N114H TcFIGase exhibits 65%  
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Table 3.2: Metal content analysis of TcFIGase.  
 
 
Metal : protein molar ratio 
Mn Fe Co Ni Cu Zn Mg Ca 
Wild-type TcFIGase 0.84 0.22 0.04 0.003 0.008 0.04 0.005 0.01 
N114H TcFIGase 0.85 0.03 0.24 0.004 0.004 0.03 0.08 0.03 
Wild-type TcFIGase after 
treatment with metal ion 
chelators
a 
0.80 0.31 0.05 0.002 0.005 0.01 0.003 0.04 
Wild-type TcFIGase,  pH 4.2
b 
0.11 0.20 0.04 0.0002 0.002 0.008  n.d.
c 
0.01 
Wild-type TcFIGaseox
 
0.84 0.14 0.08 0.0014 0.004 0.02 n.d. 0.004 
Wild-type TcFIGase, minimal 
media + MnCl2
d 
1.05 0.02 0.03 0.0004 n.d. 0.03 0.10 0.001 
a
 Treatment with 55 mM DPA and 80 mM EDTA for 24 hours; chelators then dialyzed out prior to analysis.  
b 
 The pH was gradually lowered to 4.2 by dialysis and then raised to 8.0 for ICP-AES.   
c
 n.d., not detected. 
d 
Protein expressed and purified from minimal media supplemented with 100 μM MnCl2 upon induction. 
 
 
 
Table 3.3: Steady-State Kinetics of TcFIGase at pH 9.5.  
Enzyme kcat (s
-1
) KM (mM) kcat/KM (M
-1
s
-1
) 
Wild-type TcFIGase
a 
           200      ± 20              40 ± 10            5200    ± 200  
Wild-type TcFIGaseox
a 
           140      ± 20              40 ± 20            3500    ± 200 
Wild-type TcFIGase
b 
           140      ± 40            100 ± 30            1400    ± 200 
N114H TcFIGase
a 
             80      ± 10              20 ± 10            3400    ± 200 
R144E TcFIGase
b,d 
               0.05 ±   0.02                9 ±   4
 
                 5.2 ±     0.6 
R144A TcFIGase
b 
               3.2   ±   0.5              90 ± 10                37    ±     2 
R144K TcFIGase
b 
           190      ± 20            160 ± 20            1200    ± 100 
Mn
2+
-TcFIGase
c 
           110      ± 20              50 ± 10            2300    ± 300  
Co
2+
-TcFIGase
c 
             50      ± 10              70 ± 20              800    ± 200 
Ni
2+
-TcFIGase
c 
             40      ± 10              90 ± 20              400    ± 100 
Mg
2+
-TcFIGase
c
              90      ± 40            200 ± 60              400    ±   30 
a 
Enzyme expressed and purified from LB media. 
b 
Enzyme expressed and purified from minimal media supplemented with 100 µM MnCl2 prior to 
induction. 
c 
Enzyme prepared by reconstituting the metal-free apoenzyme with divalent metal ions. 
d 
Apparent KM from Hill equation due to allosteric behavior. 
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catalytic efficiency compared to wild-type TcFIGase (Table 3.3). Thus, asparagine and histidine 
metal ligands appear to be easily interchangeable in the metalloureohydrolase active site, as first 
demonstrated in structure-function studies of H101N rat arginase I. 
Inspection of the TcFIGase active site reveals a single arginine residue, R144, that is 
strictly conserved among formiminoglutamase enzymes from different organisms. To investigate 
the possible function of this residue, the R144A, R144E and R144K mutants were prepared and 
assayed (Table 3.3). Each mutant was expressed and purified from minimal media supplemented 
with MnCl2 to exclude potential contamination by other metal ions. The sole incorporation of Mn
2+
 
via this method was verified by ICP-AES analysis of the wild-type enzyme (Table 3.2). The 
R144A mutation causes a 38-fold reduction in catalytic efficiency, and the R144E mutation 
causes an even more severe 269-fold reduction in catalytic efficiency, relative to that measured 
for the wild-type enzyme. Notably, the R144K mutation retains near-normal catalytic efficiency 
(85% compared with the wild-type enzyme). These data suggest that the positively-charged R144 
side chain is critical for maximal catalysis.  
Finally, to study the metal ion preference for catalysis by TcFIGase, apo-TcFIGase was 
reconstituted with different divalent metal ions and the catalytic activities of these metallo-
substituted enzymes were measured (Figure 3.6). ICTP-AES measurement verified the 
preparation of apo-TcFIGase prior to reconstitution with different metal ions; equilibration of 
protein samples at low pH, and not treatment with metal ion chelators, successfully enabled metal 
ion dissociation. The apoenzyme retains 4% residual activity, which presumably results from a 
low concentration of residual Mn
2+
 ions contained in the protein sample as detected by ICP-AES 
(Table 3.2). The Mn
2+
-reconstituted enzyme exhibits 67% activity compared to the native wild-
type enzyme. The inability to restore full activity by reconstituting the metal-free apoenzyme with 
Mn
2+
 suggests that the acidic pH treatment required to dissociate active site metal ions might 
cause some irreversible damage to the protein. This would be consistent with our observation 
that the apoenzyme is less stable than the metal-loaded enzyme and more susceptible to  
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Figure 3.6: (Left) Dependence of TcFIGase activity on metal ions. Metal-free apoenzyme was 
prepared by depleting the metal ions at low pH using wild-type enzyme expressed and purified 
from LB media. Metal-substituted TcFIGase was reconstituted with two equivalents metal ions 
and assayed for activity using 10 mM substrate. Activity was compared in terms of initial velocity. 
(Right) Dependence of TcFIGase catalysis on metal ion stoichiometry. Metal-free enzyme (20 
μM) was incubated with increasing molar equivalents (eq) of divalent metal ions in assay buffer at 
4 °C for 30 minutes. The reaction was initiated by addition of 1 mM substrate and monitored as 
described in the text. Maximal catalysis requires ca. 2 Mn
2+
 ions per monomer. 
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precipitation. However, in comparison with all other divalent metal ions tested, reconstitution of 
the apoenzyme with Mn
2+
 confers the highest level of catalytic activity. Therefore, Mn
2+
 is most 
likely to be the natural cofactor of TcFIGase. Furthermore, titration of metal-free TcFIGase with 
increasing concentrations of Mn
2+
 indicates that maximal activity requires the binding of more 
than one metal ion (Figure 3.6), suggesting that a binuclear manganese cluster is required for 
catalysis. 
The oxidized form of the wild-type enzyme, TcFIGaseox, exhibits 67% catalytic efficiency 
compared to wild-type TcFIGase. The slightly lower activity of TcFIGaseox could be a 
consequence of the narrowed active site entrance. Regardless, formation of the C35-C242 
disulfide linkage does not appear to have a significant influence on catalysis. Neither of these 
cysteine residues are conserved among formiminoglutamases from different species and are 
instead substituted by small aliphatic amino acids residues (mainly valine and alanine). Hence, 
the C35-C242 disulfide linkage is probably an artifact rather than a functional allosteric linkage for 
the regulation of enzyme activity.  
3.4 Discussion 
The results outlined above demonstrate that TcFIGase is a manganese-dependent 
metallohydrolase, which is consistent with the essential catalytic role of Mn
2+
 in the ureohydrolase 
family of metalloenzymes as well as previous findings with formiminoglutamases from other 
species. The depletion of Mn
2+
 to yield apo-TcFIGase leads to a dramatic loss of activity, as 
shown in Figure 3.6. Catalytic activity is restored by the incubation of apo-TcFIGase with the 
divalent metal ions Mg
2+
, Mn
2+
, Co
2+
 and Ni
2+
, with maximal activity resulting from incubation with 
Mn
2+
. However, in contrast with a binuclear manganese ureohydrolase such as arginase, in which 
a binuclear manganese cluster was first definitively demonstrated by electron paramagnetic 
resonance spectroscopy, TcFIGase contains only 1 equivalent of Mn
2+
 bound tightly per 
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monomer in solution as determined by ICP-AES (Table 3.2). Even so, maximal catalytic activity 
requires ca. 2 Mn
2+
 ions bound per TcFIGase monomer (Figure 3.6).  
Furthermore, the X-ray crystal structure shows that both the A and B metal binding sites 
in TcFIGase are capable of binding Mn
2+
 ions when crystals of apo-TcFIGase are soaked in a 
buffer solution containing millimolar Mn
2+
 ion concentrations. To account for the differences 
between ICP-AES measurements on the one hand, and Mn
2+
 titration studies and X-ray crystal 
structures on the other hand, we hypothesize that the Mn
2+
B ion is more tightly bound and the 
Mn
2+
A ion is more weakly bound. Resultantly, the Mn
2+
A ion is more labile. This metal binding 
behavior is in accord with the observation that the Mn
2+
B site is preferentially the first to be 
occupied when crystals of apo-TcFIGase are soaked in a Mn
2+
-containing buffer solution as the 
pH is gradually raised (data not shown); it is additionally in accord with crystal structures of Mn
2+
2-
TcFIGaseox, in which the Mn
2+
B occupancy is always full whereas the Mn
2+
A occupancy is 
variable. This postulate is also consistent with ICP-AES measurements showing that 1 equivalent 
of Mn
2+
 remains bound per monomer after extensive dialysis and treatment with metal ion 
chelators. It is interesting to note that similar behavior is observed for metal ion binding to rat 
arginase I, from which only Mn
2+
A can be extracted by treatment with metal ion chelators 
(Scolnick et al., 1997). However, contrasting behavior is observed for arginase from B. 
caldovelox, from which the Mn
2+
B ion is more weakly bound and preferentially removed by 
treatment with EDTA (Bewley et al., 1999). In further contrast, both metal ions of human arginase 
I are readily removed by dialysis against DPA (D'Antonio and Christianson, 2011). To investigate 
whether the weak binding of the Mn
2+
A ion of Mn
2+
2-TcFIGase is attributable to N114, N114H 
TcFIGase was prepared. This amino acid substitution restores an authentic arginase-like metal 
coordination polyhedron. Interestingly, Cavalli and colleagues
46
 show that H101N rat arginase I 
exhibits 50% activity compared to wild-type rat arginase I; following dialysis, the metal-protein 
stoichiometry is measured to be 3.3 Mn
2+
 ions/trimer, suggesting weaker binding of the Mn
2+
A ion. 
Although this result might suggest that a histidine ligand is more favorable than an asparagine 
ligand to the Mn
2+
A ion, the N114H substitution in TcFIGase does not enhance Mn
2+
A affinity, 
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since protein-metal stoichiometry in the mutant is comparable to that of the wild-type enzyme 
(Table 3.2). In the crystalline mutant, too, the Mn
2+
B ion remains fully occupied whereas the Mn
2+
A 
ion is only partially occupied.  
Amino acid sequence alignment of FIGase enzymes from different organisms suggests 
that the Mn
2+
A site is more variable than the Mn
2+
B site. The greater evolutionary potential of 
Mn
2+
A site ligands and weaker binding of Mn
2+
A is consistent with the fact that only the Mn
2+
B site 
is conserved among members of the greater arginase/deacetylase superfamily (the Mn
2+
B site of 
arginase-like enzymes such as TcFIGase corresponds to the Zn
2+
 site of histone deacetylases) 
(Lombardi and Cole, et al., 2011). The arginases and deacetylases share a common α/β fold and 
thus likely evolved from a common metallohydrolase ancestor. Therefore, FIGase, which shows 
notable variability in the Mn
2+
A binding site among the ureohydrolases, could represent a 
"snapshot" of an intermediate evolutionary state for the metal binding site between the arginases 
and the deacetylases.   
Despite the absence of a structure of TcFIGase complexed with a substrate or transition 
state analogue, important mechanistic inferences can be drawn from the structure of inactivated 
B. caldovelox arginase complexed with L-arginine and the structures of arginase from various 
organisms complexed with the boronic acid substrate analogue 2(S)-amino-6-boronohexanoic 
acid. This analogue binds to arginase as the tetrahedral boronate anion, which mimics the 
tetrahedral intermediate and its flanking transition states in the arginase reaction. By analogy with 
ligand binding in the active site of arginase, we have modeled the binding of substrate L-
formiminoglutamate in the active site of Mn
2+
2-TcFIGase (Figure 3.7). This model shows that four 
residues universally conserved among FIGase enzymes – R144, N38, S154 and E273 – could be 
involved in substrate binding. The negatively charged carboxylate side chain of E273 may play a 
role in substrate recognition by interacting with the positively charged iminium group of L-
formiminoglutamate; the corresponding glutamate residue of arginase similarly interacts with the 
positively charged guanidinium group of L-arginine (Cox et al., 1999). The side chain of N38 is 
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well positioned to make a direct hydrogen bond with the α-carboxylate group of L-
formiminoglutamate, and the side chains of S154, E273, and C35 may also make water-mediated 
hydrogen bonds with this α-carboxylate group. Finally, R144 is well positioned to form a salt link 
with the side chain carboxylate group of L-formiminoglutamate. Indeed, the catalytic activities of 
R144A, R144E, and R144K TcFIGase indicate that a positive charge at this position is crucial for 
maximal catalysis (Table 3.3). Since two solvent molecules are bound to the binuclear 
manganese cluster of TcFIGase, it could be questioned as to which of these solvent molecules is 
the catalytic nucleophile. However, the pKa of a metal-bridging solvent molecule will be lower 
than that of a solvent molecule coordinated to just a single metal ion; therefore, a higher 
concentration of nucleophilic hydroxide ions would occupy a metal-bridging position compared 
with a single-metal coordination position. Also notable is the fact that as modeled in Figure 3.7, 
the lone electron pair of the presumed metal-bridging hydroxide ion is aligned with the Bürgi-
Dunitz trajectory for nucleophilic attack at the π* orbital of the substrate imino group. Interestingly, 
the model additionally suggests that the Nδ atom of the formimino group would be oriented 
toward Mn
2+
B – perhaps implying that Mn
2+
A is not as important for transition state stabilization. 
This contrasts with the mechanistic proposal set forth for arginase, in which the Nη2 atom of L-
arginine coordinates to Mn
2+
A as the tetrahedral intermediate is approached.  
Mechanistic inferences emanating from structure-function studies of TcFIGase are 
summarized in the mechanistic proposal presented in Figure 3.7, in which the side chains of 
N38, R144, S154, and E273 function in substrate binding. We propose that TcFIGase utilized a 
metal-activated hydroxide mechanism for the hydrolysis of the substrate formimino group, which 
proceeds through a neutral tetrahedral intermediate stabilized by metal coordination as well as 
hydrogen bonds with D142 and E273. Proton transfer from the hydroxyl group to the leaving 
amino group of the tetrahedral intermediate facilitates collapse of the tetrahedral intermediate and 
product dissociation. In general, an amine must be protonated in order to be a leaving group in 
the collapse of a tetrahedral intermediate. Since D142 is close to both the metal-bridging 
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hydroxide ion and the α-amino group of formiminoglutamate in the model of the enzyme-
substrate complex shown in Figure 3.7, it is possible that D142 mediates this proton transfer – 
this would ensure that L-glutamate and not ammonia is the leaving group in the collapse of the 
tetrahedral intermediate. There is no suitably-oriented proton donor group that could enable the 
departure of ammonia based on the model of the enzyme-substrate complex, e.g., as achieved 
by H269 in N-formimino-L-glutamate iminohydrolase (Marti-Arbona and Raushel, 2006; Marti-
Arbona et al., 2006); this enzyme adopts an unrelated fold and catalyzes the HutF reaction shown 
in Figure 3.1. The binding and ionization of additional solvent completes the catalytic cycle of 
TcFIGase. 
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Figure 3.7: Sequence alignment of formiminoglutamase from different species. The 
conserved active site residues are highlighted in orange. The two unique Cys residues (only 
present in T. cruzi) are highlighted in green 
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Figure 3.8: Hypothetic model of substrate binding in TcFIGase and proposed catalytic 
mechanism for formiminoglutamase. Reprinted with permission from Hai, Y., Dugery, R. J., 
Healy, D., & Christianson, D. W. Biochemistry 2013, 52 (51), 9294-9309. Copyright 2013 
American Chemical Society. 
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Chapter 4: Crystal Structure of an Arginase-Like Protein from Trypanosoma 
brucei That Evolved without a Binuclear Manganese Cluster 
This work is published in Hai, Y., Kerkhoven, E. J., Barrett, M. P., & Christianson, D. W. 
Biochemistry, 2015, 54 (2), 458-471;  
4.1 Introduction 
Human African trypanosomiasis is a neglected tropical disease caused by Trypanosoma 
brucei, parasitic protozoa transmitted by the tsetse fly (Barrett et al., 2003). In humans, this 
disease is more commonly known as sleeping sickness, and in livestock, it is known as nagana 
(Brun et al., 2010). Early-stage infection involves parasitic infestation of the hemolymphatic 
system and in humans presents with nonlethal symptoms, such as chronic intermittent fever and 
headache. Late-stage infection begins as the parasite crosses the blood-brain barrier, giving rise 
to neurological and psychiatric dysfunction, including sleep disorders (Barrett, 2006). If left 
untreated, late-stage infection is almost always lethal. The incidence of human trypanosomiasis 
has diminished in recent years, and the World Health Organization has set a target date of 2030 
to eliminate the disease as caused by the subspecies Trypanosoma brucei gambiense. However, 
there is a dearth of effective drugs for the treatment of early- and late-stage infections (Fairlamb, 
2003). Current first-line treatment depends on eflornithine (D,L-α-difluoromethylornithine) therapy , 
particularly in combination with nifurtimox (Brun et al., 2011). Eflornithine is a mechanism-based 
inhibitor of ornithine decarboxylase, which catalyzes a key step in the biosynthesis of polyamines 
that facilitate growth and proliferation of the parasite (Li et al., 1998). Possibly, other enzymes of 
polyamine biosynthesis could also serve as drug targets for the treatment of parasitic infections 
(Casero and Marton, 2007). In the related parasite, Leishmania mexicana, knockout mutants 
confirm that arginase is required for parasite viability (Roberts et al., 2004), so the inhibition of 
arginase is a validated strategy in the search for new antiparasitic agents.  
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Interestingly, T. brucei contains a single gene, Tb927.8.2020, that encodes an arginase-
like protein, henceforth designated "TbARG"; this gene is syntenic with a gene in Leishmania that 
is present in addition to the verified arginase (Roberts et al., 2004). The amino acid sequence of 
TbARG shares only 24% identity with rat arginase I, and even less with arginases from other 
organisms, but this minimal level of sequence identity is sufficiently high to suggest a homologous 
three-dimensional structure. Strikingly, however, analysis of the amino acid sequence suggests 
that TbARG lacks all but one of the ligands that coordinate to the catalytically-obligatory Mn
2+
 
ions found in the arginases. Accordingly, TbARG may not be a metalloprotein. There is precedent 
for the evolution of alternative metal-binding function in the arginase fold – this fold is also 
adopted by metal-dependent deacetylases such as polyamine deacetylase or the histone 
deacetylases, which utilize a single Zn
2+
 ion for catalysis (Lombardi and Cole et al., 2011). 
However, there is no precedent for the complete loss of metal-binding function in the arginase 
fold. 
Here, we report the X-ray crystal structure determination of TbARG, conclusively 
demonstrating that this protein adopts the arginase fold. We also show that TbARG is the first 
arginase-like protein that lacks the capacity for binding metal ions in its active site. However, we 
can restore metal ion binding by re-introducing metal ligands into the active site through site-
directed mutagenesis. Facial restoration of Mn
2+
B site but not Mn
2+
 site is consistent with the 
evolutionary trend that Mn
2+
B site is more conserved: Mn
2+
B site corresponds to the catalytic Zn
2+
 
site in zinc-dependent deacetylases. Removal of the protein from bloodstream form-
trypanosomes by gene knockout reveals it to be non-essential, and no changes in L-arginine or L-
ornithine levels are detected in knockout cells. Finally, we have screened wild-type TbARG for 
ligand binding activity against a library of small molecules, and we find a slight preference for the 
binding of cationic amino acids such as lysine. Even so, the molecular function of this protein 
remains an enigma.  
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4.2 Materials and Methods 
4.2.1 Materials 
Tris(2-carboxyethyl)phosphine hydrochloride (98%, TCEP) was purchased from Gold 
Biotechnology. 50% (w/v) polyethylene glycol (PEG) 3350 solution, 50% Jeffamine ED-2001, and 
100% Tacsimate solution (pH 7.0) were purchased from Hampton Research. All the peptides 
used in this study were purchased from Bachem. All other chemicals were purchased from either 
Fisher Scientific or Sigma-Aldrich. 
4.2.2 Expression and purification of TbARG 
The pET-28a plasmid encoding wild-type TbARG (UniprotKB Q581Y0, gene name 
Tb927.8.2020) with a 20-residue N-terminal His6-tag plus a thrombin cleavage site was 
transformed into E. coli BL21 (DE3) and B834 (DE3) cells (Novagen Inc.). Native TbARG was 
overexpressed in E. coli BL21 (DE3) grown in Lysogeny-Broth (LB) media supplemented with 50 
mg/L kanamycin. Expression was induced by 1 mM isopropyl β-D-1-thiogalactopyranoside 
(Carbosynth) for 16 hours at 22 °C when OD600 reached 0.6-0.7. Cells were harvested by 
centrifugation at 5000 g for 10 minutes. The cell pellet was suspended in 50 mL of buffer A [50 
mM K2HPO4 (pH 8.0), 300 mM NaCl, 10% (v/v) glycerol]. Cells were lysed by sonication on ice 
using a Sonifer 450 (Branson) and the cell lysate was further incubated with 5 μg/mL DNAse I 
(Sigma) and 6 μg/mL RNAse A (Roche Applied Science) at 4 °C for 30 min. Cellular debris was 
removed by centrifugation at 15,000 rpm for 1 hour. The clarified supernatant was applied to a 
Talon column (Clontech Laboratories, Mountain view, CA) pre-equilibrated with buffer A. TbARG 
was purified with a 200 mL gradient from 10 mM imidazole to 300 mM imidazole. Pooled fractions 
were dialyzed into buffer B [15 mM K2HPO4 (pH 7.5), 2 mM β-mercaptoethanol (BME) and 100 
μM MnCl2] and subsequently loaded onto a 10 mL Q-HP anion exchange column (GE 
Healthcare). Protein was eluted with a 500 mL gradient from 0–800 mM NaCl. The estimated 
purity of protein samples was greater than 95% based on SDS-PAGE. Fractions containing 
TbARG were combined and concentrated using Amicon ultra filter units (Millipore) with 10 kDa 
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molecular weight-cutoff followed by exchange into buffer C [50 mM bicine (pH 8.5), 100 μM 
MnCl2, 1 mM TCEP] using a Superdex 200 preparative grade 26/60 size exclusion column (GE 
Healthcare). Mutants were expressed and purified using a procedure similar to that employed for 
wild-type TbARG, except that minimal medium [1x M9 salts, 0.5% casamino acids, 20 mM D-(+)-
glucose, 2 mM MgSO4, 100 μM CaCl2] supplemented with 200 μM MnCl2 was used to avoid 
metal contamination, and the induction temperature was lowered to 16 °C. Selenomethionine-
derivatized (Se-Met) TbARG was overexpressed in E. coli B834 (DE3) cells grown in Seleno-Met 
Medium Base (AthenaES) supplemented with SelenoMet Nutrient Mix (AthenaES) and 40 mg L
-1
 
seleno-L-methionine (Acros). The expression and purification of Se-Met TbARG was performed 
using a procedure essentially identical to that used for wild-type TbARG, except that 2 mM TCEP 
was included in buffer A and buffer C, and 5 mM BME was included in buffer B. 
4.2.3 Mutagensis 
To re-engineer metal binding sites in TbARG, selected active site residues were mutated 
to reintroduce the Mn
2+
A site and the Mn
2+
B site separately, as well as both sites simultaneously. 
Five mutants were generated using the QuickChange method (Stratagene) and verified by DNA 
sequencing. Briefly, mutants MA1 (S149D, S153D) and MA2 (S149D, S153D, G124H, Y267A) 
were prepared to reintroduce the Mn
2+
A site; mutant MB (S149D, R151H, S226D) was prepared 
to reintroduce the Mn
2+
B site; and mutants MA1B (S149D, S153D, R151H, S226D) and MA2B 
(S149D, S153D, G124H, Y267A, R151H, S226D) were prepared to mimic both sites 
simultaneously. 
4.2.4 Thermal stability shift assay 
To evaluate potential ligands capable of binding to TbARG, a thermal stability shift assay 
was performed by screening a small library of ligands based on the protocol described by Niesen 
and colleagues
 
(Niesen et al., 2007) with minor modification. Protein-ligand mixtures [20 μL of 50 
mM HEPES (pH 7.5), 100 mM NaCl, 5x SYPRO Orange (Invitrogen),  3 μM TbARG, and 1-5 mM 
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ligand] were dispensed into MicroAmp® Fast 96-well Reaction Plates (Applied Biosystems). 
Thermal melting experiments were performed with the StepOnePlus
TM
 Real-Time PCR System 
(Applied Biosystems). The melt curve was programmed with a ramp rate of 1°C/s from 25 °C to 
95 °C. All experiments were performed in triplicate and data analysis was performed using the 
StepOnePlus
TM 
software. 
4.2.5 Activity assays 
To evaluate possible biological functions of TbARG, several enzyme activity assays were 
performed. Ureohydrolase activity was assessed using the colorimetric assay developed by 
Archibald.
 
The following compounds were used as potential substrates for ureohydrolase activity 
assay:  L-arginine, agmatine, Nα-acetyl-L-arginine, L-homoarginine, α-guanidinoglutaric acid, 3-
guanidinopropionic acid, 4-guanidinobutyric acid, and L-2-amino-3-guanidinopropionic acid. 
Lysine deacetylase activity was assessed using the Fluor-de-Lys
®
 deacetylase substrate (BML-
KI104 ENZO Life Sciences) and the Fluor-de-Lys
®
-HDAC8 deacetylase substrate (BML-KI178, 
ENZO Life Sciences) according to the manufacturer's instructions. Arginine deiminase activity 
was assessed using a colorimetric assay to detect L-citrulline formation from L-arginine.
34
 
Formiminoglutamase activity was measured colorimetrically with the substrate L-
formiminoglutamic acid (Dalton Pharma Services, Toronto, Canada). The binding of NADPH and 
NADH binding was investigated by monitoring the fluorescence emission change of NAD(P)H 
upon titrating NAD(P)H into TbARG solutions. Fluorescence emission spectra (from 400 nm to 
600 nm) were recorded with a Varian Cary Eclipse fluorescence spectrophotometer with 
excitation wavelength at 340 nm.   
4.2.6 Metal content analysis 
To analyze TbARG and its site-specific mutants for bound metal ions, inductively-coupled 
plasma-atomic emission spectrometry (ICP-AES) was employed. Prior to analysis, samples were 
extensively dialyzed against 10 mM bicine (pH 8.5) to remove free trace metal ions. Samples 
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were sent to the Center for Applied Isotope Studies, University of Georgia (Athens, GA), for 
analysis.  
4.2.7 Crystallography 
Crystals of TbARG and its mutants were prepared by the sitting-drop vapor diffusion 
method at 21 °C. For wild-type TbARG in the oxidized form (space group R32:H), a 0.4 μL drop 
of protein solution [20 mg/mL TbARG, 50 mM bicine (pH 8.5), 100 μM MnCl2, 1 mM TCEP] was 
mixed with a 0.4 μL drop of precipitant solution [2% v/v tacsimate (pH 7.0), 5% v/v 2-propanol, 
0.1 M imidazole (pH 7.0), 8% PEG 3350] and equilibrated against a 80 μL reservoir of precipitant 
solution. For wild-type TbARG in the reduced form (space group P3), a 0.4 μL drop of protein 
solution [20 mg/mL TbARG, 50 mM bicine (pH 8.5), 100 μM MnCl2, 10 mM TCEP] was mixed 
with a 0.4 μL drop of precipitant solution [0.1 M HEPES (pH 7.5), 18% PEG 3350]. For TbARG 
mutant MB, a 0.4 μL drop of protein solution [20 mg/mL TbARG mutant MB, 50 mM bicine (pH 
8.5), 100 μM MnCl2, 1 mM TCEP] was mixed with a 0.4 μL drop of precipitant solution [20% (v/v) 
Jeffamine ED-2001, 0.1 M imidazole (pH 7.0)]. For TbARG mutant MA1, a 0.4 μL drop of protein 
solution [20 mg/mL TbARG mutant MA1, 50 mM bicine (pH 8.5), 200 μM NiCl2, 1 mM TCEP] was 
mixed with a 0.4 μL drop of precipitant solution [0.2 M KF, 20% (v/v) PEG 3350]. For TbARG 
mutant MA1B, a 0.4 μL drop of protein solution [20 mg/mL TbARG mutant MA1B, 50 mM bicine 
(pH 8.5), 200 μM NiCl2, 100 μM MnCl2 1 mM TCEP] was mixed with a 0.4 μL drop of precipitant 
solution [0.2 M KNO3, 20% (v/v) PEG 3350]. For Se-Met TbARG, a 5 μL drop of protein solution 
[20 mg/mL protein, 50 mM bicine (pH 8.5), 100 μM MnCl2, 1 mM TCEP] was mixed with a 5 μL 
drop of precipitant solution [0.1 M HEPES (pH 7.0), 5% 2-methyl-2,4-pentanediol, 10% PEG 
3350] and equilibrated against a 500 μL reservoir of precipitant solution. Crystals appeared after 
2-3 days and were flash-cooled after transfer to a cryoprotectant solution consisting of the 
reservoir solution plus 20% (v/v) glycerol, with the exception that the crystal of wild-type TbARG 
in space group P3 was cryoprotected with reservoir solution plus 25% (v/v) 2-methyl-2,4-
pentanediol and 25% PEG 400. Diffraction data were collected on beamline X29 at the National 
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Synchrotron Light Source (NSLS, Brookhaven National Laboratory, New York). Crystals of native 
TbARG diffracted X-rays to 2.4 Å resolution and belonged to space group H32 with one monomer 
per asymmetric unit (Matthews coefficient VM = 2.49 Å
3
/Da, solvent content = 51%).  
Attempts to phase the initial electron density map by molecular replacement using known 
structures of arginase/deacetylase family proteins were unsuccessful. For experimental phasing, 
single wavelength anomalous dispersion (SAD) data were collected from a single crystal of Se-
Met TbARG at the peak wavelength of 0.9788 Å (as determined by X-ray fluorescence scan). The 
Se-Met TbARG crystal diffracted X-rays to 2.6 Å resolution and belonged to space group P321. 
With two monomers in the asymmetric unit the Matthews coefficient VM = 3.22 Å
3
/Da, 
corresponding to a solvent content of 62%. Diffraction data were integrated and scaled with 
HKL2000 (Otwinowski and Minor, 1997).  
The structure of Se-Met TbARG was determined by SAD with data truncated to 3.2 Å 
resolution. Initially, 21 selenium sites in the asymmetric unit were located using the program 
HKL2MAP (Pape and Schneider, 2004). Two additional sites were located by using the program 
PHENIX AutoSol (Adams et al., 2010). A Bijvoet difference Fourier map showing the positions of 
selenium atoms in monomer A is found in Figure 4.1. Initial experimental phases were improved 
by noncrystallographic symmetry averaging and solvent flattening using RESOLVE (PHENIX) 
and phases were extended to 2.7 Å resolution. Automatic model building performed by 
phenix.autobuild successfully fit 70% of the protein residues. Iterative cycles of refinement and 
manual model building against 2.55 Å resolution data were performed using phenix.refine and 
Coot (Emsley et al., 2010). Data collection and reduction statistics are recorded in Table 4.1.   
4.3 Results 
4.3.1 Crystal structure of TbARG 
TbARG crystallizes as a hexamer in both H32 and P321 space groups (Figure 4.2), but 
as a trimer in space group P3 (data not shown). The hexamer consists of a dimer of trimers 
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assembled with D3 (H32 crystal form) or pseudo-D3 (P321 crystal form) point group 
symmetry, burying ~5000 Å
2 
surface area between two trimers and ~7100 Å
2
 surface area within 
each trimer. Notably, three intermolecular C209-C209 disulfide linkages form between monomers 
related by 2-fold crystallographic symmetry in the H32 crystal form, but not in the P321 crystal 
form. Disulfide linkage formation brings the two trimers closer together and is accompanied by 
significant conformational changes in the C-termini that enable closer contact. The tertiary 
structures of TbARG in all crystal forms are essentially identical (r.m.s. deviation of 0.23 Å for 252 
Cα atoms between the P321 and H32 crystal forms; r.m.s. deviation of 0.38 Å for 254 Cα atoms 
between the P3 and H32 crystal forms), apart from conformational changes of the C-terminus and 
loop L6 (G206-P218), which contains C209. The hexameric architecture of TbARG resembles 
that of prokaryotic arginase and arginase-like enzymes, as well as eukaryotic Plasmodium 
falciparum arginase. However, the TbARG hexamer assembles in an orientation such that the 
central parallel β-sheet of each trimer points away from the dimer interface. In contrast, the 
central parallel β-sheet of each trimer is oriented toward the dimer interface in previously-reported 
hexameric arginase structures, such that the active sites are buried between two trimers. It 
seems that the close association of one TbARG trimer with another in the crystal can be 
mediated by either face of the trimer as one compares hexameric quaternary structures, perhaps 
suggesting that the dimerization of trimers is artifactual. Under reducing conditions, TbARG is 
determined to be a trimer in solution by size exclusion chromatography. Thus, the trimer is most 
likely to be the physiologically significant species, and the disulfide linkage observed in the 
reduced form of the hexamer is probably artifactual.  
Despite very low amino acid sequence identity (ca. 20%) shared with other 
ureohydrolase family proteins and the loss of ligands to the catalytically-essential binuclear 
manganese cluster indicated by amino acid sequence alignments, the TbARG monomer adopts 
the classical α/β arginase/deacetylase fold first observed in the crystal structure of rat arginase I 
(Figure 4.3).The overall topology of TbARG is characteristic of the arginase/deacetylase family  
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Table 4.1:  Data Collection and Refinement Statistics of TbARG. 
 Se-Met 
(reduced) 
Wild-type 
(reduced) 
Wild-type  
(oxidized) 
Mutant MA1 
(reduced) 
Mutant MB 
(oxidized) 
Mutant 
MA1B 
(reduced) 
Data collection       
Wavelength (Å)  0.9788  
(Se-Peak) 
1.075 1.075 1.075 1.075 1.075 
Space group P321 P3 H32 C2 P321 C2 
Unit cell  
a, b, c (Å) 
 
α, β, γ (
o
) 
 
139.0, 139.0,  
90.5 
90.0, 90.0,  
120.0 
 
139.2, 139.2, 
90.2 
90.0, 90.0, 
120.0 
 
153.2, 153.2, 
85.4 
90.0, 90.0, 
120.0 
 
83.2, 138.1, 
90.9  
90.0, 102.0, 
90.0 
 
135.6, 135.6, 
86.7 
90.0, 90.0, 
120.0 
 
82.1, 173.4,  
87.8  
90.0, 102.3,  
90.0 
Resolution (Å)
 
42.36 – 2.55  
(2.64 – 2.55) 
42.23 – 1.80 
(2.64 – 1.80) 
40.66 – 2.38 
(2.47–2.38) 
44.49 – 2.18 
(2.26 – 2.18) 
48.61– 3.10 
(3.21– 3.10) 
42.90 – 1.95 
(2.02 – 1.95) 
Total reflections 727053  
(70959) 
1614161 
(143386) 
280023 (23240) 314490 (27545) 341313  
(32185) 
385476  
(22261) 
Unique 
reflections
 
33080  
(3262) 
181427 (18150) 15479 (1527) 51646  
(5101) 
16959  
(1673) 
64646  
(4543) 
Completeness 
(%) 
99.9  
(98.8) 
100.0 (100.0) 99.9  
(99.8) 
99.9  
(99.3) 
100.0  
(100.0) 
94.3  
(73.4) 
I / σI 30.2 (4.5) 24.5 (2.1) 31.4 (2.0) 13.2 (2.0) 14.0 (2.0) 17.1 (2.0) 
Redundancy 22.0 (21.8) 8.9 (7.9) 18.1 (15.2) 6.1 (5.4) 20.1 (18.7) 6.0 (4.9) 
Rmerge
 
0.152  
(1.01) 
0.084 (1.095) 0.107  
(1.40) 
0.127  
(0.76) 
0.194  
( 1.13) 
0.091  
(0.54) 
Rpim
 
0.033 (0.22) 0.032 (0.41) 0.026 (0.35) 0.056 (0.35) 0.056 (0.38) 0.039 (0.64) 
Wilson B factor 
(Å
2
) 
37.4 20.0 63.3 25.8 57.0 29.9 
Se-SAD 
phasing 
      
No. of Se atoms 23 (out of 
possible 26) 
     
Figure of Merit 
(FOM) 
0.404      
FOM after  
Density 
modification 
(DM) 
 
0.672 
     
Refinement       
Rwork (%)
 
22.1 (26.2) 19.6 (29.4) 22.7 (40.5) 20.5 (29.7) 21.5 (28.1) 20.1 (31.6) 
Rfree (%) 26.1 (33.4) 23.4 (32.7) 25.6 (40.6) 23.8 (36.1) 27.4 (34.7) 23.7 (34.7) 
twinning fraction 0 0.45 0 0 0 0 
twin law N/A h, -h-k, -l N/A N/A N/A N/A 
No. of molecules 2 6 1 3 2 3 
No. of atoms 
         Protein 
         Water 
         Ligand 
        Metal ions 
 
4833 
161 
12 
0 
 
13320 
308 
16 
0 
 
2405 
96 
6 
0 
 
7101 
163 
32 
0 
 
4651 
31 
12 
2 
 
7081 
129 
48 
3 
Average B 
factors (Å
2
) 
      
Protein 43 25 84 40 51 52 
Solvent 38 21 74 34 39 47 
Ligand 68 24 74 55 48 67 
Metal ions N/A N/A N/A N/A 42 33 
RMSD bond 
lengths (Å) 
0.005 0.010 0.005 0.005 0.006 0.006 
RMSD bond 
angles (
o
) 
0.9 1.3 0.9 0.9 1.0 0.9 
Ramachandran 
plot (%) 
      
allowed 90.2 88.7 91.9 92.9 88.1 91.1 
additional 
allowed 
9.6 11.2 6.9 6.7 10.5 8.5 
generously 
allowed 
0.0 0.1 1.2 0.4 1.4 0.4 
disallowed 0.2 0.0 0.0 0.0 0.0 0.0 
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Figure 4.1: Bijvoet difference Fourier map (contoured at 3σ) indicates the positions of 12 Se-Met 
residues in a Cα trace of monomer A of TbARG; 11 sites are found in monomer B of the 
asymmetric unit (not shown). 
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Figure 4.2: Hexameric structures of TbARG in P321 (a) and H32 (b) space group. In the P321 
crystal form, the top trimer (dark blue) and the bottom trimer (light blue) result from crystal 
symmetry operations with two separate monomers in the asymmetric unit. Red arrows indicate 
two-fold symmetry axes. In the H32 crystal form, the entire hexamer results from crystal 
symmetry operations with one monomer in the asymmetric unit. C209 is shown in ball-and-stick 
representation and forms intermolecular disulfide linkages in the H32 crystal form. Note that in the 
P321 crystal form, the C-termini of the bottom trimer (light blue) are disordered and are not 
shown. 
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Figure 4.3: (a) Stereoview of the TbARG monomer. Secondary structure elements are defined by 
the DSSP algorithm. (b) Topology diagram of TbARG. Two inserted secondary structural 
elements relative to the classic arginase-deacetylase fold are highlighted in red: α helix A0 and β 
strand 1a. 
 100 
 
with strand order 2-1-3-8-7-4-5-6, with an additional β-strand inserted between strands 1 and 2 
(β1a) and an additional α-helix (αA0) at the N-terminus (Figure 4.3). Structural analysis using the 
DALI server
 
(Holm and Rosenström, 2010) shows that ureohydrolase family proteins are the most 
closely related structural homologues of TbARG, followed by zinc-dependent deacetylases. The 
closest structural homologue is proclavaminate amidino hydrolase from Streptomyces 
clavuligerus, with an r.m.s. deviation of 2.2 Å for 254 Cα atoms.  
The active site of an enzyme belonging to the arginase/deacetylase family is located at 
the edge of β strands 8, 7, and 4; loops L1, L4, and L5 flank the active site and largely define the 
active site contour and substrate specificity. Although loop L5 is structurally similar between 
TbARG and human arginase I, loops L1 and L4 exhibit significant differences when the two 
structures are superimposed. In particular, loops L1 and L4 and their connecting helices shift 
back away from the mouth of the active site, resulting in a broader cleft in TbARG. Even so, the 
putative active site cleft of TbARG is ~9 Å deep and is characterized by negative electrostatic 
surface potential (Figure 4.4). The crystal structure of TbARG confirms the lack of any bound 
metal ions in the putative active site. Therefore, the structure of TbARG is the first of an 
arginase/deacetylase family member lacking a metal binding site. Active site comparisons reveal 
that only the μ-η
1
,η
1
 bridging aspartate ligand of human arginase I (D232) is conserved in TbARG 
as D224. The remaining aspartate and histidine ligands are substituted by serine, glycine, and 
arginine residues, as shown in Figure 4.4. Interestingly, the side chain of Y267 occupies the 
steric void caused by the substitution of H101 in human arginase I by G124 in TbARG. Assembly 
of the TbARG trimer is generally similar overall to the assembly of arginase trimers from other 
species, particularly with regard to the orientation of each monomer with respect to the 3-fold 
symmetry axis. However, oligomerization motifs in TbARG differ from those observed in other 
arginases. In mammalian arginases, the S-shaped tail at the C-terminus mediates significant 
intermonomer contacts, and two salt-link networks stabilize trimer assembly: D204A-R255B-E256A 
and D204A-R308B-E262B (human arginase I numbering convention). These networks are not  
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Figure 4.4: (a) Stereoview of the TbARG monomer. Secondary structure elements are defined by 
the DSSP algorithm. (b) Topology diagram of TbARG. Two inserted secondary structural 
elements relative to the classic arginase-deacetylase fold are highlighted in red: α helix A0 and β 
strand 1a. 
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conserved in TbARG. Instead, loops L6, L7, and L8 predominantly mediate the trimerization of 
TbARG. A cluster of hydrophobic residues, including F208 (L6), A231 and F232 (L7), V275 and 
L283 (L8), is buried along the 3-fold symmetry axis. Additionally, several inter- and intra-subunit 
hydrogen bonds are observed that involve loops L7 and L8 (Figure 4.3). The backbone NH group 
of K278A (L8A) donates a hydrogen bond to the backbone carbonyl of D274B (L8B). The side 
chain of R277A (L8A) donates two hydrogen bonds to the backbone carbonyls of P234B and 
V236B (L7B), and also forms an intramonomer salt link with D279A. These interactions may be 
important for maintaining loop conformations that support trimer assembly. Parenthetically, we 
note that the 9-residue insertion in loop L8 of TbARG relative to human arginase I is reminiscent 
of the 11-residue insertion in loop L8 of protozoan Plasmodium falciparum arginase, which is also 
involved in trimer assembly. 
4.3.2 Protein engineering and crystal structure of TbARG mutants 
Although most of the active site metal ligands are absent in TbARG, the backbone atoms 
of corresponding residues superimpose well with those of human arginase I, indicating that the 
overall protein scaffold is relatively unchanged in TbARG. Accordingly, we hypothesized that 
arginase-like metal-binding sites could be reintroduced in TbARG through site-directed 
mutagenesis. As outlined in Materials and Methods, mutants MA2, MB, and MA2B were designed 
to fully reintroduce the Mn
2+
A, Mn
2+
B, and binuclear Mn
2+
A-Mn
2+
B sites, respectively, in TbARG. 
Our rationale in this work was that if we could successfully reintroduce a binuclear manganese 
cluster in TbARG, we might be able to confer a new chemical function in the putative active site. 
However, mutants MA2 and MA2B were not robustly expressed and exhibited poor behavior in 
solution, i.e., they formed aggregates that eluted with the void volume in size-exclusion 
chromatography. Accordingly, mutants MA1, MB, and MA1B were used for further study. Recall 
that mutant MA1 contains S149D and S153D to partially reintroduce the Mn
2+
A site; however, this 
mutant lacks a histidine metal ligand that would ordinarily complete the Mn
2+
A coordination 
polyhedron in arginase. Mutant MB contains S149D, R151H, and S226D to reintroduce the Mn
2+
B  
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Table 4.2:  Metal Content of TbARG as Determined by ICP-AES. 
 
   
Protein 
Metal : protein molar ratio 
Mn Fe Co Ni Cu Zn 
Expressed from minimal medium supplemented 
with 200 μM MnCl2 
      
Mutant MA1 (S149D, S153D) 0.09 0.00 0.02 0.00 0.00 0.02 
Mutant MB (S149D, R151H, S226D) 0.89 0.00 0.06 0.00 0.00 0.06 
Mutant MA1B (S149D, R151H, S153D S226D) 0.92 0.00 0.01 0.00 0.00 0.05 
Expressed from LB medium       
Wild-type 0.00 0.00 0.00 0.00 0.00 0.03 
Mutant MA1 (S149D, S153D) 0.09 0.01 0.00 0.01 0.00 0.40 
Mutant MB (S149D, R151H, S226D) 0.74 0.02 0.02 0.003 0.006 0.20 
Mutant MA1 (S149D, S153D)
a 
0.01 0.00
 
0.19 0.80 0.00 0.07 
a
Prior to sample preparation (dialysis) for ICP-AES analysis, sample was incubated with 0.5 
mM CoCl2 and 0.5 mM NiCl2 for 30 minutes on ice.  
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site, and mutant MA1B contains S149D, S153D, R151H, and S226D to partially reintroduce the 
Mn
2+
A site along with the fully-reintroduced Mn
2+
B site. Metal content analysis by ICP-AES 
indicates that the engineered mutants are capable of binding metal ions, in contrast with wild-type 
TbARG (Table 4.2). Mutant MB contains Mn
2+
, whereas mutant MA1 preferentially binds to Ni
2+
 
and is also capable of binding Co
2+
 and Zn
2+
, but not Mn
2+
. To confirm the incorporation of metal 
ions at the designed metal binding site, we determined the crystal structures of mutant MB in its 
oxidized form at 3.1 Å resolution, and mutants MA1 and MA1B in their reduced forms at 2.2 Å 
and 2.0 Å resolution, respectively. The overall structures of all mutants are quite similar to the 
structure of wild-type TbARG with r.m.s. deviations of 0.31 Å for 270 Cα atoms in mutant MB, 
0.38 Å for 303 Cα atoms in mutant MA1, and 0.38 Å for 304 Cα atoms in mutant MA1B.  
The binding of Mn
2+
 to the engineered metal B site in mutants MB and MA1B is confirmed 
by the appearance of strong peaks in simulated annealing omit maps. In mutant MA1B, the Mn
2+
 
ion is coordinated by H151 Nδ, D149 Oδ1, D224 Oδ1, D226 Oδ1, and a solvent molecule with 
distorted octahedral geometry (Figure 4.5). For mutant MB, the Mn
2+
 ion adopts similar 
coordination geometry except that the metal-bound solvent molecule is observed only in 
monomer A in the asymmetric unit (Figure 4.6); in monomer B, the corresponding solvent 
molecule is too far from Mn
2+
 to be considered an inner-sphere coordination interaction, so the 
metal coordination geometry is classified as square pyramidal. In both mutants MA1B and MB, 
the D226 Oδ2•••Mn
2+
 distance (2.6-2.7 Å) is too long for an inner-sphere coordination interaction. 
Even so, structural comparisons of TbARG mutants MA1B and MB with human arginase I show 
that the metal coordination geometries of the engineered metal B sites in TbARG mutants are 
very similar to the natural Mn
2+
B site in human arginase I (Figures 4.5b and 4.6b). However, 
there are differences in the position of the non-protein metal ligand: metal-bound solvent 
molecules in mutants MA1B and MB deviate from the position of the metal-bridging hydroxide ion 
in human arginase I by 1.0 Å and 1.3 Å, respectively. In contrast to the ICP-AES data, no bound 
Ni
2+
 ions are observed in the electron density maps of mutants MA1 or mutant MA1B. Inspection  
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Figure 4.5: (a) Simulated annealing omit maps of the Mn
2+
 ion in mutant MA1B (blue mesh, 
contoured at 14σ) and its non-protein ligand (green mesh, contoured at 4σ). The Mn
2+
 ion is 
shown as a purple sphere and water molecules are shown as small red spheres. Red dashed 
lines indicate metal coordination interactions. (b) Superposition of human arginase I (light yellow, 
PDB code: 2ZAV) with mutant MA1B. Green dashed lines indicate hydrogen bonds. Metal 
coordination interactions in human arginase I are shown as blue dashed lines. 
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Figure 4.6: (a) Simulated annealing omit maps of the Mn
2+
 ion from monomer B (blue mesh, 
contoured at 14σ) and its non-protein ligand (green mesh, contoured at 3σ) in mutant MB. The 
Mn
2+
 ion is shown as a purple sphere and water molecules are shown as small red spheres. Red 
dashed lines indicate metal coordination interactions. (b) Superposition of human arginase I (light 
yellow, PDB code: 2ZAV) with mutant MB. Green dashed lines indicate hydrogen bonds. Metal 
coordination interactions in human arginase I are shown as blue dashed lines. 
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of the crystal structure of each mutant reveals that the side chain of D153 is not ideally oriented 
for metal coordination and would require conformational change to incorporate metal ions at the 
engineered A site; the superposition of human arginase I with mutant MA1B in Figure 4.6b 
illustrates this feature. The unfavorable orientation of D153, as well as the lack of the histidine 
side chain ordinarily conserved in site A, are likely responsible for the lack of a bound metal ion at 
the Mn
2+
A site. The partial metal binding behavior detected in ICP-AES measurements may very 
well arise from nonspecific binding to the hexahistidine tag installed at the N-terminus to enable 
facile protein purification. We hypothesize that the Mn
2+
A site must be fully reconstituted with an 
additional histidine ligand to reintroduce significant metal binding activity, as designed in mutant 
MA2. Unfortunately, this mutant was poorly behaved in solution and was not amenable to 
biophysical measurements.  
4.3.3 Ligand Binding and Activity Assays 
Although the putative active site of wild-type TbARG lacks the characteristic binuclear 
manganese cluster of an arginase-like enzyme or a single metal ion binding site like that of a 
histone deacetylase or polyamine deacetylase, it is characterized by a ~9 Å-deep cleft with 
negative electrostatic surface potential that could conceivably accommodate the binding of 
cationic amino acid ligands such as L-arginine or L-lysine (Figure 4.3). Using the thermal stability 
shift assay described by Niesen and colleagues, which is based on the principle that protein 
thermostability increases in a protein-ligand complex, we studied the binding of 58 different 
ligands, including cationic amino acids such as L-arginine, L-lysine, and L-ornithine, and 6 
different divalent metal ions (a complete listing is found in Table 4.3). None of the ligands tested 
significantly increased the melting temperature (Tm) of the protein; the largest increase was 
observed for D-lysine, with ΔTm = 1.4 ± 0.2˚; for L-lysine, ΔTm = 1.3 ± 0.2˚, and for L-arginine, ΔTm 
= 0.4 ± 0.1˚. As a point of calibration for the significance of such relatively small shifts in thermal 
stability, ΔTm values of 2˚ or greater can generally be regarded as significant (Giuliani et al., 
2008), although there can be occasional exceptions to this empirically derived threshold. Thus, 
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we used X-ray crystallography as a secondary screen for binding in crystal soaking experiments 
with millimolar concentrations of L-lysine and L-arginine: no evidence for binding was observed. 
Accordingly, it is unlikely that any of the compounds listed in Table 4.3 are biologically-relevant 
ligands for TbARG. We also evaluated the binding of NADPH and NADH using fluorescence 
spectroscopy. No changes were observed in fluorescence emission spectra upon titrating 
NAD(P)H into TbARG solutions, thereby ruling out any possible functional role for this cofactor. 
Reasoning that a substrate might not bind tightly enough to an enzyme to yield a significantly high 
ΔTm value in a thermal shift assay, and hypothesizing that TbARG might have divergently evolved 
with a metal-independent mechanism for ureohydrolase activity, we additionally tested TbARG for 
arginase-like hydrolytic activity with 8 guanidinium derivatives, including L-arginine, agmatine, and 
3-guanidinopropionic acid. We also tested for arginine deiminase activity, formiminoglutamase 
activity, and lysine deacetylase activity as outlined in Materials and Methods. TbARG exhibited no 
catalytic activity in any of these assays. Therefore, the potential ligand binding and/or catalytic 
function of TbARG remains unknown. 
4.4 Discussion 
While the biological function of TbARG remains undetermined, the crystal structure 
provides definitive confirmation that TbARG adopts the tertiary structure and quaternary structure 
of an arginase despite only weak similarity at the level of primary structure (24% and 22% amino 
acid sequence identities with rat and human arginases I, respectively). The crystal structure 
clearly shows that wild-type TbARG lacks metal ligands and metal ions normally characteristic of 
an arginase-like enzyme. However, we demonstrate that metal-binding activity can be 
reintroduced in the putative active site by mutagenesis. The question remains, however, as to 
what chemical or biological function wild-type TbARG serves in the life cycle of T. brucei.  The 
genome of T. brucei is unique in that it encodes for no arginase-like protein except for TbARG 
(Berriman et al., 2005); in comparison, the genome of another parasite, Leishmania mexicana 
(Aslett et al., 2010), encodes a TbARG-like protein (related by 68% amino acid sequence identity)  
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Table 4.3: Thermal Stability Shift Assay of TbARG. 
 
Ligand ΔTm (°C) Ligand ΔTm (°C) 
D-Lysine 1.4 ± 0.2 MnCl2 -0.1 ± 0.1 
L-Lysine 1.3 ± 0.2 L-Valine -0.3 ± 0.1 
N
G
-Methyl-L-arginine 1.3 ± 0.2 L-Phenylalanine -0.3 ± 0.2 
L-Arg-L-Ala dipeptide 1.2 ± 0.2 trans-4-Hydroxy-L-
proline 
-0.3 ± 0.5 
L-Arg-L-Phe dipeptide 1.2 ± 0.2 Nα-Acetyl-L-arginine -0.3 ± 0.4 
L-Ala-L-Arg dipeptide 1.2 ± 0.2 L-Glutamine -0.4 ± 0.3 
L-Aspartic acid 1.1 ± 0.2 γ-Guanidinobutyric acid -0.4 ± 0.2 
Thymine 1.1 ± 0.1 L-2-Amino-3-
guanidinopropionic acid 
-0.4 ± 0.2 
γ-Aminobutyric acid 1.1 ± 0.2 3-Guanidinopropionic 
acid 
-0.4 ± 0.2 
Coenzyme A 1.1 ± 0.1 L-Leucine -0.4 ± 0.2 
Uracil 1.0 ± 0.3 Aminoguanine -0.5 ± 0.2 
D-Glutamic acid 1.0 ± 0.1 N-Acetylputrescine -0.5 ± 0.1 
Nα-Acetyl L-lysine 1.0 ± 0.1 L-Ornithine -0.6 ± 0.3 
Adenine 0.8 ± 0.1 L-Tryptophan -0.6 ± 0.2 
L-Phe-L-Ala dipeptide 0.7 ± 0.1 Agmatine -0.7 ± 0.2 
N
G
,N
G
-Dimethyl-L-arginine 0.7 ± 0.1 L-Norleucine -0.7 ± 0.2 
NiCl2 0.6 ± 0.3  
(-22.0 ± 0.3)
a 
Nε,Nε,Nε,-Trimethyl-L-
lysine 
-0.8 ± 0.1 
L-Arg-L-Lys dipeptide 0.5 ± 0.1 2,6-Diaminopimelic acid -0.8 ± 0.4 
L-Arg-L-Asp dipeptide 0.5 ± 0.1 N
G
-hydroxy-L-arginine -1.0 ± 0.2 
L-Asparagine 0.5 ± 0.1 Pyridoxal -1.0 ± 0.4 
L-Arginine 0.4 ± 0.1 MgCl2 -1.3 ± 0.3 
L-Arg-Gly-L-Asp 0.4 ± 0.1 L-Cysteine -1.4 ± 0.5 
Glycine 0.3 ± 0.1 Imidazole -1.5 ± 0.4 
D-Asparagine 0.2 ± 0.2 1,6-Diaminohexane -1.6 ± 0.5 
Putrescine 0.1 ± 0.2 D,L-Arginine -1.6 ± 0.3 
Nα-Acetyl-L-asparagine 0.1 ± 0.1 D,L-
Difluoromethylornithine 
-1.6 ± 0.4 
L-Norvaline 0.1 ± 0.1 L-Glutamate -1.7 ± 0.1 
  Spermine -2.0 ± 0.6 
  CaCl2 -2.1 ± 0.2 
  FeCl3 -2.8 ± 0.1 
  Spermidine -3.0 ± 0.2 
  Nicotinamide -3.9 ± 0.4 
  AdoMet  -4.7 ± 0.2 
  2-Amino-6-
boronohexanoic acid  
-4.8 ± 0.2 
  ZnCl2 N/A
b 
  Pyridoxal 5’-phosphate N/A
b 
  FAD N/A
b 
 
a
 Biphasic melt curve was observed with two apparent melting temperatures. 
b
 The melt curve did not yield a clear inflection point so Tm was not calculated. 
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as well as a functional arginase. The TbARG is not syntenic to the functional Leishmania 
arginase. Interestingly, a TbARG-like protein with similarly high amino acid sequence identities is 
found in other parasites that infect animals, insects, and plants (Figure 4.7). Like TbARG, none of 
these proteins contain an arginase-like metal binding site, yet residues in the putative active site 
are largely conserved. 
Based on the amino acid sequence alignment in Figure 4.7, potential functional residues 
in the putative active site of TbARG would be highly conserved and include H147, D224, and 
Y267. The conservation of such polar residues could support a variety of chemical functions in 
catalysis. For example, the carboxylate side chain of D224 might serve as general base (although 
this residue appears as N224 in Phytomonas, where the asparagine side chain would be less 
effective as a general base), and the imidazole side chain of H147 might serve as a general acid. 
It is interesting to note that Y267 appears as a histidine in all other homologues shown in Figure 
7, perhaps implying that this residue, too, might be capable of serving in some catalytic function 
as a general acid. However, the identity of a substrate for any catalytic function remains elusive. 
Analysis of TbARG using structural bioinformatics approaches has not provided any additional 
clues regarding a potential biological function. For example, the COFACTOR server (Roy and 
Zhang, 2012) returns only arginases and arginase-like enzymes, all of which contain intact 
binuclear manganese clusters.  
While it is perhaps unsatisfying that a catalytic function cannot be assigned to TbARG, 
that T. brucei contains this protein instead of a functional arginase is nonetheless informative. 
Functional arginase enzymes in other parasites generate a cellular pool of L-ornithine that is 
subsequently converted into putrescine by ornithine decarboxylase, a key step in polyamine 
biosynthesis (Heby et al., 2003). That T. brucei contains a functional ornithine decarboxylase 
(Phillips et al., 1988), but not a functional arginase, indicates that the L-ornithine utilized by T. 
brucei for polyamine biosynthesis must derive from an alternative pathway. For example, L-
ornithine could derive from acetyl-L-ornithine, given that the T. brucei genome encodes a putative 
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acetylornithine deacetylase (ArgE; gene Tb927.1.3000 on chromosome 1). However, the T. 
brucei genome lacks ArgA-ArgD enzymes, which in other organisms function with ArgE to 
generate L-ornithine from L-glutamate (ArgE also functions in prokaryotic L-arginine biosynthesis) 
(McGregor et al., 2005). Thus, lacking any other source of L-ornithine for polyamine biosynthesis, 
T. brucei must import L-ornithine from its host to maintain viability. This is corroborated by 
transport assays
 
(Vincent et al., 2012) showing that T. brucei is capable of importing L-ornithine 
with a Km of 310 μM and a Vmax of 15.9 pmol (10
7
 cells
−1
) min
−1
. With L-ornithine levels in human 
blood and cerebrospinal fluid at 54–100 µM and 5 µM respectively, T. brucei is able to directly 
transport L-ornithine from its environment to fulfill its requirements, signaling that T. brucei does 
not require a functional arginase. 
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Figure 4.7:  Amino acid sequence alignment of TbARG (T_brucei/1-331) with similar proteins 
from other parasites.  
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Chapter 5: Structure of Histone Deacetylase 6 and Molecular Basis for 
Catalysis and Inhibition 
This work is accepted and to be published in Hai, Y., & Christianson, D. W. Nat. Chem. Biol., 
2016, in press 
5.1 Introduction 
Histone deacetylase 6 (HDAC6) is unique among all 11 human Zn
2+
-dependent HDACs 
in that it contains tandem catalytic domains CD1 and CD2 (Grozinger et al., 1999), as well as a 
ubiquitin binding domain
 
(Ouyang et al., 2012) through which polyubiquitinated misfolded protein 
cargo is recruited to dynein motors for transport to aggresomes (Kawaguchi et al., 2003). 
Anchored in the cytoplasm by serine/glutamate-rich repeat motifs (Bertos et al., 2004), HDAC6 
catalyzes the deacetylation of K40 in the α-tubulin subunit of the microtubule (Hubbert et al., 
2002), thereby regulating microtubule dynamics: HDAC6 inhibition leads to hyperacetylation of α-
tubulin and suppression of microtubule dynamics, while overexpression of HDAC6 reduces 
tubulin acetylation levels and increases cell motility (Szyk et al., 2014). Other HDAC6 substrates 
include Hsp90
 
(Kovacs et al., 2005) and the microtubule-associated protein Tau (Cohen et al., 
2005), implicating HDAC6 in the pathology of Alzheimer’s disease (Min et al., 2010). 
  Curiously, it is not completely clear whether both CD1 and CD2 domains of HDAC6 are 
fully functional. Early studies indicated that both catalytic domains are active toward histone 
substrates, with only CD2 exhibiting tubulin deacetylase activity (Grozinger et al., 1999; Haggarty 
et al., 2003), whereas subsequent studies suggested that only CD2 is catalytically active (Zou et 
al., 2006). While both domains may be required for activity (Zhang et al, 2006), it is possible that 
CD1 could serve as a microtubule binding domain (Schreiber and Bernstein, 2002). Additionally, 
HDAC6 CD1 exhibits E3 ubiquitin ligase activity but not deacetylase activity toward MSH2 protein 
(Zhang et al., 2014).  
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Despite these unresolved structure-function relationships, no crystal structures of HDAC6 
catalytic domains have been available thus hindering our efforts to reconcile the aforementioned 
discrepancies about domain activity. In this chapter, we determined X-ray crystal structures of 
HDAC6 CD2 from Homo sapiens (human) and HDAC6 CD1 and CD2 from Danio rerio 
(zebrafish), demonstrating that the zebrafish enzyme is a valid and robust surrogate for the 
human enzyme. Additionally, we did activity measurements showing that CD2 from both species 
exhibits broad substrate specificity, whereas CD1 is highly specific for the hydrolysis of C-terminal 
acetyllysine substrates. Crystal structures of zebrafish CD2 mutants complexed with acetyllysine-
containing peptide substrates provide snapshots of catalysis, including the metastable tetrahedral 
intermediate. Finally, crystal structures of zebrafish CD2 complexed with numerous inhibitors 
provide key insight regarding the molecular basis of affinity, including an alternative hydroxamate-
Zn
2+
 coordination mode that characterizes isozyme-specific inhibition. 
5.2 Materials and Methods 
5.2.1 General Methods 
PCR reactions were performed using the PfuUltra High-Fidelity DNA polymerase (Agilent 
Technologies). Restriction enzymes were purchased from New England Biolabs and used 
according to the manufacturer’s instructions. Custom oligonucleotides were synthesized by 
Integrated DNA Technologies. Escherichia coli strain NEB5α (New England Biolabs) was used 
for cloning procedures. Assay were purchased from GenScript
®
, and Enzo
® 
Life Sciences. HC 
toxin was purchased from Cayman Chemicals. A sample of 7-[(3-aminopropyl)amino]-1,1,1-
trifluoroheptan-2-one was synthesized according to published procedures
 
(Decroos et al., 2013) 
and determined to be >95% pure by mass spectrometry, NMR spectroscopy, and X-ray 
crystallographic structure validation. All other HDAC inhibitors were purchased from ApexBio
®
. All 
substrates and inhibitors were purchased as >95% pure preparations and used without further 
purification.  
 115 
 
 
Figure 5.1: HDAC6 inhibitors used in this study. Abbreviations: SAHA, suberanilohydroxamic 
acid; fl-SAHA, fluorescein-SAHA; HPOB, N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-
oxoethyl)benzamide. 
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5.2.2 Protein expression and purification 
For human HDAC6 protein expression, different expression constructs were made by 
subcloning the corresponding gene from the HDAC6Flag plasmid (a gift from Prof. Eric Verdin, 
University of California, San Francisco; Addgene plasmid #13823)
 
(Fischle et al., 1999) into a 
modified pET28a(+) vector (a gift from Dr. Scott Gradia, University of California, Berkeley; 
Addgene plasmid #29656) in-frame with a TEV-cleavable N-terminal His-MBP-tag (MBP, maltose 
binding protein) using ligation independent cloning. Human HDAC6 proteins were all expressed in 
E. coli BL21 (DE3) Codon Plus RIL (Stratagene) in 2x YT medium in the presence of 50 mg/L 
kanamycin and 30 mg/L chloramphenicol. Expression was induced by 75 µM isopropyl β-D-1-
thiogalactopyranoside (Carbosynth) when OD600 reached 1.0, and cell cultures were grown for an 
additional 18 h at 16 
o
C. The growth medium was supplemented with 200 µM ZnSO4 30 min 
before induction. Cells were harvested by centrifugation and resuspended in lysis buffer [50 mM 
K2HPO4 (pH 8.0), 300 mM NaCl, 10 mM MgCl2, 10% glycerol, 0.1 mg/mL lysozyme (Sigma), 50 
µg/ml DNase I (Sigma), and protease inhibitor tablets (Roche Applied Science)]. Cells were lysed 
by sonication and the cell lysate was cleared by centrifugation at 26,000 g for 1 h at 4 
o
C. The 
supernatant was loaded onto a Ni-NTA affinity column (Qiagen) and the target protein was eluted 
with buffer A [50 mM K2HPO4 (pH 8.0), 1 mM TCEP, 300 mM NaCl, 300 mM imidazole, 5% 
glycerol]. Peak fractions were directly loaded onto an Amylose resin column (New England 
Biolabs) and digested on-column using TEV protease to remove the His-MBP tag in buffer B [20 
mM Tris (pH 8.0), 100 mM NaCl, 1 mM TCEP, 5% glycerol]. Untagged proteins were further 
purified by anion-exchange chromatography (HiTrap Q, GE Healthcare) and then size-exclusion 
chromatography in buffer C [50 mM HEPES (pH 7.5), 100 mM KCl, 1 mM TCEP, 5% glycerol] 
with a HiLoad superdex 200 column. The human CD1-CD2 construct (hCD12) was concentrated 
to ~10 mg/mL and flash-frozen in liquid nitrogen, whereas the individual human CD1 and CD2 
domains (hCD1 and hCD2, respectively) were concentrated to 2 mg/mL and used immediately 
after purification without further storage. Proteins precipitated after freezing or being concentrated 
over 2 mg/mL.  
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To improve the solubility and stability of hCD1 and hCD2, the intact MBP-tagged proteins 
were used for crystallization. However, extensive trials did not yield any crystals. We reasoned 
that this was probably due to the linker peptide (containing a TEV cleavage site) between MBP 
and each HDAC6 domain, which could introduce unwanted flexibility and thus inhibit crystal 
formation. Therefore, we fused the MBP tag to the N-terminus of each human HDAC6 domain 
with a shorter linker (3 alanine residues) by overlap extension PCR. Three charged residues in 
the C-terminal alpha helix of MBP (E350, K363, D364) were also replaced by alanines, as first 
described in the crystallization of human T cell leukemia virus type 1 (HTLV-1) envelope protein 
gp21 (Center et al., 1998; Smyth et al., 2003). The chimeric constructs MBP-hCD1 and MBP-
hCD2 were cloned into a modified pET28a(+) vector (a gift from Dr. Scott Gradia, University of 
California, Berkeley; Addgene plasmid #29653) in-frame with a TEV cleavable N-terminal His-tag 
using ligation independent cloning, and expressed and purified in the same way but without TEV 
cleavage. The zebrafish HDAC6 gene (residues 60-798, Uniprot F8W4B7) was synthesized with 
codon optimization by Genscript. The tandem catalytic domains (residues 60-798) and each 
individual catalytic domain (zCD1, residues 60-419; zCD2, residues 440-798) were subcloned 
into the same expression vector in fusion with a TEV-cleavable N-terminal His-MBP tag, in similar 
manner as outlined above for human HDAC6. The zebrafish HDAC6 proteins were expressed 
and purified in the same way except that E. coli BL21 (DE3) cells (Stratagene) were used as 
expression host.  
5.2.3 Isothermal titration calorimetry 
A MicroCal iTC200 calorimeter (GE Healthcare) was used for all ITC measurements. For 
the titration of peptide Ac-Ser-Asp-Lys(Ac)-Thr-NH2 [corresponding to residues S38-T41 of α-
tubulin] into the active site of Y386F-Y782F hCD2, protein was dialyzed against assay buffer [25 
mM HEPES (pH 7.5), 100 mM KCl, 1 mM TCEP, 5% DMSO] for 12 h prior to assay. Data were 
analyzed using the program Origin.   
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5.2.4 Crystallization 
The MBP-hCD2–trichostatin A (TSA) complex was crystallized using the sitting drop 
vapor diffusion method at 4 
o
C. Purified MBP-hCD2 (13 mg/mL) was first incubated with 2 mM 
TSA, 5% DMSO, 10 mM maltose, and 30 mM Gly-Gly-Gly in buffer C on ice for 30 min, and then 
0.4 µL of protein solution was mixed with precipitant solution [0.2 M potassium sodium tartrate, 
20% PEG 3350]. Plate-like crystals of the MBP-hCD2–TSA complex appeared after 6 months.  
The zCD1–TSA complex was crystallized using the sitting drop vapor diffusion method at 
4 
o
C by mixing 0.35 µL of purified zCD1 [10 mg/mL protein preincubated with 2 mM TSA in 5% 
DMSO] on ice with 0.35 µL precipitant solution [0.2 M ammonium sulfate, 0.1 M MES (pH 6.5), 
25% PEG monomethyl ether 5,000].  Plate-like crystals appeared in 2 weeks.  
The zCD2 structures were all crystallized using the sitting drop vapor diffusion method. 
For zCD2 complexed with suberoylanilide hydroxamic acid (SAHA), 0.35 µL of purified zCD2 [10 
mg/mL protein preincubated with 4 mM SAHA in 5% DMSO] with 0.35 µL precipitant solution [0.1 
M Bis-Tris (pH 6.5), 0.2 M MgCl2, 25% PEG monomethyl ether 5,000] were mixed at 21 
o
C. Plate-
like crystals appeared after 1 week. The zCD2–TSA complex was crystallized at 21 
o
C by mixing 
0.35 µL of purified zCD2 [16 mg/mL protein preincubated with 2 mM TSA in 5% DMSO] with 
precipitant solution [0.1 M ammonium iodide, 20% PEG 3350]. Thick plate-like crystals appeared 
in 4 days. The zCD2–Belinostat complex was crystallized at 4 
o
C by mixing 0.35 µL of purified 
zCD2 [10 mg/mL protein preincubated with 4 mM Belinostat in 5% DMSO] with precipitant 
solution [0.1 M Bis-Tris (pH 5.5), 25% PEG 3350]. Plate-like crystals appeared after 6 days. The 
zCD2 complex with the HDAC6-specific inhibitor N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-
2-oxoethyl)benzamide (HPOB) was crystallized at 4 
o
C by mixing 0.35 µL of purified zCD2 [10 
mg/mL protein preincubated with 4 mM HPOB in 5% DMSO] with precipitant solution [0.1 M Tris 
(pH 8.5), 25% PEG 3350]. Large, thin, plate-like crystals appeared after 4 days. The zCD2-
Panobinostat complex was crystallized at 4 
o
C by mixing 0.3 µL of purified zCD2 [8 mg/mL 
protein preincubated with 4 mM Panobinostat in 5% DMSO] with precipitant solution [0.1 M MES 
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(pH 6.5), 12% PEG 20,000]. Thin plate-like crystals appeared after a month. The zCD2-HC toxin 
complex was crystallized at 4 
o
C by mixing 0.3 µL of purified zCD2 [8 mg/mL protein preincubated 
with 4 mM HC toxin in 5% DMSO] with precipitant solution [0.2 M sodium nitrate, 20% PEG 
3350]. Thick plate-like crystals appeared after three weeks.  Unliganded zCD2 was crystallized at 
4 
o
C by mixing 0.35 µL of purified zCD2 [10 mg/mL protein preincubated with 4 mM Rocilinostat 
in 5% DMSO] with precipitant solution [0.1 M sodium acetate, 0.1 M sodium formate, 20% PEG 
3350]. Crystals appeared after 2 weeks (subsequent structure determination revealed that 
Rocilinostat was not bound to the enzyme). The zCD2 complex with the trifluoroketone transition 
state analogue inhibitor was crystallized at 4
 o
C by mixing 0.35 µL of purified zCD2 (10 mg/mL 
protein preincubated with 5 mM inhibitor in buffer C) with precipitant solution [0.2 M sodium 
bromide, 20% PEG 3350]. Crystals appeared after 4 days. The zCD2-acetate complex was 
crystallized at 4 
o
C by mixing 0.35 µL of purified zCD2 (10 mg/mL) with precipitant solution [0.2 M 
sodium acetate, 30% PEG 8000]. Crystals appeared after 3 days.  
The H574A zCD2–substrate 8 (Ac-RGK(ac)-AMC (AMC = 7-amino-4-methyl-coumarin)) 
complex was crystallized using the sitting drop vapor diffusion method at 4 
o
C by mixing 0.35 µL 
of protein solution [10 mg/mL protein preincubated with the histone H4-based tripeptide assay 
substrate Ac-Arg-Gly-Lys(Ac)-aminomethylcoumarin in 30 mM Tricine (pH 7.3), 100 mM KCl, 5% 
glycerol, 1 mM TCEP, 5% DMSO] with 0.35 µL precipitant solution [0.1 M Bis-Tris (pH 6.5), 25% 
PEG 3350]. Clusters of crystal plates appeared after two weeks; single crystals for X-ray 
diffraction analysis were obtained by breaking up crystal clusters. The Y745F zCD2–substrate 1 
(Ac-SDK(ac)-AMC) complex was crystallized using the sitting drop vapor diffusion method at 4 
o
C 
by mixing 0.35 µL of protein solution [5 mg/mL protein preincubated with the α-tubulin K40 based 
tripeptide assay substrate Ac-Ser-Asp-Lys(Ac)-aminomethylcoumarin in buffer C supplemented 
with 5% DMSO] with 0.35 µL precipitant solution [0.1 M Bicine (pH 9.0), 2% v/v 1,4-dioxane, 10% 
PEG 20000]. Thick crystal plates appeared overnight. The zCD2–oxamflatin complex was 
crystallized using the sitting drop vapor diffusion method at 4 
o
C by mixing 0.35 µL of protein 
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solution [9 mg/mL protein preincubated with oxamflatin in buffer C supplemented with 5% DMSO] 
with 0.35 µL precipitant solution [0.1 M HEPES (pH 7.5), 10% v/v 2-propanol, 20% PEG 4000]. 
Small thin crystal plates appeared after 3 days. All crystals were soaked in a cryoprotectant 
solution comprised of mother liquor supplemented with 25-30% glycerol prior to flash-freezing in 
liquid nitrogen.  
5.2.5 Crystal structure determination 
For the zCD1-TSA complex, the zCD2-TSA complex, and the zCD2-SAHA complex, X-
ray diffraction data were recorded at the Stanford Synchrotron Radiation Lightsource (SSRL), 
beamline 14-1 (λ = 1.28184 Å). For the MBP-hCD2-TSA complex, unliganded zCD2, the H574A 
zCD2-substrate 8 complex, and the zCD2-Belinostat complex, X-ray diffraction data were 
recorded at the Advanced Photon Source (APS), beamline NE-CAT 24-ID-E (λ = 0.97918 Å). For 
all other structures, X-ray diffraction data were recorded at the Advanced Light Source (ALS), 
beamline 4.2.2 (λ = 1.00003 Å). Data reduction and integration for all datasets was achieved with 
HKL2000; data collection and reduction statistics are recorded in Tables 5.1–5.4. Although Rmerge 
values were relatively high for some datasets, analysis of CC1/2 values indicated that these 
datasets were of sufficient quality for satisfactory structure determination and refinement. All 
structures were solved by molecular replacement using the program Phaser. For the structure of 
the zCD2–SAHA complex, a model of the HDAC4 catalytic domain in a closed-loop conformation 
(PDB entry 4CBT) was used as the search probe (Burli et al., 2013). For all other zCD1 and 
zCD2 structures, the structure of the zCD2-SAHA complex less inhibitor and water molecules 
was used as a search probe. For the structure determination of the fusion protein MBP-hCD2–
TSA complex, maltose binding protein (PDB entry 4EDQ) and the zCD2–TSA complex less 
ligands and solvent molecules were used as search probes. The graphics program Coot was 
used for model building and Phenix was used for crystallographic refinement.
 
Refinement 
statistics for each final model are recorded in Tables 5.1–5.4. The quality of each model was 
verified with PROCHECK and MolProbity (Chen et al., 2010). Figures were prepared with Pymol 
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and UCSF Chimera (Pettersen et al., 2014). The Ramachandran statistics for each model are as 
follows: zCD1-TSA complex: 90.3% allowed, 9.4% additionally allowed; zCD2-TSA complex: 
91.6% allowed, 7.8% additionally allowed; MBP-hCD2-TSA complex: 88.5% allowed, 10.8% 
additionally allowed; unliganded zCD2: 91.1% allowed, 8.6% additionally allowed; H574A zCD2-
substrate 8 complex: 92.2% allowed, 7.3% additionally allowed; Y785F zCD2-substrate 1 
complex: 90.6% allowed, 8.7% additionally allowed; Y785F zCD2-substrate 1 complex: 90.6% 
allowed, 8.7% additionally allowed; zCD2-HC toxin complex: 90.6% allowed, 8.8% additionally 
allowed; zCD2-trifluoroketone inhibitor complex: 90.5% allowed, 9.0% additionally allowed; zCD2-
acetate complex: 90.4% allowed, 9.1% additionally allowed; zCD2-SAHA complex: 91.4% 
allowed, 8.0% additionally allowed; zCD2-Belinostat complex: 91.1% allowed, 8.5% additionally 
allowed; zCD2-HPOB complex: 91.0% allowed, 8.7% additionally allowed; zCD2-Panobinostat 
complex: 89.9% allowed, 9.6% additionally allowed; zCD2-Oxamflatin complex: 89.3% allowed, 
10.0% additionally allowed. No backbone torsion angles adopt disallowed conformations in any 
structure. 
5.2.6 HDAC6 activity assays 
Assays were performed in triplicate at room temperature. Briefly, substrates and 
enzymes were diluted into HDAC assay buffer [50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM 
KCl, 1.0 mM MgCl2] at varying concentrations. To initiate the reaction, 25 µL of substrate solution 
was added to 25 µL of enzyme solution (3 – 250 nM). The reaction was stopped by adding the 
developer solution [1 µM trypsin and 10 µM TSA in HDAC assay buffer]. After 10-30 min, the 
reaction mixture was transferred to a NUNC 384 well optical bottom black plate (Thermo Fisher 
Scientific) and the fluorescence was measured using a Tecan Infinite M1000Pro plate reader (λex 
= 360 nm, λem = 455 nm). Enzyme activity was calculated based on the standard curve using 
Fluor de lys
®
 deacetylated standard (Enzo
®
 Life Sciences). Data were analyzed by logistic 
regression for IC50 determination and the inhibition constant Ki was calculated based on the 
Cheng-Prusoff equation, Ki = IC50 / (1+[S]/KM) (Cheng and Prusoff, 1973).  
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Table 5.1: Data reduction and refinement statistics of HDAC6. 
    
 zCD1-TSA 
complex 
zCD2-TSA 
complex 
MBP-hCD2-TSA 
complex 
Unliganded zCD2 
Data collection     
Space group P21 P21212 P212121 P1 
Cell dimensions     
     a, b, c (Å),  
     α, β, γ (
o
)       
52.9, 123.7, 55.2 
90.0, 113.8, 90.0 
83.9, 94.4, 51.7 
90.0, 90.0, 90.0 
49.3, 149.0, 216.3 
90.0, 90.0, 90.0 
48.5, 55.4, 74.2 
73.6, 89.8, 82.6 
Resolution (Å)
* 
45.04 - 2.15  
(2.24 - 2.15) 
50.00 - 1.59 
(1.66 - 1.59) 
149.00 - 2.79 
(2.90 - 2.79) 
50.00 - 2.00 
(2.08 - 2.00) 
Rmerge
 
0.178 (0.701) 0.061 (0.033) 0.204 (1.853) 0.162 (0.501) 
Rpim 0.122 (0.493) 0.050 (0.297) 0.141 (0.607) 0.162 (0.509) 
I / σI
 
10.6 (2.0) 23.7 (4.3) 12.9 (1.9) 6.4 (1.8) 
Completeness (%)
 
99.0 (95.9) 100.0 (100.0) 100.0 (100.0) 97.0 (96.6) 
Redundancy
a 
3.1 (2.8) 2.5 (2.4) 11.0 (11.3)
 
1.9 (1.9) 
CC1/2
 
0.754 (0.536) 0.935 (0.865) 0.986 (0.585) 0.967 (0.662) 
Refinement
 
    
Resolution (Å) 45.04 - 2.15 
(2.23 - 2.15) 
44.01  - 1.59 
(1.65 - 1.59) 
87.54 - 2.79  
(2.89 - 2.79) 
15.91 - 2.00 
(2.07 - 2.00) 
No. reflections 34834 (3335) 55924 (5519) 40788 (4012) 47957 (4586) 
Rwork / Rfree 0.211/0.255   
(0.282/0.325) 
0.129/0.163  
(0.128/0.187) 
0.213/0.275 
(0.313/0.377) 
0.224/0.272 
(0.276/0.316) 
No. atoms
 
    
Protein 5558 2836 3260 5541 
Ligand/ion 63 77 77 12 
Water 164 376 355 305 
B factors (Å
2
)     
Protein 32 13 55 17 
Ligand/ion 34 32 62 25 
Water 30 28 59 21 
R.m.s. deviations     
   bond lengths (Å) 0.006 0.010 0.004 0.006 
   bond angles (
o
) 0.9 1.2 0.8 1.0 
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Table 5.2: Data reduction and refinement statistics of HDAC6. 
 
 H574A zCD2-substrate 
8 complex 
Y785F zCD2- 
substrate 1 
complex 
zCD2-HC toxin 
complex 
zCD2-trifluoro- 
ketone inhibitor 
complex 
Data collection     
Space group P21 P21212 P21212 P212121 
Cell dimensions     
     a, b, c (Å),  
     α, β, γ (
o
)       
55.0, 84.0, 87.0 
90.0, 98.1, 90.0 
83.3, 94.7,51.6 
90.0, 90.0 90.0 
83.5, 94.1, 51.5 
90.0, 90.0, 90.0 
74.6, 92.4, 96.2 
90.0, 90.0, 90.0 
Resolution (Å)
* 
50.00 - 1.80  
(1.87 - 1.80) 
50.00 - 1.82 
(1.88 - 1.82) 
50.00 - 1.73 
(1.79 - 1.73) 
50.00 - 2.16 
(2.24 - 2.16) 
Rmerge
 
0.142 (0.713) 0.164 (0.655) 0.151 (0.442) 0.148 (0.334) 
Rpim 0.098 (0.509) 0.049 (0.344) 0.061 (0.273) 0.061 (0.178) 
I / σI
 
9.9 (1.8) 13.6 (1.1) 14.0 (1.6) 13.5 (3.0) 
Completeness (%)
 
98.9 (99.9) 99.4 (94.1) 98.7 (90.6) 98.8 (90.3) 
Redundancy
a 
3.0 (3.0) 11.0 (4.1) 6.6 (3.1) 6.6 (3.9)
 
CC1/2
 
0.975 (0.524) 0.958 (0.692) 0.976 (0.808) 0.977 (0.933) 
Refinement
 
    
Resolution (Å) 12.34 - 1.80 
(1.87 - 1.80) 
45.32 - 1.81 
(1.88 - 1.81) 
47.07 - 1.73 
(1.79 - 1.73) 
49.71 - 2.16 
(2.24 - 2.16) 
No. reflections 70922 (6942) 37343 (3333) 42831 (3774) 35829 (3223) 
Rwork / Rfree 0.162/0.194   
(0.238/0.270) 
0.157/0.183  
(0.260/0.265) 
0.152/0.173 
(0.224/0.244) 
0.196/0.242 
(0.221/0.275) 
No. atoms
 
    
Protein 5718 2792 2817 5581 
Ligand/ion 28 33 25 24 
Water 25 29 27 23 
B factors (Å
2
)     
Protein 5718 2792 2817 5581 
Ligand/ion 28 33 25 24 
Water 25 29 27 23 
R.m.s. deviations     
   bond lengths (Å) 0.008 0.009 0.012 0.005 
   bond angles (
o
) 1.0 1.1 1.2 1.0 
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Table 5.3: Data reduction and refinement statistics of HDAC6. 
 
 zCD2-acetate 
complex 
zCD2-SAHA 
complex 
zCD2-Belinostat 
complex 
zCD2-HPOB 
complex 
Data collection      
Space group P212121 P21 P212121 P1 
Cell dimensions     
     a, b, c (Å),  
     α, β, γ (
o
)       
75.1, 91.8, 96.2 
90.0, 90.0, 90.0 
54.8, 83.6, 86.8 
90.0, 98.1, 90.0 
76.0, 95.5, 96.3 
90.0, 90.0, 90.0 
48.7, 56.6, 74.8 
106.4, 90.1, 
97.1 
Resolution (Å)
* 
50.00 - 2.25 
(2.33 - 2.25) 
50.00 - 1.32 
(1.38 - 1.32) 
50.00 - 1.85 
(1.92 - 1.85) 
50.60 - 1.90 
(1.97 - 1.90) 
Rmerge
 
0.130 (0.356) 0.124 (1.170) 0.167 (0.831) 0.143 (0.754) 
Rpim 0.055 (0.212) 0.043 (0.481) 0.078 (0.328) 0.114 (0.640) 
I / σI
 
14.5 (2.8) 40.0 (2.0) 13.0 (1.6) 6.9 (1.6) 
Completeness (%)
 
99.3 (93.9) 95.0 (90.7) 99.7 (100) 97.5 (95.7) 
Redundancy
a 
6.3 (3.5) 3.3 (3.1) 7.5  (7.4) 3.2 (3.2) 
CC1/2
 
0.969 (0.856) 0.706 (0.215) 0.996 (0.895) 0.982 (0.480) 
Refinement
 
    
Resolution (Å) 49.77 - 2.24 
(2.33 - 2.24) 
36.26 - 1.32 
(1.37 - 1.32) 
17.06 - 1.86  
(1.92 - 1.86)  
50.55 - 1.90 
(1.97 - 1.90) 
No. reflections 32149 (2879) 170694 
(15998) 
(59011/5804) 58345 (5700) 
Rwork / Rfree 0.212/0.234 
(0.280/0.319) 
0.125/0.147   
(0.241/0.273) 
0.183/0.224  
(0.267/0.314) 
0.181/0.288 
(0.221/0.356) 
No. atoms
 
    
Protein 5603 5733 5570 5572 
Ligand/ion 22 83 52 52 
Water 26 644 343 442 
B factors (Å
2
)     
Protein 5603 18 22 18 
Ligand/ion 22 28 27 36 
Water 26 30 28 27 
R.m.s. deviations     
   bond lengths (Å) 0.005 0.010 0.006 0.009 
   bond angles (
o
) 1.0 1.2 0.9 1.1 
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Table 5.4: Data reduction and refinement statistics. 
 zCD2-Panobinostat complex zCD2-Oxamflatin 
complex 
Data collection    
Space group P21212 P21212 
Cell dimensions   
     a, b, c (Å),  
     α, β, γ (
o
)       
65.2, 91.9, 140.4 
90.0, 90.0, 90.0 
83.5, 94.4, 51.6  
90.0, 90.0, 90.0 
Resolution (Å)
* 
50.00 - 2.60 
(2.71 - 2.60) 
50.00 - 2.54 
(2.63 - 2.54) 
Rmerge
 
0.217 (0.699) 0.137 (0.311) 
Rpim 0.088 (0.334) 0.065 (0.185) 
I / σI
 
8.3 (1.6) 11.6 (3.1) 
Completeness (%)
 
99.4 (95.6) 98.8 (92.1) 
Redundancy
a 
6.9 (4.8)
 
4.9 (3.1) 
CC1/2
 
0.984 (0.703) 0.974 (0.882) 
Refinement
 
  
Resolution (Å) 49.71 - 2.60 
(2.69 - 2.60) 
47.22 - 2.54 
(2.63 - 2.54) 
No. reflections 26488 (2368) 13596 (1131) 
Rwork / Rfree 0.189/0.265 (0.234/0.325) 0.147/0.157 (0.194/0.214) 
No. atoms
 
  
Protein 5595 2778 
Ligand/ion 80 27 
Water 205 143 
B factors (Å
2
)   
Protein 26 17 
Ligand/ion 38 26 
Water 26 20 
R.m.s. deviations   
   bond lengths (Å) 0.005 0.009 
   bond angles (
o
) 0.9 1.1 
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Evaluation of specific activity of HDAC6 with nonfluorogenic peptide substrates was 
based on the reaction of fluorescamine with liberated primary amino groups after deacetylation 
(Hildmann et al., 2004). Briefly, 25 µL of enzyme (0.05 – 2 µM) in phosphate buffer [20 mM 
K2HPO4 (pH 7.8), 100 mM NaCl, 5 mM KCl] was added to 25 µL of substrate solution (2 mM) to 
initiate reaction. After incubation for 15-60 min at room temperature, the reaction was quenched 
by the addition of 50 µL fluorescamine (2 mM) in DMSO; fluorescence was recorded with a Tecan 
Infinite M1000Pro plate reader (λex = 390 nm, λem = 470 nm). Assays were performed in triplicate 
at room temperature. For the study of steady-state kinetics of HDAC6 with nonfluorogenic peptide 
substrates, a discontinuous liquid chromatography-mass spectrometry (LC-MS) was developed. 
Briefly, 4 µL of enzyme (0.03 – 10 µM) in HEPES buffer [20 mM HEPES (pH 7.5), 100 mM NaCl, 
5 mM KCl, 1 mM MgCl2] was added to 36 µL of substrate solution to initiate reaction. After 
incubation for 15-60 min at room temperature, the reaction was quenched by addition of 50 µL of 
acetonitrile followed by 10 µL of NaHCO3 (1.6 M, pH 10.0). To efficiently separate the 
deacetylation products of substrate 9 Ac-GAK(ac), 10 Ac-AK(ac), 11 Ac-AK(ac)A-NH2, 12 and Ac-
AK(ac)P-NH2, the deacetylation products were derivatized with dansyl chloride (10 mM in 
acetonitrile) at 50 
º
C for 1 hr. The deacetylation products were detected by liquid 
chromatography-mass spectrometry (LC-MS) using a Waters SQD equipped with an Acquity 
UPLC (Waters, Milford, MA, USA) and quantified by using the standard curves generated from 
the mass signals of the corresponding deacetylated synthetic peptide. Note that the product of 
the reaction with substrate 13 Ac-TK(ac)PIW-NH2 can be efficiently separated from the reaction 
mixture for MS characterization; thus, product dansylation was not required for this particular 
assay. Assays were performed in triplicate at room temperature. 
5.2.7 Fluorescence anisotropy assays.  
The fluorescence anisotropy assay was performed with fluorescein-labeled SAHA (fl-
SAHA, a gift kindly provided by Prof. Carol Fierke, University of Michigan) and measured using a 
TECAN infinite F200Pro plate reader (λex = 485 nm, λem = 535 nm) (Kim et al., 2015). Briefly, 30 
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nM fl-SAHA was titrated with enzyme (0-15 µM) and incubated at room temperature for 20 
minutes. The Kd values were determined by fitting the binding isotherm with equation using 
GraphPad Prism software.  
 (1) 
   
5.3. Results 
5.3.1 Substrate specificity of CD1 and CD2 
To isolate the catalytic activities of individual domains in the tandem domain constructs 
hCD12 and zCD12, we inactivated each domain by mutating the catalytic tyrosine or histidine 
(Y386 in hCD1, Y782 in hCD2, H194 in zCD1, H574 in zCD2), or the histidine Zn
2+
 ligand (H255 
in hCD1, H651 in hCD2). Detailed steady-state kinetics measured with representative substrates 
1 and 8, derived from α-tubulin and histone H4, respectively (Table 5.5), indicated that mutation 
of hCD2, but not hCD1, leads to more than 400-fold decreased catalytic efficiency (kcat/KM). The 
individual hCD2 domain was slightly less active (5-fold) than hCD12, whereas no activity was 
detected with hCD1 at up to 5 µM protein. These results were consistent with the binding of a 
fluorescent inhibitor to only a single high-affinity site in hCD12 (Figure 5.2).  
Significant hCD1 activity in Y782F hCD12 was only observed with C-terminal acetyllysine 
peptide substrates 9 and 10, indicating that hCD1 was indeed catalytically active, but exhibited 
strict substrate specificity for substrates bearing C-terminal acetyllysine residues (Table 5.6). 
Steady-state kinetics showed that hCD1 (Y782F hCD12) exhibited robust catalytic efficiency 
(~1,000 M
-1
s
-1
) compared to hCD2 (Y386F hCD12) with substrates 9 and 10. The hydrolysis of C-
terminal acetyllysine substrates by hCD1 required an intact tandem domain assembly, since 
hCD1 was not catalytically active as an isolated domain. This behavior was similar to that 
observed for murine HDAC6, for which both domains were required for catalytic activity. 
Presumably, the hCD2 domain, even though inactivated by the Y782F substitution, structurally  
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Table 5.5. Steady-state kinetics of HDAC6.
a 
Substrate 1 (Ac-SDK(ac)-AMC) KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 22 ± 6 0.05 ± 0.01 (2.3 ± 0.9) x 10
3
 
hCD12 Y386F 26 ± 9 0.06 ± 0.02 (2.3 ± 0.9) x 10
3
 
hCD12 Y782F 62 ± 4 0.00030 ± 0.00002 4.8 ± 0.3 
hCD12 Y386F/Y782F 69 ± 3 0.00021 ± 0.00001 3.0 ± 0.2  
zCD12 38 ± 6 0.8 ± 0.1 (2.10 ± 0.08) x 10
4
 
zCD12 H194A 31 ± 9 0.7 ± 0.1 (2.3 ± 0.8) x 10
4
 
zCD12 H574A 65 ± 9 0.082 ± 0.007 (1.2 ± 0.1) x 10
3
 
zCD1 87 ± 9 0.079 ± 0.006 (0.9 ± 0.1) x 10
3
 
zCD2 29 ± 9 0.56 ± 0.09 (1.9 ± 0.5) x 10
4
 
Substrate 8 (Ac-RGK(ac)-AMC) KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hFLWT
b
 7 ± 4 0.04 ± 0.01 (6 ± 1) x 10
3
 
hCD12 11 ± 4 0.049 ± 0.009 (4.4 ± 0.9) x 10
3
 
hCD1
c 
n.a. n.a. n.a. 
hCD2 22 ± 3 0.020 ± 0.002 (0.91 ± 0.03) x 10
3
 
hCD12 Y386F 16 ± 4 0.06 ± 0.02 (4 ± 1) x 10
3
 
hCD12 Y782F 42 ± 4 0.0003 ± 0.0001 7 ± 2 
hCD12 Y386F/Y782F 39 ± 3 0.0004 ± 0.0002 9 ± 2 
hCD12 Y225F/Y782F 56 ± 9 0.048 ± 0.004 (0.86 ± 0.06)  x 10
3
 
hCD12 K353L/Y782F 52 ± 6 0.002 ± 0.001 40 ± 10     
hCD2 D567A 26 ± 3 0.022 ± 0.006 (0.8 ± 0.1) x 10
3
 
hCD2 S568A 21 ± 5 0.0020 ± 0.0007 90 ± 10 
zCD12 28 ± 3 0.98 ± 0.09 (3.5 ± 0.5) x 10
4
 
zCD12 H194A 19 ± 6 0.60 ± 0.05 (3.2 ± 0.4) x 10
4
 
zCD12 H574A 38 ± 7 0.23 ± 0.07 (6.2 ± 0.9) x 10
3
 
zCD1 43 ± 6 0.20 ± 0.06 (4.7 ± 0.3) x 10
3
 
zCD1 K330L 32 ± 7 0.155 ± 0.009 (5 ± 1)  x 10
3
 
zCD1 H82F/F202Y 47 ± 4 0.016 ± 0.006 (0.34 ± 0.9) x 10
3
 
zCD2 22 ± 9 0.69 ± 0.08 (3.1 ± 0.5) x 10
4
 
zCD2 H573A   8 ± 3 0.00021 ± 0.00004 26 ± 4 
zCD2 H574A   9 ± 2 0.0006 ± 0.0001 67 ± 6 
zCD2 N530A 40 ± 10 0.7 ± 0.1 (1.7 ± 0.9) x 10
4
 
zCD2 S531A 240 ± 40 0.03 ± 0.01 (0.12 ± 0.04) x 10
3
 
a
Data represent mean values ± s.e.m. (n=3). 
b
hFLWT, human full-length wild-type HDAC6 from 
Enzo Life Sciences. 
c
n.a., no activity.  
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Table 5.6: Steady-state kinetics of HDAC6.
a 
Substrate 9 Ac-GAK(ac) KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 100 ± 20 0.26 ± 0.02 (2.7 ± 0.5) x 10
3
 
hCD12 Y386F 90 ± 40 0.18 ± 0.04 (1.9 ± 0.9) x 10
3
 
hCD12 Y782F 50 ± 10 0.080 ± 0.006 (1.5 ± 0.4) x 10
3
 
zCD1 100 ± 20 0.9 ± 0.1 (8.6 ± 0.9) x 10
3
 
zCD2 140 ± 50 1.2 ± 0.3 (8.0 ± 2.0) x 10
3
 
zCD12 110 ± 30 2.0 ± 0.3 (1.9 ± 0.4) x 10
4
 
Substrate 10 Ac-AK(ac) KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 80 ± 20 0.20 ± 0.02 (2.3 ± 0.4) x 10
3
 
hCD12 Y386F 120 ± 20 0.13 ± 0.01 (2.3 ± 0.4) x 10
3
 
hCD12 Y782F 80 ± 10 0.078 ± 0.005 (1.0 ± 0.1) x 10
3
 
zCD1 120 ± 40 0.9 ± 0.2 (7.0 ± 2.0) x 10
3
 
zCD2 110 ± 20 0.82 ± 0.08 (7.3 ± 0.7) x 10
3
 
zCD12 80 ± 20 1.5 ± 0.1 (1.9 ± 0.2) x 10
4
 
Substrate 11 Ac-AK(ac)A-NH2 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 210 ± 70
 
0.11 ± 0.04 (0.59 ± 0.08) x 10
3
 
hCD12 Y386F 140 ± 60 0.10 ± 0.02 (0.7 ± 0.2) x 10
3
 
hCD12 Y782F n.a.
b 
n.a. n.a. 
zCD1 n.d.
c
 n.d. 11 ± 6 
zCD2 110 ± 20 0.44 ± 0.04 (4.0 ± 0.4) x 10
3
 
zCD12 150 ± 30 0.62 ± 0.08 (4.2 ± 0.5) x 10
3
 
Substrate 12 Ac-AK(ac)P-NH2 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 70 ± 30 0.25 ± 0.04 (4 ± 1) x 10
3
 
hCD12 Y386F 80 ± 30 0.26 ± 0.04 (3.1 ± 0.9) x 10
3
 
hCD12 Y782F n.a. n.a. n.a. 
zCD1 90 ± 30 0.047 ± 0.006 (0.6 ± 0.1) x 10
3
 
zCD2 80 ± 20 0.9 ± 0.1 (1.2 ± 0.2) x 10
4
 
zCD12 70 ± 10 1.3 ± 0.1  (1.8 ± 0.3) x 10
4
 
Substrate 13 Ac-TK(ac)PIW-NH2 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 70 ± 20 0.07 ± 0.01 (0.9 ± 0.1) x 10
3
 
hCD12 Y386F 60 ± 7 0.060 ± 0.002 (0.97 ± 0.08) x 10
3
 
hCD12 Y782F n.d. n.d. 3 ± 1 
zCD1 n.d. n.d. 20 ± 10 
zCD2 130 ± 50 0.39 ± 0.07 (3.0 ± 0.7) x 10
3
 
zCD12 200 ± 40 0.58 ± 0.06 (2.9 ± 0.4) x 10
3
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Substrate 14 Ac-RGK(ac)G-NH2 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
hCD12 Y782F n.d. n.d. 150 ± 30 
a
Data represent mean values ± s.e.m. (n=3). 
b
n.a., no activity. 
d
n.d., not determined.   
 
 
 
 
 
 
 
 
 
 
 
Table 5.7: Inhibition of zHDAC6 CD2.  
 TSA HPOB HC 
toxin 
Trifluoro
-ketone 
Belino-
stat 
Panobino-
stat 
SAHA Oxamflatin 
IC50 
(nM) 
1.4 
 ± 0.2 
1.8 
 ± 0.3 
600 
 ± 90 
1400  
± 200 
1.9  
± 0.3 
2.5  
± 0.5 
1.1  
± 0.3 
7.5  
± 0.9 
Ki  
(nM) 
0.8  
± 0.1 
1.0 
 ± 0.2 
350 
 ± 50 
800  
± 100 
1.1  
± 0.2 
1.4  
± 0.3 
0.6 
 ± 0.2 
4.3  
± 0.5 
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          (c) 
Figure 5.2: Ligand binding to catalytic domains of hHDAC6. (a) Fluorescence anisotropy 
assay. Ligand fl-SAHA binding to wild-type enzyme is characterized by a biphasic curve and the 
elevated plateau indicates protein-protein interaction at high enzyme concentration ([E]>5000 
nM). The curve in the low enzyme concentration region ([E]>5000 nM) is fitted with equation (1) 
yielding an apparent dissociation constant Kd. To resolve the ambiguity of domain-binding, we 
then disabled ligand binding in each domain by mutating Zn
2+
 ligand H255V in hCD1 and H651V 
in hCD2. H255V hCD12 retains high affinity ligand binding activity, whereas H651V hCD12 
exhibits 150-fold diminished affinity. These results are consistent with high-affinity binding only to 
hCD2. Data represent mean ± s.d. (n = 3).  (b) Binding affinities for other constructs. Data 
represent mean ± s.e.m. (n = 3). (c) Isothermal titration calorimetry of the binding of a 
tetrapeptide, Ac-Ser-Asp-Lys(Ac)-Thr-NH2 derived from the α-tubulin, to the inactive double 
mutant Y386F/Y782F hCD12. The binding isotherm fits to a single-site curve with 1:1 
stoichiometry, consistent with peptide binding only to hCD2. Line fitting yields stoichiometry n = 
0.9 ± 0.1, ∆H = –17 ± 3 kcal/mol, and dissociation constant Kd = 11 ± 2 µM.
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stabilized the hCD1 domain in hCD12 for optimal catalytic activity. We next characterized steady-
state kinetics of the zebrafish orthologue using substrates 1 and 8–13 (Table 5.5–5.6). The 
zebrafish orthologue shows high sequence similarity/identity with human orthologue (Figure 5.3), 
and behaves very well in vitro, thus makes it an ideal target for structural study.  
In contrast to hHDAC6, both catalytic domains of zHDAC6 were active when assayed 
with fluorogenic substrates, even when assayed as individual domains. However, zCD1 was less 
active than zCD2 (kcat/KM is reduced 21-fold and 7-fold for substrates 1 and 8, respectively). Even 
so, zCD1 similarly preferred substrates 9 and 10, which bear C-terminal acetyllysine residues. 
Steady-state kinetics showed that zCD1 was as active as zCD2 with substrates 9 and 10, but less 
active than zCD2 with substrates 11–13 (20–380-fold reduced kcat/KM). In addition, both hCD2 
and zCD2 exhibited broad substrate specificity. Steady-state kinetics showed that the catalytic 
efficiency was reduced by only 3–4-fold when the least favored substrates 11 and 13 were 
compared to the optimal substrate 12 (Table 5.6). Taken together, these results demonstrated 
that in the full-length human and zebrafish enzymes, CD2 exhibited broad substrate specificity for 
endo- and exo-acetyllysine peptide substrates X-K(Ac)-X, X-K(Ac)-Pro-X, and X-K(Ac)-CO2
–
, 
whereas hCD1 exhibited strict substrate specificity for exo-acetyllysine peptide substrates X-
K(Ac)-CO2
–
; substrate specificity for zCD1 was somewhat more relaxed.  
5.3.2 Crystal structures of human CD2 and zebrafish CD2 
The crystal structure of hCD2 as a fusion construct with maltose binding protein was 
similar to that of zCD2), with an r.m.s. deviation of 0.43 Å for 314 Cα atoms; both were 
cocrystallized with the inhibitor trichostatin A (TSA). Although zCD2 exhibited ~10-fold enhanced 
catalytic activity compared with hCD2, their active site contours were highly similar (Figure 5.4). 
In the zCD2 active site, only N530 and N645 were not conserved, appearing as D567 and M682 
in hCD2; moreover, these residues were at the outer rim of the active site and were quite distant 
from bound inhibitors. Therefore, the zebrafish enzyme was judged to be a valid surrogate for the  
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Figure 5.3: Sequence alignment of HDAC6 orthologues. In each domain, the Zn
2+
 ion binding 
residues are highlighted in red, the conserved catalytic residues in the active site are highlighted 
in orange, the aspartate residue interacting with the backbone NH groups flanking the 
acetyllysine substrate (D101 in HDAC8) is highlighted in sky blue, the newly identified conserved 
serine residue important for substrate binding in HDAC6 is highlighted in magenta, and the 
conserved buried active site cysteine residue is highlighted in green. Remaining conserved 
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residues with are highlighted in blue. Amino acid sequence identities/similarities are 62%/77% for 
hCD1 and zCD1, and 59%/75% for hCD2 and zCD2. Reprinted with permission from Macmillan 
Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol. 2016, in press. Copyright 
2016.  
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Figure 5.4: Crystal structure of MBP-hCD2 and zCD2 both in complex with TSA. (a) 
Simulated annealing omit map (grey mesh, 3.0σ) shows ligands bound to each protein. The linker 
(red) consists of the C-terminus of MBP (containing mutations D358A, E359A, K362A, D363A, 
R367N, and ΔI368-K370) linked to an Ala3 segment, which then connects to the N-terminus of 
hCD2. This engineered linker forms an α-helix (red) that provides a complementary surface that 
facilitates MBP-hCD2 interactions. (b) Superposition of the hCD2-TSA (wheat; orange TSA) and 
zCD2-TSA (light blue; blue TSA) complexes. Residues D770-H771 in zCD2 are disordered and 
indicated by a dotted line on the right-hand side of the image. The Zn
2+
 ion and K
+
 ions in hCD2 
are white and purple spheres, respectively; the corresponding metal ions in zCD2 are blue 
spheres. Only two active site residues differ between zCD2 and hCD2: N530 and N645 of zCD2 
appear as D567 and M682 in hCD2, and these residues are located at the mouth of the active 
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site, distant from the ligand binding site. (c) Molecular surface comparison of hCD2 (left) and 
zCD2 (right), color-coded by electrostatic potential (red to blue, -10 to 10 kT/e). TSA ligands are 
shown in ball-and-stick fashion to indicate the active site. Note that the metal ions are not 
included in the electrostatic potential calculation and thus both the active site tunnel shows 
negative potential due to the metal – ion coordinating ligand residues. Reprinted with permission 
from Macmillan Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol. 2016, in 
press. Copyright 2016.  
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Figure 5.5: Snapshots of catalysis by HDAC6 zCD2. Simulated annealing maps are contoured 
at 3.0-4.0σ; metal coordination and hydrogen bond interactions are indicated by red and black 
dashed lines, respectively. Underneath each structure, a mechanistic scheme illustrates the 
corresponding complex in catalysis by the wild-type enzyme. (a) Active site of unliganded zCD2, 
showing the nucleophilic Zn
2+
-bound water molecule hydrogen bonding with H573 and H574; a 
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vacant coordination site is observed on the "Y745 side" of Zn
2+
. (b) The scissile acetyllysine 
carbonyl of substrate 1 (derived from α-tubulin) coordinates to the formerly vacant site on Zn
2+
 
without displacing the Zn
2+
-bound water molecule in Y745F zCD2. (c) In the active site of H574A 
zCD2, the acetyllysine carbonyl of substrate 8 (derived from histone H4) is activated by Zn
2+
 and 
Y745 to undergo nucleophilic attack, yielding a tetrahedral intermediate. The oxyanion is 
stabilized by Zn
2+
 and Y745; the hydroxyl group, which corresponds to the former Zn
2+
-bound 
water molecule, is more distant from Zn
2+
 and hydrogen bonds with H573. (d) In the wild-type 
enzyme, collapse of the tetrahedral intermediate yields products lysine and acetate. Acetate 
coordinates to Zn
2+
 nearly symmetrically; this structure represents a product complex in which 
lysine has already dissociated from the active site. Reprinted with permission from Macmillan 
Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol. 2016, in press, copyright 
2016.  
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human enzyme. Furthermore, zCD2 consistently yielded higher quality crystals, which facilitated 
X-ray structural analysis. 
Crystal structures of zCD2 provided snapshots of all key steps along the reaction 
coordinate of catalysis, comprising the most thorough view of structure-mechanism relationships 
ever achieved for a histone deacetylase. First, the crystal structure of the resting enzyme showed 
that the catalytic Zn
2+
 ion resides at the base of a ~10 Å deep tunnel, liganded by D612, H614, 
D705, and a water molecule with distorted tetrahedral coordination geometry. The Zn
2+
-bound 
water molecule also formed hydrogen bonds with H573 and H574. A seemingly vacant 
coordination site on Zn
2+
 would allow for the binding of a ligand that could also interact with Y745 
(Figure 5.5a). To study the precatalytic enzyme-substrate complex, we prepared Y745F zCD2, 
which exhibited compromised activity due to the loss of substrate activation by Y745. This 
enabled cocrystallization with the intact form of substrate 1 derived from the α-tubulin K40 
acetylation site. The 1.82 Å-resolution structure of the enzyme-substrate complex revealed that 
the scissile carbonyl of acetyllysine coordinates to the formerly vacant site on Zn
2+
 without 
displacing the Zn
2+
-bound water molecule, resulting in a pentacoordinate metal ion poised for 
catalysis (Figure 5.5b).  
Surprisingly, the next snapshot of catalysis – the tetrahedral intermediate – was provided 
by the 1.80 Å-resolution structure of the complex between substrate 8 (derived from histone H4) 
and H574A zCD2. This mutant exhibited compromised activity due to the loss of the catalytically 
obligatory general acid. The electron density map indicated that the scissile carbonyl of acetyl-
lysine underwent nucleophilic attack by a water molecule activated by H573 and Zn
2+
 to yield a 
tetrahedral intermediate, trapped in the active site due to the loss of the general acid H574 
(Figure 5.5c). The structure revealed that oxyanion atom O1 is stabilized by coordination to Zn
2+
 
(2.1 Å) and a hydrogen bond with Y745; hydroxyl group O2 is somewhat distant from Zn
2+
 for 
inner sphere coordination (2.6 Å), but hydrogen bonds with H573. Since the Y745F mutation 
yielded an unreacted complex with substrate 1 and the H574A mutation yielded a tetrahedral 
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intermediate with substrate 8, both Zn
2+
 and Y745 must be necessary to activate the substrate 
carbonyl for nucleophilic attack. In this complex, H573 could serve as a general base to assist 
Zn
2+
 in activating the nucleophilic water molecule, so the tandem histidines in the HDAC6 zCD2 
active site may serve separate general base-general acid functions. 
In H574A zCD2, the substrate carbonyl was sufficiently activated to undergo nucleophilic attack, 
but the resulting tetrahedral intermediate was locked in place, deep in the active site pocket – it 
could not collapse without general acid H574 to protonate the leaving amino group. Substrate 8 
likely remained bound as a metastable tetrahedral intermediate because an enzyme generally 
favors the binding of a transition state-like structure over the binding of a substrate-like structure; 
the same principle applies for the stabilization of ketones as hydrated gem-diols in the zCD2 
active site (see below) (Pauling, 1946). Parenthetically, we note that substrate binding to zCD2 
does not trigger any major conformational changes in the L1 and L2 loops surrounding the active 
site, so the active site is essentially pre-formed for substrate binding (Figure 5.6). The tetrahedral 
intermediate was also mimicked by the binding of a trifluoroketone inhibitor
 
(Decroos et al., 2013) 
as a tetrahedral gem-diol with Ki = 0.8 µM (Figure 5.6, Table 5.7). The binding of the gem-diol 
moiety was comparable to that observed for the binding of the tetrahedral intermediate with 
substrate 8, making asymmetric metal coordination interactions with Zn
2+
-O1 and Zn
2+
-O2 
distances of 2.0 Å and 2.5 Å, respectively. The stronger interaction of O1 with Zn
2+
 may indicate 
ionization to an oxyanion, which would also be inductively stabilized by the adjacent 
trifluoromethyl group (Liang and Abeles, 1987). Additionally, O1 formed a hydrogen bond with 
Y745, and O2 formed a hydrogen bond with H573 and H574. Finally, similar interactions were 
observed for the binding of the product acetate anion with Zn
2+
-O1 and Zn
2+
-O2 distances of 2.2 
Å and 2.1 Å, respectively (Figure 5.5d). Nearly symmetric bidentate carboxylate-Zn
2+
 
coordination was facilitated by the negative charge delocalized over both carboxylate oxygen 
atoms. 
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Figure 5.6: Stereo figure structure of zCD2-substrate complexes and zCD2-transition state 
analogues. (a) Superposition of the zCD2-substrate 1 complex (light blue, dashed line indicating 
the disordered loop D770-H771) with unliganded zCD2 (wheat, dashed line indicating the 
disordered loop residues H771-L772). The substrate is indicated by a stick-figure; its N-terminal 
acetyl group and the serine side chain are not modeled due to disorder. The catalytic Zn
2+
 ion is a 
white sphere and two K
+
 ions are salmon spheres. Only minimal structural changes accompany 
substrate binding. (b) Superposition of the zCD2-substrate 8 complex (light blue) with unliganded  
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zCD2 (wheat, dashed line indicating the disordered loop residues H771-L772). The substrate is 
indicated by a stick figure; its N-terminal acetyl group and the arginine side chain are not modeled 
due to disorder. The catalytic Zn
2+
 ion is a white sphere and two K
+
 ions are salmon spheres. 
Only minimal structural changes accompany substrate binding. (c) Simulated annealing omit map 
(blue mesh, 3.0σ) of the trifluoroketone inhibitor 7-[(3-aminopropyl)amino]-1,1,1-trifluoroheptan-2-
one bound as a tetrahedral gem-diolate, which mimics the tetrahedral intermediate and its 
flanking transition states in catalysis (orange stick figure; F atoms are green); inhibitor O1 is 
closer to Zn
2+
 than O2, likely due to electrostatic stabilization of O1 as the oxyanion by Zn
2+
 
coordination as well as the adjacent CF3 group. Reprinted with permission from Macmillan 
Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol. 2016, in press. Copyright 
2016.  
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5.3.3 Structure basis of peptide recognition by HDAC6 CD2 
Binding interactions of peptide substrates to HDAC6 zCD2 and the well-studied class I 
enzyme HDAC8 differ significantly. In HDAC8, highly conserved D101 accepts hydrogen bonds 
from the two backbone amide groups flanking the scissile acetyllysine residue (Vannini et al., 
2007; Dowling and Gantt, et al., 2008). However, the corresponding residue in zCD2, N530, was 
offset such that S531 of zCD2 structurally aligned with D101 of HDAC8 and accepted a hydrogen 
bond from the backbone NH group of acetyllysine in substrates 1 and 8 (Figure 5.7). The 
backbone amide group following acetyllysine hydrogen bonded only with a water molecule, 
suggesting that any amino acid – including proline – could be accommodated at this position. 
Accordingly, we observed significant catalytic activity for HDAC6 zCD2, but not HDAC8, using 
substrates with Lys(Ac)-Pro linkages (Figure 5.8).  
To confirm the importance of S531 for HDAC6-substrate recognition, and to test the 
proposal that the conserved, adjacent aspartate/asparagine is not important for substrate binding, 
we prepared the N530A and S531A mutants of zCD2, and the D567A and S568A mutants of 
hCD2 (Table 5.4, Figure 5.9). Consistent with our structural conclusions, mutations of zCD2 
N530 and hCD2 D567 did not significantly affect activity, whereas mutations of hCD2 S568 and 
zCD2 S531 decreased catalytic efficiency by 10-fold and 258-fold, respectively. Therefore, this 
serine residue, which is strictly conserved in both catalytic domains of HDAC6 orthologues across 
all species (Figure 5.3), is crucial for positioning the scissile acetyllysine residue in the enzyme-
substrate complex.   
5.3.4 Structure basis of cyclicpeptide recognition by HDAC6 CD2 
Additional inferences on peptide molecular recognition were provided by the structure of 
the zCD2 complex with HC toxin (cyclo-(L-Ala-D-Ala-L-Aoe-D-Pro); Aoe = 2-amino-8-oxo-9,10-
epoxydecanoic acid), a cyclic tetrapeptide isolated from the maize pathogen Helminthosporium 
carbonum (Figure 5.10) (Brosch et al., 1995; Furumai et al., 2001). The carbonyl group of the 
Aoe side chain is isosteric with the carbonyl group of acetyllysine, and the adjacent epoxide  
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Figure 5.7: Peptide recognition by zCD2. (Top) Simulated annealing omit map (blue mesh, 
3.0σ) of the substrate 1 and 8, respectively. (Bottom) Comparison of substrate binding to HDAC6 
(light blue; orange substrate 1) and HDAC8 (salmon; cyan substrate; PDB entry 2V5W).  
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Figure 5.8: Specific activities of human and zebrafish HDAC6 constructs assayed with 
nonfluorogenic substrates 9–13 (substrates are illustrated in Supplementary Fig. 1a; data 
represent mean values ± s.d. (n=3)). No activity is observed with hCD1 and Y386F/Y782F 
hCD12, so these constructs do not appear in the figure. Reprinted with permission from 
Macmillan Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol., 2016, in 
press. Copyright 2016.  
 
 
 
Figure 5.9: Steady-state kinetics of HDAC6 CD2 tandem Ser/Asp pair mutants. Data 
represent mean values ± s.d. (n=3)). 
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moiety is a potent electrophile capable of covalently modifying a suitably positioned nucleophile in 
HDAC active sites. Accordingly, HC toxin exhibits irreversible inhibition against maize HD1-B (a 
class I HDAC), but reversible inhibition against HD1-A (a class II HDAC). Similarly, trapoxin 
contains the Aoe moiety and is a potent irreversible inhibitor of HDAC1, but it is a reversible 
inhibitor of HDAC6. Thus, there must be slight differences in the positioning of an active site 
nucleophile in the HDAC6 active site compared with class I HDACs. 
No major conformational changes of HDAC6 accompanied the binding of HC toxin to zCD2 (Ki = 
0.35 µM) (Table 5.7). The crystal structure revealed that the Aoe side chain extends into the 
active site tunnel, partially mimicking the substrate acetyllysine; the epoxide ring is clearly intact, 
but oriented toward the thiol side chain of C584. Unexpectedly, the ketone carbonyl of Aoe was 
hydrated so that the inhibitor binds as a gem-diol(ate), much like that observed for the 
trifluoroketone or for the tetrahedral intermediate with substrate 8. The crystal structure revealed 
that the Aoe O1 atom coordinates to Zn
2+
 (2.0 Å) and hydrogen bonds with Y745; the O2 atom 
makes a weak coordination interaction with Zn
2+
 (2.5 Å), and hydrogen bonds with H573 and 
H574. It was surprising that the unactivated ketone of the α,β-epoxyketone moiety underwent 
hydration in the zCD2 active site. Significantly, interactions of the macrocyclic peptide backbone 
of HC toxin were similar to interactions with the substrate peptide backbone. The backbone NH 
group of Aoe donated a hydrogen bond to S531, and water-mediated hydrogen bond networks 
were observed between the backbone carbonyl of Aoe and H614, and the backbone NH group of 
HC toxin L-Ala and H463. Interestingly, the L-Ala–D-Ala and the L-Aoe–D-Pro peptide linkages of 
HC toxin adopted cis configurations, giving the cyclic tetrapeptide unusual alternating cis-trans-
cis-trans peptide bond geometry. This distinguishes HC toxin from other cyclotetrapeptides of 
known structure, such as trapoxin A, which contain just one cis peptide linkage.   
Based on the aforementioned substrate specificity studies, the crystal structures of zCD2 
complexes with HC toxin and substrates, and the structural homology between zCD2 and hCD2,  
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Figure 5.10: Crystal structure of HC-toxin bound to zHDAC6 CD2. (Top) HC toxin represents 
a class of naturally existing tetracyclic nonribosomal peptide that can inhibit HDAC. (Bottom) 
Simulated annealing omit map (blue mesh, 2.5σ) of HC toxin, respectively. Reprinted with 
permission from Macmillan Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. 
Biol. 2016, in press. Copyright 2016.  
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 we suggest that the amide bond following the scissile acetyllysine residue is dispensable for 
substrate binding to zCD2 and hCD2, since it makes no direct interactions with active site 
residues. Accordingly, we hypothesize that the L-Aoe-D-Pro-L-Ala fragment of HC toxin partially 
mimics a potential substrate site located in a reverse turn, such as X-Lys(Ac)-Pro-X, as well as 
other proline-containing loop structures or segments containing cis-Lys(Ac)-X linkages.  
5.3.6 Structure basis of HDAC6 CD1 substrate specificity 
Curiously, despite conservation of all residues important for substrate binding and 
catalysis, zCD1 and hCD1 exhibited low or no activity when assayed with traditional fluorogenic 
substrates, but instead were very specific for the hydrolysis of exo-acetyllysine substrates 9 and 
10, X-K(Ac)-CO2
–
 (Table 5.6). The crystal structure of the zCD1-TSA complex (Figure 5.11) 
suggested a likely explanation. The structure of this complex was similar to that of the zCD2-TSA 
complex, with an r.m.s. deviation of 0.58 Å for 311 C atoms. The Zn
2+
 ions, catalytic residues, 
and L1 and L2 loops flanking the active sites aligned well. However, the inhibitor TSA adopted a 
notably different binding orientation in each active site (Figure 5.11). In zCD1, the active site was 
slightly more constricted, due in part to the protruding side chain of K330, which donates a 
hydrogen bond to the carbonyl group of the "cap" moiety of TSA and sterically displaces it toward 
the L1 loop. The corresponding residue in zCD2 was L712, which does not protrude as far into 
the active site. Another difference evident in the active site of zCD1 was the conformational 
change of W78 toward the bound inhibitor, resulting from a steric interaction with E138 on a 
nearby helix. This residue appeared as P519 in zCD2 and did not trigger a conformational 
change of the corresponding tryptophan residue, W459. Based on the interaction of K330 with the 
carbonyl group of TSA, we hypothesized that K330 is a "gatekeeper" that confers specificity 
toward C-terminal acetyllysine substrates by hydrogen bonding with the -carboxylate group of 
acetyllysine. Consistent with this hypothesis, K330L zCD1 exhibited more relaxed substrate 
specificity in comparison with wild-type zCD1 (Figure 5.8).  
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Figure 5.11: Crystal structure of zCD1. (Top) The overall structure of the zCD1-TSA complex 
(light blue) is highly similar to that of the zCD2-TSA complex (green), with an r.m.s. deviation of 
0.58 Å for 311 Cα atoms. The simulated annealing omit map (blue mesh, 3.0σ) indicates TSA 
(orange) bound in the active site of zCD1; Zn
2+
 ions are shown as white spheres. (Middle) 
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Superposition of the zCD1-TSA complex (wheat) and the zCD2-TSA complex (light blue). Zn
2+
 
ions are white and light blue spheres, respectively. TSA binds with different orientations to zCD1 
(light green) and zCD2 (light blue); K330 in zCD1, which corresponds to the smaller residue L712 
in zCD2, is responsible for the alternative orientation of TSA. Also highlighted with van der Waals 
surfaces are zCD1 residues F202 and H82, which are found as Y225 and F105 in hCD1. 
(Bottom) Model of acetyllysine docked in the active site of H82F/F202Y zCD1 (these mutations 
"humanize" zCD1 to serve as a surrogate for hCD1). The α-carboxylate of the C-terminal 
acetyllysine substrate is proposed to hydrogen bond with Y202 and K330 (black dashed lines). 
Reprinted with permission from Macmillan Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. 
Nat. Chem. Biol. 2016, in press. Copyright 2016.  
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Two amino acid substitutions further constrict the active site of hCD1 in addition to K353 
(which corresponds to K330 of zCD1): F202 and H82 in zCD1 (Figure 5.11) appear as Y225 and 
F105 in hCD1. To "humanize" zCD1, we prepared and assayed H82F/F202Y zCD1. These amino 
acid substitutions abolished activity with endo-acetyllysine peptide substrate 8 and conferred 
significant specificity for substrates 9 and 10, which bear an exo-acetyllysine group (Table 5.5–
5.6). We hypothesized that the hydroxyl group of Y202 hydrogen bonds with the -carboxylate 
group of the acetyllysine substrates to abolish the binding of endo-acetylysine substrates, such 
that both K330 and Y202 (K353 and Y225 in hCD1) enforce specificity for substrates bearing an 
exo-acetyllysine group, X-K(Ac)-CO2
–
, as modeled in Figure 5.11. Indeed, Y225F/Y782F hCD12 
exhibited nearly 100-fold enhanced activity with endo-acetyllysine fluorogenic substrates when 
compared to hCD12 Y782F, whereas K353L/Y782F hCD12 exhibited a more modest 10-fold 
activity enhancement. Therefore, Y225 in hCD1 is another "gatekeeper" that confers specificity 
toward C-terminal acetyllysine substrates. 
5.3.7 Structure basis of HDAC6 inhibitor selectivity 
In addition to the previously described structures of hCD2, zCD1, and zCD2 complexed 
with TSA, crystal structures of zCD2 complexed with clinically-approved broad-specificity 
hydroxamate inhibitors SAHA, Belinostat, and Panobinostat; Oxamflatin; and the HDAC6-
selective inhibitor N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB) 
were also determined. Structural comparisons of these complexes revealed critical determinants 
of affinity and selectivity. First, the "cap" moieties of broad-specificity inhibitors clustered around a 
"hot spot" on the L1 loop (D460-P484), making contacts with H463 and P464 (Figure 5.11). 
Additionally, the hydroxamate groups of all broad-specificity inhibitors tended toward bidentate 
Zn
2+
 coordination, displacing the Zn
2+
-bound water molecule of the resting enzyme, with the 
hydroxamate OH and C=O groups additionally interacting with H573 and Y745, respectively.  
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In contrast, the hydroxamate group of the HDAC6-selective inhibitor HPOB (Ki = 1.0 nM) 
coordinated to Zn
2+
 only through its OH group, and it did not displace the Zn
2+
-bound water 
molecule; the Zn
2+
 ion is pentacoordinate with square pyramidal geometry (Figure 5.12). The 
hydroxamate C=O group hydrogen bonded with the Zn
2+
-bound water molecule. The short, bulky 
linker of HPOB sterically precluded a closer approach of the hydroxamate group to Zn
2+
, which 
may also have prevented the "cap" moiety of HPOB from interacting with the L1 loop, an 
interaction that appears to be more important for binding to HDACs 1-3 than to HDAC6 (Figure 
5.13). Accordingly, the potency of HPOB against HDAC6 is comparable to SAHA-like inhibitors, 
but HPOB potency against other isozymes is significantly reduced (Lee et al., 2013). 
5.4 Discussion 
Studies reported in this chapter have illuminated the structural basis of substrate 
specificity and catalysis for the CD1 and CD2 domains of the class IIb deacetylase HDAC6. In 
particular, we have demonstrated new modes of peptide substrate recognition by HDAC6 CD1 
and CD2 that contrast with substrate binding modes previously observed for the well-studied 
class I isozyme HDAC8. The CD2 domains of human and zebrafish HDAC6 can accommodate 
proline at the +1 position relative to the scissile acetyllysine residue, whereas HDAC8 cannot 
based on the hydrogen bond between D101 and the backbone NH of the +1 residue. In contrast, 
the CD1 domains of human and zebrafish HDAC6 exhibit stringent specificity for acetyllysine 
substrates bearing a free α-carboxylate group, likely due to hydrogen bond interactions with 
gatekeeper residues K353 and Y225 (hCD1 numbering) as well as a more constricted active site 
contour. However, it remains unclear as to what biological substrates would undergo reversible 
acetylation at C-terminal lysine residues in vivo. We have also demonstrated that hCD1 could 
exhibit modest activity with the peptide bearing smallest residue Gly at +1 position (substrate 14, 
Ac-RGK(ac)G) with catalytic efficiency 150 M
-1
s
-1
. Although the activity is not as robust as a C-
terminal exo-acetyllysine substrate, it also leaves open the possibility that hCD1 may work on 
protein substrates with Gly at +1 position with relatively low efficiency.  Regardless, in view of the  
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Figure 5.12: (a) Superposition of broad-specificity HDAC hydroxamate inhibitors (thin wheat stick 
figures) and the HDAC6-specific inhibitor HPOB (thick orange stick figure). The "hot spot" L1 loop 
segment that accommodates the capping group of broad-specificity inhibitors is colored cyan (this 
segment is strictly conserved in hCD2). The backbone of zCD2 is shown as white cartoon and the 
molecular surface of hCD2 is shown for comparison (color coded by electrostatic potential, red to 
blue, -10 kT/e to 10 kT/e). Note that metal ions are not included in the electrostatic potential 
calculations. (b) Close-up view of the Zn
2+
 binding site in zCD2 complexes with broad-specificity 
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inhibitors. Both zCD2 (light blue) and hCD2 (pale green) are shown for comparison. (c) Close-up 
view of the Zn
2+
 binding site in the zCD2-HPOB complex. The simulated annealing omit map 
(blue mesh, 2.5σ) clearly defines the binding mode of the inhibitor, which coordinates to Zn
2+
 only 
through its hydroxyl group. Inhibitor binding does not displace the Zn
2+
-bound water molecule, as 
confirmed in a simulated annealing omit map (grey mesh, 3.0σ). Both zCD2 (light blue) and hCD2 
(pale green) are shown for comparison. Metal coordination and hydrogen bond interactions are 
shown as red and black dashed lines, respectively. Reprinted with permission from Macmillan 
Publishers Ltd: Nature: Hai, Y., & Christianson, D. W. Nat. Chem. Biol., 2016, in press. Copyright 
2016.  
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Figure 5.13: Active site comparison of HDAC6, HDAC1 and HDAC8. (left) Crystal structure of 
zCD2-HPOB. (middle) HPOB superimposed onto HDAC1 active site (PDB entry 4BKK). (right) 
HPOB superimposed onto HDAC8 active site (PDB entry 1T69).   
 158 
 
highly specialized binding activity and catalytic function of hCD1, we suggest that drug discovery 
programs employing in vitro assays of HDAC6 using traditional fluorogenic substrates will yield 
“hits” exclusively targeting hCD2 that miss the highly specific activity of hCD1. 
Significantly, HDAC6-peptide recognition is similar for substrates as well as the 
macrocyclic peptide inhibitor HC toxin. Moreover, in binding as the gem-diol, the α,β-epoxyketone 
moiety of HC toxin binds as a tetrahedral transition state analogue rather than a substrate 
analogue with an intact ketone carbonyl. This likely represents the binding mode of other Aoe-
containing cyclic tetrapeptides such as trapoxin A to all other HDAC isozymes, whether or not 
these inhibitors bind reversibly or irreversibly. In general, zinc hydrolases activate a substrate 
carbonyl group for direct nucleophilic attack by a water molecule using Zn
2+
 coordination and a 
hydrogen bond interaction to polarize the carbonyl group; the nucleophilic water molecule is 
activated by Zn
2+
 coordination and a general base. Thus, any carbonyl, whether that of a peptide, 
ester, ketone, or aldehyde, is subject to facile hydration in the active site of a zinc hydrolase as 
long as the carbonyl is isosteric with that of the natural substrate. Since the carbonyl group of the 
Aoe side chain is isosteric with the scissile carbonyl of acetyllysine, the binding of Aoe-containing 
peptides to any HDAC should enable facile hydration of the Aoe ketone carbonyl, as observed in 
the zCD2-HC toxin complex. Moreover, the structure of the zCD2-HC toxin complex reveals an 
important clue regarding the irreversible inhibition of class I HDAC isozymes by Aoe-containing 
cyclic tetrapeptides. Based on the geometry observed in the zCD2-HC toxin complex, the likely 
active site nucleophile is the strictly conserved residue C584, which is interestingly to be 
nonessential for catalysis (Daniel et al.). The thiol side chain of this residue is oriented for 
nucleophilic attack at the less hindered epoxide carbon. Presumably, inhibitor binding to class I 
HDAC active sites allows for a closer contact between the nucleophilic thiol and the electrophilic 
epoxide to enable covalent bond formation.  
Finally, comparison of different zCD2-inhibitor structures highlights the structural basis for 
HDAC6-specific inhibitor design, which exploits a previously unobserved Zn
2+
 coordination mode 
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by the hydroxamate group of HPOB: inhibitor binding does not require displacement of Zn
2+
-
bound water. Additionally, the L1 and L2 loops flanking the active site are relatively rigid, as 
revealed in the 12 zCD2 structures reported herein, making HDAC6 an ideal receptor for in silico 
docking experiments. In closing, we expect that these structural data will enable and accelerate 
advances in structure-based drug design in the continuing search for new therapies for human 
disease.  
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Chapter 6: Crystal Structure of Histone Deacetylase 10, a Vertebrate 
Polyamine Deacetylase 
 
Manuscript of this work is in preparation: Hai, Y., & Christianson, D. W. 2016 
6.1 Introduction 
Polyamines such as spermidine and spermine, and their diamine precursor putrescine, 
are ubiquitous and essential in all living systems (Tabor, C. W. and Tabor, H., 1984; Cohen, 
1998; Thomas, T. and Thomas, T. J., 2001). These cellular polycations are present at millimolar 
concentrations and are mainly associated with negatively charged biomolecules such as RNA, 
DNA, lipids, and proteins. Polyamines play fundamental roles in diverse biological processes, 
including replication, transcription, and translation, and these roles can involve noncovalent as 
well as covalent interactions. For example, the aminobutyl group of spermidine is utilized for 
hypusination of a lysine residue in the eukaryotic translation initiation factor 5A (elf5A), and this 
modification is required for the viability, growth, and proliferation of eukaryotic cells (Saini et al, 
2009). In order to coordinate intracellular polyamine metabolism with the needs of the cell, 
polyamine metabolism is an elaborately orchestrated balance of cellular uptake, transport, 
biosynthesis, and catabolism (Figure 6.1) (Wallace et al., 2003; Pegg, 2009; Coffino et al., 2001). 
Dysregulation of polyamine metabolism is frequently associated with cancer and other 
hyperproliferative diseases, so enzymes of polyamine metabolism are emerging drug targets 
(Gerner et al, 2004; Casero and Marton, 2007). 
A critical strategy for the regulation of polyamine function is reversible acetylation. This 
strategy is analogous to the regulation of protein function by reversible acetylation of lysine side 
chains by histone acetyltransferases and histone deacetylases (also known more generally as 
lysine acetyltransferases and lysine deacetylases). In eukaryotes, polyamine metabolism is 
partially compartmentalized in the nucleus. Spermidine is acetylated at the N
8
 position by N-
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acetyltransferases (which also exhibits histone acetyltransferase activity) in the mammalian cell 
nucleus (Libby, 1980) and then exported to the cytosol where it is deacetylated by a metal-
dependent N
8
-acetylspermidine deacetylase (also known as polyamine deacetylase, PDAC) 
(Blankenship, 1978; Dredar et al, 1989). Notably, PDAC does not deacetylate N
1
-
acetylspermidine or N
1
-acetylspermine, which are also present in the cytosol (Marchant et al, 
1986). Thus, the catalytic specificity of PDAC is very strict with regard to the length of the 
substrate as well as the location of the secondary amino group within the substrate.  
To date, the identity of the cytosolic PDAC in eukaryotes has remained elusive. However, 
selective inhibitors have been developed for PDAC (Dredar et al, 1989; Huang et al, 1992), and 
inhibition of PDAC influences differentiation of PC12 cells (Mudumba et al, 2002). Structural and 
enzymological studies of bacterial acetylpolyamine amidohydrolase (APAH) (Lombardi and 
Angell, et al, 2011), a Zn
2+
-dependent polyamine deacetylase belonging to the 
arginase/deacetylase superfamily, suggested that the enigmatic PDAC in eukaryotes might be 
one of the cytosolic Zn
2+
-dependent histone deacetylases.  
We reported the X-ray crystal structures of both catalytic domains of HDAC6 (Chapter 5), 
showing that K353 serves as a gatekeeper in catalytic domain I (human HDAC6 CD1); K353 
contributes to the unusual substrate specificity of HDAC6 CD1 for C-terminal exo-acetyllysine 
substrates. Interestingly, HDAC10 contains a glutamate residue at the corresponding position, 
E274, which in other human HDACs is otherwise conserved as leucine or methionine (Figure 
6.2). Furthermore, E272 is strictly conserved in vertebrate HDAC10 orthologues (E274 in 
zebrafish HDAC10) (Figure 6.3). Accordingly, we hypothesized that E274 could similarly serve as 
a gatekeeper in the active site of HDAC10, where it might confer specificity for cationic polyamine 
substrates. Moreover, HDAC10 is highly expressed in liver, spleen, and kidney (Kao et al, 2002; 
Tong et al., 2002), enriched in cytoplasm (Tong et al., 2002), and being resistant to inhibition of 
sodium butyrate (Guardiola and Yao, 2002), which matches the tissue distribution, subcellular 
localization, and in vitro inhibition results observed for the enigmatic PDAC 30 years ago 
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(Blankenship, 1978), we further hypothesized that HDAC10 might be the elusive mammalian and 
even vertebrate PDAC. 
Here, we show that HDAC10, a cytosolic class IIb histone deacetylase, exhibits robust 
catalytic activity in vitro against acetylpolyamines such as acetylputrescine, acetylcadaverine, and 
N
8
-acetylspermidine, but not N
1
-acetylspermidine or N
1
-acetylspermine; furthermore, HDAC10 
exhibited minimal or no activity against a panel of acetyllysine-containing peptides. Therefore, we 
conclude that HDAC10 is the long-sought cytoplasmic PDAC in vertebrate polyamine 
metabolism. Accordingly, we suggest that HDAC10 be renamed "PDAC", or "HDAC10/PDAC". 
The crystal structure of HDAC10/PDAC from Danio rerio (zebrafish) reveals two active site 
features conserved in HDAC10/PDAC enzymes from different vertebrate species that contribute 
to selectivity for polyamine substrates: (1) a 310-helix insertion in active site loop L1 that constricts 
the mouth of the active site, effectively lengthening the active site tunnel to favor the binding of 
long, narrow polyamine substrates and disfavor the binding of shorter acetyllysine substrates; and 
(2) a glutamate "gatekeeper" that can make favorable electrostatic interactions with cationic 
polyamine substrates and also further constricts the active site. The crystal structure of HDAC10 
further reveals a monomer with two domains; the second domain shares the arginase-
deacetylase fold with the PDAC domain, yet contains no active site. Accordingly, this pseudo-
deacetylase domain is designated "ΨDAC". The ΨDAC domain appears to be important for 
stabilizing and solubilizing the PDAC domain for catalytic function 
6.2 Materials and Methods 
6.2.1 Materials 
PCR reactions were performed using the PfuUltra High-Fidelity DNA polymerase (Agilent 
Technologies). Restriction enzymes were purchased from New England Biolabs and used 
according to the manufacturer’s instructions. Custom oligonucleotides were synthesized by 
Integrated DNA Technologies. Escherichia coli strain NEB5α (New England Biolabs) was used  
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Figure 6.1: Polyamine metabolism in mammalian cells. Abbreviations: ODC, ornithine 
decarboxylase; SRM, spermidine synthase; PAT, polyamine acetyltransferase; PDAC, polyamine 
deacetylase; SMS, spermine synthase; SSAT, spermidine/spermine N1-acetyltransferase; APAO, 
acetylpolyamine oxidase.  
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Figure 6.2: Gatekeeper residues in HDACs. (left) Sequence alignment of catalytic domain 
residues from 11 human HDACs. The unique lysine identified in HDAC6CD1 that confers 
specificity to recognize exo-C-terminal-acetyllysine peptide is highlighted in skyblue. The 
corresponding glutamate only present in HDAC10 is highlighted in red. (right) Cartoon 
representation of experimentally determined crystal structures shows the location of gatekeeper 
K330 in zebrafish HDAC6 CD1 (wheat), L712 in zebrafish HDAC6 CD2 (lightblue), and 
gatekeeper M274 in human HDAC8 (cyan).  
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Figure 6.3: Sequence alignment of HDAC10 orthologues. Sequence alignment prepared with 
Clustal Omega, figure prepared with Jalview. The unique Glu residue conserved in all HDAC10 
catalytic domains is highlighted in red. Universal 310 helix insertion is highlighted in purple. 
Conserved negative surface residues around the active site are colored in orange. Other 
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conserved residues with are highlighted in blue. Note that the catalytic domain is highly 
conserved in vertebrates, whereas the C-terminal leucine-rich domain only shows high sequence 
homology within mammals.  
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for cloning procedures. Peptides were synthesized by Genscript
®
. N-(3-aminopropyl)acetamide is 
purchased from Chem-Implex International, Inc. Acetylcadaverine was purchased from TCI. N
1
-
acetylspermidine dihydrochloride was purchased from Cayman Chemicals, Inc. Acetylputrescine, 
N
8
-acetylspermidine dihydrochloride, N
1
-acetylspermine trihydrochloride, N-butylacetamide, N-
(aminooctyl)acetamide were purchased form Sigma-Aldrich. N
1
, N
8
-diacetylspermidine was 
purchased from Toronto Research Chemicals. TSA and SAHA were purchased from ApexBio. All 
substrates and ligands are used without further purification (>95% purity). fl-SAHA was kindly 
provided by Dr. Carol Fierke (University of Michigan). The transition state analogue inhibitor 7-[(3-
aminopropyl)amino]-1,1,1-trifluoroheptan-2-one (AAT) was synthesized as previously described 
(Decroos et al., 2012). Substrates and ligands structures are shown in Figure 6.4. 
6.2.2 Protein expression and purification 
The human HDAC10 gene (Q969S8, residues 2-669) and zebrafish HDAC10 gene 
(Uniprot Q803K0, residues 2-675) were both synthesized and codon-optimized by Genscript, and 
then sub-cloned into a modified pET28a(+) vector (a gift from Dr. Scott Gradia, University of 
California, Berkeley; Addgene plasmid #29656) in-frame with a TEV-cleavable N-terminal His-
MBP-tag (MBP, maltose binding protein) using ligation independent cloning. All proteins were 
expressed in E. coli BL21 (DE3) (Agilent) cells in 2x YT medium in the presence of 50 mg/L 
kanamycin and purified based on the protocol previously described for HDAC6.
15
 Briefly, 
expression was induced when OD600 reached 1.0 by addition of 75 µM isopropyl β-D-1-
thiogalactopyranoside (Carbosynth) and 500 µM ZnSO4 (Fisher Scientific), and cell cultures were 
grown for an additional 18 h at 16 
o
C. Cells were harvested by centrifugation at 6,000 g and 
resuspended in lysis buffer [50 mM K2HPO4 (pH 8.0), 300 mM NaCl, 10 mM MgCl2, 10% glycerol, 
0.1 mg/mL lysozyme (Sigma), 50 µg/ml DNase I (Sigma), and protease inhibitor tablets (Roche 
Applied Science)]. Cells were lysed by sonication and the cell lysate was cleared by 
centrifugation at 26,000 g for 1 h at 4 
o
C. The supernatant was loaded onto a Ni-NTA affinity 
column (Qiagen) and the target protein was eluted with buffer A [50 mM K2HPO4 (pH 8.0), 1 mM 
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TCEP, 300 mM NaCl, 300 mM imidazole, 5% glycerol]. Peak fractions were directly loaded onto 
an Amylose resin column (New England Biolabs).  
 For human HDAC10, the MBP-tag was not cleaved off. The MBP-fusion hHDAC10 was 
eluted from Amylose resin by buffer B plus 10 mM maltose (Sigma-Aldrich), and further purified 
by anion-exchange chromatography. For zebrafish HDAC10, the proteins were digested on-
column using TEV protease in buffer B [20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM TCEP, 5% 
glycerol] to remove the His-MBP tag, and further purified by anion-exchange chromatography 
(HiTrap Q, GE Healthcare). Both zHDAC10 and hHDAC10 were finally loaded onto a HiLoad 
Superdex 200 column equilibrated in buffer C [50 mM HEPES (pH 7.5), 300 mM KCl, 1 mM 
TCEP, 5% glycerol]. Proteins were concentrated to >10 mg/mL and flash-cooled in liquid nitrogen 
and stored at -80 
o
C for further use.  
 For the preparation of zHDAC10Δ, 10 mg/mL of zHDAC10 in buffer C was incubated with 
trypsin (Sigma-Aldrich) with a 1000:1 ratio of zHDAC10:trypsin (w/w) overnight at 4 
o
C, and then 
reloaded onto a Hiload Superdex 200 column equilibrated in buffer C. Peak fractions 
corresponding to the co-elution of the PDAC-ΨDAC complex were pooled and concentrated to 30 
mg/mL (the PDAC-ΨDAC domains did not dissociate upon proteolytic nicking of the interdomain 
linker). The PDAC domain (residues 2-370) remained intact after proteolytic nicking as 
determined by LC-MS/MS. zHDAC10Δ proteins were flash-cooled in liquid nitrogen and stored at 
-80 
o
C for further use. 
6.2.4 Crystallography 
The Y307F zHDAC10Δ-AAT complex was crystallized using the sitting drop vapor 
diffusion method at 4 
o
C. Protein (30 mg/mL) was first incubated with 5 mM AAT ligand in buffer 
C on ice for 30 min, and then 0.4 µL of protein solution was mixed with 0.4 µL of precipitant 
solution [0.2 M KH2PO4, 20% PEG 3350] and equilibrated against a 80-µL reservoir of precipitant 
solution. Rod-like crystals appeared after 24 hours. Crystals were soaked in a cryoprotectant 
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solution comprised of precipitant solution supplemented with 40% ethylene glycol prior to flash-
cooling in liquid nitrogen. X-ray diffraction data were recorded at the Stanford Synchrotron 
Radiation Lightsource (SSRL), beamline 14-1. Data reduction and integration was achieved with 
HKL2000 (Otwinoski and Minor, 1997); data collection and reduction statistics are recorded in 
Table 6.1. The structure of zHDAC10Δ (Y307F)-AAT complex was solved by molecular 
replacement using the program Phaser
 
(McCoy et al., 2007) and a model of the zHDAC6 CD1-
TSA complex (PDB entry 5EEF) less ligands was used as the search probe. Initial phases from 
the Phaser solution were judged to be correct based on the initial electron density map, in which 
much of the omitted ΨDAC domain was clearly visible. The program phenix.autobuild was used 
to generate a ~70%-complete model. Iterative model building was then performed with Coot 
(Emsley et al., 2010) and model refinement was performed by Phenix (Adams et al., 2010). The 
final model of the Y306F zHDAC10Δ-AAT complex included residue 2-364 (PDAC domain), and 
residues 412-434 and 437-676 (ΨDAC domain). Final refinement statistics are recorded in Table 
6.1. The quality of each model was verified with PROCHECK and MolProbity (Laskowski et al., 
1993; Chen et al., 2010). 
6.2.5 Activity Assays 
Fluorogenic substrates were custom synthesized by Genscript. Assays were performed 
in triplicate at room temperature. Briefly, substrates and enzymes were diluted into HDAC assay 
buffer [50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2] at varying 
concentrations. To initiate the reaction, 25 µL of substrate solution was added to 25 µL of enzyme 
solution (5 µM). The reaction was stopped by adding the developer solution [1 µM trypsin and 10 
µM SAHA in HDAC assay buffer]. After 20 min, the reaction mixture was transferred to a NUNC 
384 well optical bottom black plate (Thermo Fisher Scientific) and the fluorescence was 
measured using a Tecan Infinite M1000Pro plate reader (λex = 360 nm, λem = 460 nm). Enzyme 
activity was calculated based on the standard curve using Fluor de lys
®
 deacetylated standard 
(Enzo
®
 Life Sciences). 
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Figure 6.4: Substrates and ligands used for HDAC10 structural and biochemical study.  
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 Table 6.1: Data collection and refinement statistics of HDAC10 and HDAC6 mutant.  
 
 Y307F zHDAC10Δ-AAT complex L712E zCD2-AAT 
Data collection   
Wavelength (Å) 1.28211 1.18076 
Space group  P3121 P212121 
Resolution (Å)
a 
45.82–2.75 50.00–1.60 (1.65–1.60) 
Unique reflections measured 24593 (2357) 89180 (4332) 
Unit cell parameters  (a, b, c; Å) 80.52, 80.52, 243.18 73.28, 94.36, 96.94 
Completeness (%) 99.8 (97.9) 99.6 (98.9) 
I/σI
  
15.4 (1.3) 17.6 (1.4) 
Rsym
b 
0.118 (0.947) 0.163 (1.505) 
Rpim
c
 0.056 (0.556) 0.065 (0.638) 
Redundancy 7.2 (6.4) 7.2 (6.4) 
CC1/2
d 
0.98 (0.36) 0.94 (0.45) 
Overall B factor from Wilson plot 
(Å
2
) 
54 16 
Refinement   
No. of reflections, refinement/test 
set 
22252/2281 80732/8380 
Rwork (%)
e 
19.2 (31.8) 14.6 (25.3) 
Rfree (%)
e 
22.3 (38.1) 18.8 (32.9) 
No. of non-hydrogen atoms per 
monomer 
  
protein
 
4904 5665 
solvent 50 581 
ligands 90 70 
R.m.s. deviations   
bonds (Å) 0.004 0.007 
angles (deg) 0.80 1.06 
Average B factors (Å
2
)   
protein 61 18 
solvent 49 30 
ligands 56 22 
Ramachandran favored (%)
f 
97 97 
Ramachandran outliers (%)
f 
0.16 0.14 
a
Numbers in parentheses refer to the highest resolution shell. 
b
Rmerge = ∑h∑i|I(h)i – I(h)|/ ∑h∑iI(h)i, where I(h) is the 
intensity of reflection h, ∑h is the sum over all reflections and ∑i is the sum over i measurements of reflection h. 
c
Rpim = 
∑sqrt(1/n-1)|I - I|/∑I, where n is the number of observations (redundancy) and I is the average intensity calculated from 
replicate data. 
d
CC1/2 = 
2/(
2 + 
2), where 
2
 is the true measurement error variance and 
2
 is the independent 
measurement error variance. 
e
Rwork = ∑||Fo| – |Fc||/∑|Fo| for reflections contained in the working set. Rfree for reflections 
contained in the test set held aside during refinement. |Fo| and |Fc| are the observed and calculated structure factor 
amplitudes, respectively. 
f
Calculated with Molprobity.  
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 To study steady-state kinetics with nonfluorogenic peptide substrates and 
acetylpolyamines, a discontinuous liquid chromatography-mass spectrometry (LC-MS) was 
employed based on the protocol of assaying nonfluorogenic acetyllysine peptide substrates for 
HDAC6. Assays were performed in triplicate. Briefly, 5 µL of enzyme (0.050 – 20 µM) in HEPES 
buffer [20 mM HEPES (pH 7.5), 100 mM NaCl, 5 mM KCl, 1 mM MgCl2] was added to 36 µL of 
substrate solution to initiate reaction. After incubation for 15-60 min at room temperature, the 
reaction was quenched by addition of 50 µL of 20 mM dansyl chloride dissolved in acetonitrile 
followed by 10 µL of NaHCO3 (1.6 M, pH 10.0). The deacetylation products were derivatized with 
dansyl chloride at 50 
º
C for 2 hrs. The deacetylation products were detected by liquid 
chromatography-mass spectrometry (LC-MS) using a Waters SQD equipped with an Acquity 
UPLC (Waters, Milford, MA, USA) and quantified by using the standard curves generated from 
the mass signals of the corresponding deacetylated polyamines and peptides.   
6.2.7 Electrostatic surface potential calculations 
The electrostatic potential of the protein surface was calculated using the APBS 
implemented in PyMol (Dolinsky et al., 2008). The following parameters were used for 
calculations: T = 298.15 K, pH = 7.5, AMBER forcefield, linearized Poisson-Boltzmann equation. 
The PQR file was generated using the web server PDB2PQR (Dolinsky et al., 2008). Metal ions 
were manually added into the PQR file prior to the electrostatic potential calculation. The charge 
and radius of metal ions were set to +2 and 0.74 Å for Zn
2+
; +1 and 1.33 Å for K
+
.  
6.3 Results 
6.3.1 PDAC activity of HDAC10 
To determine steady-state kinetic parameters for the hydrolysis of a variety of 
acetylpolyamine and acetyllysine substrates, we prepared full-length recombinant HDAC10 from 
human (Homo sapiens, hHDAC10) and zebrafish (Danio rerio, zHDAC10). The catalytic domains 
of these orthologues are highly similar based on 63%/79% sequence identity/similarity; only full-
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length constructs yielded soluble proteins. We first assayed acetyllysine deacetylase activity 
against two commercial available aminomethylcoumarin (AMC)-conjugated fluorogenic 
acetyllysine peptides, GAK(ac)-AMC and RGK(ac)-AMc. Both hHDAC10 and zHDAC10 exhibited 
very low activity (Figure 6.5, Table 6.2). These measurements were consistent with earlier 
studies reporting that HDAC10 activity was not measurable using fluorogenic peptide substrates 
(Bradner et al., 2010). We also tested the activity with 8 nonfluorogenic peptide substrates to 
avoid potential bias introduced by the bulky AMC group. Again, we observed very low or no 
catalytic activity (Figure 6.5, Table 6.2). In comparison with its closest relative, the cytosolic 
isozyme HDAC6, HDAC10 was not a robust acetyllysine deacetylase.  
We next tested the polyamine deacetylase activity of hHDAC10 and zHDAC10 using a 
liquid chromatography-mass spectrometry (LC-MS)-based discontinuous assay (Figure 6.5, 
Table 6.2). Both enzymes exhibited optimal catalytic activity and specificity for N
8
-acetyl-
spermidine hydrolysis. For the hydrolysis of N
8
-acetylspermidine by hHDAC10 and zHDAC10, 
kcat/KM = 2900 ± 200 M
-1
s
-1
 and 4600 ± 300 M
-1
s
-1
, respectively; in comparison, N
1
-
acetylspermidine was a poor substrate with kcat/KM = 24 ± 5 M
-1
s
-1
 and 7 ± 2 M
-1
s
-1
, respectively. 
In general, substrate specificity trends matched those of the cryptic mammalian N
8
-
acetylspermidine deacetylase activity first identified in rat liver 30 years ago. As a positive control, 
we measured the N
8
-acetylspermidine hydrolase activity of the bacterial deacetylase APAH, 
which exhibited comparable preference for polyamine deacetylase activity compared with 
hHDAC10 and zHDAC10 and broader overall substrate specificity. As a negative control, we 
examined the N
8
-acetylspermidine deacetylase activity of human and zebrafish HDAC6. HDAC6 
preferentially catalyzes the deacetylation of the acetyllysine peptide substrate with a catalytic 
efficiency more than 100-fold greater than that for the deacetylation of N
8
-acetylspermidine. 
Therefore, HDAC6 is clearly a cytosolic acetyllysine deacetylase, and HDAC10 is the cytosolic 
N
8
-acetylspermidine deacetylase, designated PDAC in Figure 6.1.  While the polyamine 
deacetylase activity of zHDAC10 and hHDAC10 was highest with N
8
-acetylspermidine, significant 
 174 
 
catalytic activity was also observed with acetylcadaverine and acetylputrescine, as well as N-(8-
aminooctyl)acetamide; the shorter substrates N-(3-aminopropyl)acetamide exhibited minimal or 
no activity. These results suggested that the ideal length of a PDAC substrate ranged 8–12 atoms 
long. The N4 amino group of N
8
-acetylspermidine was required for optimal activity in comparison 
with N-(8-aminooctyl)acetamide, which lacks the secondary amino group. However, the amino 
group could be located at N4 or N5, based on the substantial catalytic activity measured with 
acetylcadaverine and acetylputrescine. The amino group could not be at N3, based on the lack of 
substantial catalytic activity with N
1
-acetylspermidine and N-(3-aminopropyl)acetamide. 
Additionally, given the appreciable catalytic activity measured for N
1
,N
8
-diacetylspermidine, we 
concluded that the positive charge of the N
1
-amino group of N8-acetylspermidine contributed to 
enzyme-substrate recognition, but it was not critical for catalytic activity. In contrast with HDAC10, 
the bacterial polyamine deacetylase APAH exhibited broad substrate specificity with all polyamine 
substrates except for N-butylacetamide; it also exhibited weak lysine deacetylase activity (Table 
6.2, Figure 6.6). 
6.3.2 Gatekeeper Glu identified in HDAC10 is essential but not sufficient for PDAC activity 
To test our hypothesis that E274 is a gatekeeper that confers substrate specificity for N
8
-
acetylspermidine, we prepared E274L zHDAC10. This substitution significantly diminished N
8
-
acetylspermidine deacetylase activity by 20-fold and enhanced acetyllysine deacetylase activity 
by approximately 100-fold (Figure 6.7). Thus, the single-point mutation E274L completely 
reversed the substrate specificity of zHDAC10, converting it from a PDAC into an HDAC, which 
also demonstrates its essential role for HDAC10 PDAC activity.  
Intrigued by the role of E274 in determining the substrate specificity of zHDAC10, we 
wondered whether the introduction of a glutamate residue at the corresponding position in the 
related cytosolic isozyme HDAC6 would sufficiently switch its substrate specificity from 
acetyllysine toward N
8
-acetylspermidine. To test this hypothesis, we prepared K330E zHDAC6  
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Table 6.2: Steady-state kinetics of deacetylases with acetylpolyamines and acetyllysine 
peptide substrates. 
hHDAC10 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 110 ± 20 0.14 ± 0.02 (1.3 ± 0.2) x 10
3 
acetylputrescine 170 ± 50 0.35 ± 0.04 (2.1 ± 0.3) x 10
3
 
N
8 
-acetylspermidine 100 ± 10 0.28 ± 0.02 (2.9 ± 0.2) x 10
3
 
N
1 
-acetylspermidine N.D.
1 
N.D. 24 ± 5 
N
1 
-acetylspermine 180 ± 20 0.011 ± 0.002 60 ± 10 
N
1
,N
8 
–diacetylspermidine
2 
150 ± 90 0.14 ± 0.08 900 ± 300 
N-(3-aminopropyl)acetamide N.A.
3 
N.A. N.A. 
N-butylacetamide N.D. N.D. 22 ± 5 
N-(aminooctyl)acetamide 160 ± 40 0.10 ± 0.02 620 ± 50 
TK(ac)PIW N.A.
 
N.A. N.A. 
AK(ac)P N.A.
 
N.A. N.A. 
GAK(ac) N.A.
 
N.A. N.A. 
AK(ac) N.A.
 
N.A. N.A. 
AK(ac)A 60 ± 20
 
0.0006 ± 0.0001 11 ± 3 
K(ac) 140 ± 40 0.0092 ± 0.0008 66 ± 5 
RGK(ac)G N.D. N.D. 91 ± 8 
RGK(ac)-AMC 110 ± 20 0.008 ± 0.002 70 ± 10 
GAK(ac)-AMC 10 ± 1 0.00038 ± 0.00002 38 ± 2 
zHDAC10 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 90 ± 30 0.37 ± 0.04 (3.9 ± 0.3) x 10
3
 
acetylputrescine 160 ± 50 0.7 ± 0.1 (4.2 ± 0.9) x 10
3
 
N
8 
-acetylspermidine 130 ± 20 0.58 ± 0.03 (4.6 ± 0.3) x 10
3
 
N
1 
-acetylspermidine N.D. N.D. 7 ± 2 
N
1 
-acetylspermine N.D. N.D. 17 ± 4 
N
1
,N
8 
–diacetylspermidine
2
 180 ± 40 0.48 ± 0.08  (2.7 ± 0.3) x 103 
N-(3-aminopropyl)acetamide
 
N.D. N.D. 13 ± 3 
N-butylacetamide 900 ± 200 0.06 ± 0.02 60 ± 20 
N-(aminooctyl)acetamide 170 ± 40 0.21 ± 0.02 (1.2 ± 0.2) x 10
3
 
TK(ac)PIW N.A. N.A. N.A. 
AK(ac)P N.A.
 
N.A. N.A. 
GAK(ac) N.A.
 
N.A. N.A. 
AK(ac) N.A.
 
N.A. N.A. 
AK(ac)A N.A.
 
N.A. N.A. 
K(ac) 80 ± 10
 
0.013 ± 0.003 160 ± 20 
RGK(ac)G N.D. N.D. 26 ± 5 
RGK(ac)-AMC 66 ± 8 0.0015 ± 0.0001 23 ± 9 
GAK(ac)-AMC 22 ± 4 0.00033 ± 0.00002 15 ± 2 
zHDAC10Δ KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 60 ± 10 0.036 ± 0.002 600 ± 80 
acetylputrescine 80 ± 30 0.081 ± 0.009 980 ± 90 
N
8 
-acetylspermidine 70 ± 30 0.060 ± 0.007 800 ± 100 
N
1 
-acetylspermidine N.A. N.A. N.A. 
N
1 
-acetylspermine N.D.
 
N.D. 6 ± 2 
RGK(ac)-AMC 120 ± 30 0.0016 ± 0.00001 12 ± 2 
GAK(ac)-AMC 40 ± 20 0.00003 ± 0.00001 1.0 ± 0.5 
zHDAC10 E274L KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 60 ± 20 0.020 ± 0.002 350 ± 70 
acetylputrescine 160 ± 40      0.034 ± 0.004 220 ± 30
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N
8 
-acetylspermidine 130 ± 40 0.028 ± 0.003 210 ± 30 
N
1 
-acetylspermidine N.A. N.A. N.A. 
N
1 
-acetylspermine N.A. N.A. N.A. 
RGK(ac)-AMC 70 ± 10 0.21 ± 0.01 (3.1 ± 0.2) x 103 
GAK(ac)-AMC 70 ± 20 0.053 ± 0.008 730 ± 90 
zHDAC10 D94A KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 50 ± 10 0.051 ± 0.004 940 + 20 
acetylputrescine 130 ± 30      0.126 ± 0.008 930 ± 40
 
N
8 
-acetylspermidine 150 ± 30 0.123 ± 0.009 800 ± 40 
N
1 
-acetylspermidine N.A. N.A. N.A. 
N
1 
-acetylspermine N.D. N.D. 50 ± 10 
RGK(ac)-AMC 110 ± 40 0.0013 ± 0.0002 12 ± 1 
GAK(ac)-AMC 60 ± 30 0.00007 ± 0.00001 1.0 ± 0.6 
zHDAC10 A24E/D94A KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
N
8 
-acetylspermidine 150 ± 40 0.22 ± 0.03 (1.5 ± 0.3) x 10
3
 
RGK(ac)-AMC 60 ± 20 0.0032 ± 0.0004 58 ± 8 
zHDAC10 N93A KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 260 ± 60 0.29 ± 0.04 (1.1 ± 0.2) x 10
3
 
acetylputrescine 110 ± 10        0.24 ± 0.01 (2.2 ± 0.2) x 10
3 
N
8 
-acetylspermidine 140 ± 20 0.90 ± 0.04 (6.2 ± 0.3) x 10
3
 
N
1 
-acetylspermidine N.A. N.A. N.A. 
N
1 
-acetylspermine N.D. N.D. 22 ± 4 
RGK(ac)-AMC 150 ± 40 0.0013 ± 0.0002 9 ± 1 
GAK(ac)-AMC 17 ± 4  0.00046 ± 0.00002  27 ± 3 
zHDAC10 ΔηA2 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
N
8 
-acetylspermidine 270 ± 50 (KM’)
4
 0.082 ± 0.007 300 ± 30 
RGK(ac)-AMC 60 ± 20 0.021 ± 0.002 360 ± 50 
zHDAC6 CD2 
L110loop/L712E/S531A  
KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine N.A. N.A. N.A. 
acetylputrescine N.A. N.A. N.A. 
N
8 
-acetylspermidine N.A. N.A. N.A. 
RGK(ac)-AMC 50 ± 20 0.0008 ± 0.0001 15 ± 3 
APAH KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 22 ± 4 1.5 ± 0.1 (6.8 ± 0.7) x 10
4
 
acetylputrescine 120 ± 10 (KM’)
5
 1.5 ± 0.1 (1.0 ± 0.1) x 10
4
 
N
8 
-acetylspermidine 80 ± 20 2.5 ± 0.3 (3.0 ± 0.5) x 10
4 
N
1 
-acetylspermidine 70 ± 20
 
0.60 ± 0.05 (7.4 ± 0.6) x 10
3 
N
1 
-acetylspermine 60 ± 10 0.20 ± 0.01 (2.5 ± 0.9) x 10
3
 
N-(3-aminopropyl)acetamide 180 ± 60 1.3 ± 0.2 (7 ± 1) x 10
3
 
N-(aminooctyl)acetamide 110 ± 20 1.1 ± 0.1 (1.0 ± 0.1) x 10
4
 
N-butylacetamide N.D. N.D. 380 ± 90 
K(ac) 220 ± 70 0.13 ± 0.02 600 ± 100 
RGK(ac)-AMC 110 ± 10 0.017 ± 0.001 150 ± 20 
GAK(ac)-AMC 120 ± 20 0.0067 ± 0.0005 50 ± 5 
hHDAC6 CD12 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine N.D. N.D. 80 ± 4 
acetylputrescine N.D. N.D. 18 ± 3  
N
8 
-acetylspermidine N.D. N.D. 39 ± 7 
N
1 
-acetylspermidine N.D. N.D. 0.6 ± 0.3 
N
1 
-acetylspermine N.D. N.D. 1.8 ± 0.3 
RGK(ac)-AMC
 
 11 ± 4 0.049 ± 0.009 (4.4 ± 0.8) x 103 
GAK(ac)-AMC 14 ± 2 0.039 ± 0.007 (2.8 ± 0.4) x 10
3
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zHDAC6CD1 KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine N.D. N.D. 5 ± 1 
acetylputrescine N.D. N.D. 0.93 ± 0.04 
N
8 
-acetylspermidine N.D. N.D. 1.2 ± 0.5 
N
1 
-acetylspermidine N.A. N.A. N.A.4 
N
1 
-acetylspermine N.A. N.A. N.A. 
RGK(ac)-AMC
 
 43 ± 6 0.20 ± 0.06 (4.7 ± 0.3) x 103 
zHDAC6 CD1 K330E KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine 800 ± 300 0.05 ± 0.03 60 ± 20 
acetylputrescine 500 ± 200 0.04 ± 0.01 80 ± 10 
N
8 
-acetylspermidine 400 ± 100 0.037 ± 0.009 90 ± 30 
N
1 
-acetylspermidine N.A. N.A. N.A. 
N
1 
-acetylspermine N.A. N.A. N.A. 
RGK(ac)-AMC 13 ± 3 0.19 ± 0.03 (1.5 ± 0.3) x 104 
zHDAC6 CD2 KM (µM) kcat (s
-1) kcat/KM (M
-1s-1) 
acetylcadaverine
 
N.D. N.D. 28 ± 2 
acetylputrescine N.D. N.D. 30 ± 5 
N
8 
-acetylspermidine N.D. N.D. 29 ± 3
 
N
1 
-acetylspermidine N.D. N.D. 17 ± 2 
N
1 
-acetylspermine N.A. N.A. N.A. 
N-(3-aminopropyl)acetamide N.D. N.D. 2.0 ± 0.5 
RGK(ac)-AMC 22 ± 9 0.69 ± 0.08 (3.1 ± 0.5) x 104 
zHDAC6 CD2 L712E
 
KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
acetylcadaverine N.D. N.D. 66 ± 2 
acetylputrescine 560 ± 90 0.030 ± 0.004 110 ± 10 
N
8 
-acetylspermidine N.D. N.D. 76 ± 8 
N
1 
-acetylspermidine N.D. N.D. 38 ± 5 
N
1 
-acetylspermine N.A. N.A. N.A. 
RGK(ac)-AMC 40 ± 10 0.51 ± 0.05 (1.3 ± 0.2) x 104 
Date represents mean ± s.e.m. 
1
Not Determined. 
2
Substrate inhibition was considered.
 3 
Not Active. 
4
Coopperativity was 
observed with Hill coefficient as 3.0.
 5
Coopperativity was observed with Hill coefficient as 1.9.  
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Figure 6.5: Catalytic activity of hHDAC10 and zHDAC10. Abbreviations: AcPUT, 
acetylputrescine; N
8
-AcSPD, N
8
-acetylspermidine; AcCAD, acetylcadaverine; AcDAO, N-
(aminooctyl)acetamide; N
1
,N
8
-diAcSPD, N
1
,N
8 
–diacetylspermidine; N
1
-AcSPD, N
1
-
acetylspermidine; N
1
-AcSPM, N
1
-acetylspermine; AcPAD, N-(3-aminopropyl)acetamide; BTA, N-
butylacetamide. Data represents mean ± s.d. 
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Figure 6.6: Summary of substrate (regio)selectivity of HDAC10 reveals a molecular ruler 
mechanism. For HDAC10 PDAC activity, the minimum distance between the scissle amide bond 
and the nearest positively charged (primary/secondary) group is found to be 4 methylene length 
(butylene), which is consistent with the early characterization of mammalian PDAC (Marchant et 
al., 1986).  
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Figure 6.7: Catalytic activity of E274L zHDAC10 and the raio of catalytic efficiencies 
(kcat/KM) for PDAC activity (measured with N
8
-acetylspermidine) and HDAC activity 
(measured with RGK(Ac)-AMC). The E274L mutation converts zHDAC10 into an HDAC. 
Abbreviations: APAH, acetylpolyamine amidohydrolase; hHDAC10, human HDAC10; zHDAC10, 
zebrafish HDAC10; zHDAC10Δ, proteolytically nicked zHDAC10 used for the crystal structure 
determination; hHDAC6 CD12, human HDAC6 construct containing both catalytic domains; 
zHDAC6 CD1 or CD2, zebrafish HDAC6 catalytic domain 1 or catalytic domain 2. 
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Figure 6.8: Catalytic activity of zHDAC6 CD1, CD2, and glutamate mutant  (K330E zCD1 and 
L712E zCD2). 
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     (a)             (b)                  
 
                (c) 
Figure 6.9: Crystal structure of L712E zHDAC6 CD2 mutant. (a) Simulated annealing omit 
map of ligand, glycerol, and E712 (blue mesh, contoured at 3.0 σ). Atom color-codes are as 
follows: C, white (protein) or orange (AAT and glycerol); N, blue; O, red (water molecules are 
small red spheres); F, green; Zn
2+
, large white sphere. Metal coordination and hydrogen bond 
interactions are shown as red and black dashed lines, respectively. (b) Superposition of the 
L712E zHDAC6 CD2-AAT complex with the wild-type zHDAC6 CD2-AAT complex (C = cyan). (c) 
Electrostatic potential mapped onto the surface of L712E zHDAC6 CD2 (blue, -5 kT/e; white, 0 
kT/e; red, 5 kT/e) showing a cationic active site tunnel unfavorable for polyamine binding.  
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CD1 (54% sequence identity with the zHDAC10 catalytic domain) and L712E zHDAC6 CD2 (46% 
sequence identity with the zHDAC10 catalytic domain). Surprisingly, the substitution of glutamate 
in the active sites of zHDAC6 CD1 or CD2 did not considerably affect HDAC activity (3-fold 
increase in kcat/KM for K330E zHDAC6 CD1 and 3-fold decrease in kcat/KM for L712E zHDAC6 
CD2). Although significant enhancement of PDAC activity (12–90 fold) was achieved for K330E 
zHDAC6 CD1 and a modest increase (2–3 fold) was observed for L712E zHDAC6 CD2, the 
single-site amino acid substitution was insufficient to convert either zHDAC6 CD1 or CD2 into a 
PDAC (Figure 6.7-6.8). We determined the crystal structures of L712E zHDAC6 CD2 complexed 
with the trifluoromethyl ketone transition-state analogue 7-[(3-aminopropyl)amino]-1,1,1-
trifluoroheptan-2-one (AAT).  The electron density map (Figure 6.9) indicates that AAT binds as 
the tetrahedral gem-diol(ate) and the binding mode of AAT is similar to that observed for binding 
to the wild-type enzyme, in which the gem-diol(ate) asymmetrically coordinates to the Zn
2+
 ion. 
Interestingly, the newly introduced side chain of E712 is disordered between two alternate 
conformations. In one conformation, the E712 carboxylate group makes a water-mediated 
hydrogen bond with the N4 amino group of AAT. Additionally, a glycerol molecule binds in front of 
the L1 loop near the analogue AAT and mediates hydrogen bond interactions between AAT and 
the protein. Since the surface electrostatic potential calculation indicates that the active site 
tunnel active site tunnel is cationic (Figure 6.9), as well as the interaction between the polyamine 
analogue and the enzyme appears to be relatively weak – apart from interactions of the gem-
diol(ate), only an indirect hydrogen bond with the N4 amino group is observed – this structure 
may rationalize the observation of only weak enhancement of PDAC activity in this mutant.  
6.3.3 Crystal structure of zHDAC10 reveals the X-factor 
The less profound influence of glutamate in HDAC6 suggests that some other factor(s) 
(X-factor) unique in HDAC10 must also contribute to its PDAC activity. To identify this X factor, 
we determined the 2.75 Å-resolution crystal structure of Y307F zHDAC10 complexed with the 
trifluoromethylketone transition state analogue inhibitor AAT. We treated full-length zHDAC10 
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with trypsin to yield a heterodimeric complex, designated zHDAC10Δ, comprising the N-terminal 
PDAC domain and the C-terminal leucine-rich pseudo-DAC domain (ΨDAC) (Figure 6.10). Both 
limited proteolysis and the introduction of the Y307F mutation facilitated crystallization. The 
crystal structure of the zHDAC10Δ-AAT complex (Figure 6.11) revealed a butterfly-like 
architecture with a pseudo-two-fold symmetry axis perpendicular to several α-helices defining the 
PDAC-ΨDAC domain interface. Each domain adopted the α/β fold first observed in the crystal 
structure of arginase
 
and subsequently observed in metallodeacetylases. This fold is 
characterized by a central parallel 8-stranded β-sheet flanked by α-helices on both sides. 
However, the ΨDAC domain lacked helices ηA1–A2, αA, αB2–αB3, and active site loops L1-L5 
(Figure 6.11). Interdomain interactions in the isologous pseudo-dimer were mediated by α-
helices αF and αG, loop LH (which connects αH1 and αH2), and the C-terminal tail of each 
domain, burying approximately 1700 Å
2
 surface area. A 48-residue linker was missing in the 
electron density, presumably due to proteolysis by trypsin during the protein preparation. PDAC-
ΨDAC domain assembly resembles CD1-CD2 domain of zHDAC6 (personal communication with 
Patrick Matthias), homodimeric zHDAC6 CD1 domain and the homodimeric HDAC domain of 
Clr3 (Class II HDAC) from Schizosaccharomyces pombe (Figure 6.12). 
The tertiary structure of the PDAC domain was highly similar to both CD1 and CD2 of 
HDAC6 (0.79 Å r.m.s.d. for 354 Cα atoms; 0.89 Å r.m.s.d. for 341 Cα atoms, zCD2 (calculated by 
DALI)) (Figure 6.11). The unique α helix αB3 initially identified in HDAC6, which rigidifies and 
shortens the length of the L2 loop flanking one side of the active site, was conserved in HDAC10, 
thus making this helix a hallmark of class IIb HDACs. A close-up view of the active site tunnel 
revealed a canonical HDAC active site at the base of the tunnel, with AAT binding in an extended 
conformation (Figure 6.11). The trifluoroketone moiety of AAT formed a gem-diolate, making 
asymmetric coordination interactions with Zn
2+
 (O1-Zn
2+
 and O2-Zn
2+
 coordination distances of 
2.0 Å and 2.4 Å, respectively; hydroxyl group O1 also hydrogen bonds with H136 and H137). The 
binding of AAT thus mimicked the tetrahedral intermediate and its flanking transition states in the  
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Figure 6.10: SEC Chromatogram and SDS-PAGE gel of peak fractions of zHDAC10 and 
zHDAC10Δ.  
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Figure 6.11: Crystal structure of zHDAC10. (a) The catalytic PDAC domain and the smaller, 
noncatalytic ΨDAC domain assemble with butterfly-like architecture around a pseudo-two-fold 
symmetry axis (black arrow). The unique 310-helix ηA2 (P
23
ACE) inserted in the L1 loop of 
HDAC10 orthologues is purple. (b) Superposition of the PDAC domain (blue) with the ΨDAC 
domain (green). Selected secondary structure elements are labeled: helix ηA2 is purple; helices 
αF, αG, and the loop connecting helices αH1 and αH2 mediate domain-domain interactions; 
helices αB2 and αB3, as well as loops L1-L5, comprise and flank the active site of PDAC but are 
absent in ΨDAC (for clarity, only loops L2, L3, and L5 are labeled). (c) Superposition of zHDAC10 
PDAC (blue), zHDAC6 CD1 (wheat), and zHDAC6 CD2 (light blue). The 310-helix ηA2 inserted in 
loop L1 unique to zHDAC10 is purple. This helix serves to constrict the PDAC active site. (d) 
Simmulated-annealing omit map of AAT bound in the PDAC active site contoured at 3.0σ. 
Selected active site residues are indicated.  
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Figure 6.12: Butterfly-like didomain architecture of class IIb HDAC originates from 
homodimeric yeast class II HDAC domain. (left) Homodimeric structure of zHDAC6 CD1-TSA 
complex (5EEF). (right) homodimeric S. pombe Clr3. The HDAC domain is shown in cartoon and 
color coded as (left) panel. The Argonate binding protein 2 (Arb2) domain of Clr3 is shown in grey 
ribbon.  
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Figure 6.13: Electrostatic potential mapped onto the solvent accessible surface of 
zHDAC10. The surface is color-coded from red (-5 kBT) to blue (5 kBT), where kB is the 
Boltzmann constant and T is absolute temperature. The active site is highly acidic and the 
domain interface is mainly hydrophobic.   
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Figure 6.14: Residue conservation of 250 HDAC10 orthologoue sequences analyzed by 
ConSurf (http://consurf.tau.ac.il) (Celniker et al., 2013).  
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hydrolysis of N
8
-acetylspermidine. This binding mode is comparable to that observed in the 
APAH-AAT and zHDAC6 CD2-AAT complexes (Decroos and Christianson, 2015). 
The structure of zHDAC10 allowed us to further assess the determinants of substrate 
specificity. In particular, the protein surface surrounding the active site tunnel in the PDAC 
domain was characterized by significant negative electrostatic surface potential (Figure 6.13), 
with corresponding residues largely conserved across HDAC10 orthologues (Figure 6.14). This 
anionic surface feature may facilitate enzyme-substrate association with the basic polyamine 
substrates. 
More importantly, the active site of zHDAC10 was found to be more constricted relative to 
other HDAC isozymes such as HDAC6. On one side of the active site, the gatekeeper E274 was 
close (4.2 Å) to the N4 atom of AAT (Figure 6.11). While E274 did not make direct hydrogen 
bond with the N4 atom of AAT, it was sufficiently close to make a favorable electrostatic 
interaction; the conversion of HDAC10 from a PDAC into an HDAC through the E274L mutation 
(Figure 6.7) demonstrated that this electrostatic interaction is critical for PDAC function. Besides, 
it can not be ruled out yet that the E274 may interact with the N4 atom of AAT through a water-
mediated hydrogen bond which can not be verified yet based on the current limited resolution 
(2.75 Å). 
Opposite E274, there was an unexpected additional constriction (X factor) that 
contributes to PDAC specificity: a unique one-turn 310-helix ηA2 (P
23
ACE) inserted in the L1 loop 
relative to zHDAC6 effectively extended the narrow active site tunnel by ~5 Å (Figure 6.11). This 
insertion is universally conserved in HDAC10 orthologues with minor variations, appearing 
predominantly as PECE with one example of PECS (Figure 6.3). This structural feature may 
facilitate the binding of long acetylpolyamine substrates and suppress the binding of shorter 
acetyllysine substrates (Figure 6.15). To test whether this unexpected helix ηA2 contributes to 
HDAC10 PDAC activity, we prepared a zHDAC10 ΔηA2 mutant by swapping the helix ηA2 region  
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Figure 6.15: Constriction of zHDAC10 active site by the gatekeeper E274 (red) and the 310 
ηA2 helix (purple). (left) Solvent-accessible surface of zHDAC10. (middle) Structural model of 
zHDAC10 docked with substrate RGK(ac)-AMC (orange sphere) based on the structure of 
zHDAC6 CD2-RGK(ac)-AMC complex (PDB 5EFN). Note that the side chain of Arg is disordered 
in the original HDAC6 structure and not included in the final model. The docked substrate 
indicates unfavorable steric clash between the acetyllysine carbonyl and E274, and between the 
AMC appendant group (mimicking residue at +1 position) and the ηA2 helix. (right) A hypothetical 
model of E274L zHDAC10 mutant docked with substrate RGK(ac)-AMC providing structural basis 
for the switched substrate specificity observed with E274L zHDAC10 mutant. The mutated L274 
residue is highlighted in teal. As shown in the figure, mutation at E274 facially widens the active 
site entrance and avoids the unfavorable interaction between E274 side chain and the carbonyl 
group from acetyllysine residue. 
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(D
24
PACEI
29
) with a four residue segment (S
461
HHP
464
) from the corresponding zHDAC6 CD2 L1 
loop. As a result, deletion of this helix led to a 15-fold increase of HDAC activity and 15-fold loss 
of PDAC activity (Table 6.2, Figure 6.7), which demonstrates that this 310 helix is essential for the 
PDAC activity. Thus, this 310 helix ηA2 is believed to be the aforementioned missing X factor that 
is unique to HDAC10 that explains why introducing a Glu residue at the corresponding position in 
HDAC6 is not sufficient to convert HDAC6 into a PDAC. 
However, the residual acetyllysine deacetylase activity observed from HDAC10 wild-type 
and the robust acetyllysine deacetylase activity measured for E274L zHDAC10 mutant (kcat/Km = 
(3.1 ± 0.2) x 10
3
 M
-1
s
-1
) also suggest that the one-turn 310 helix ηA2 and its flanking L1 loop may 
be malleable and dynamic such that acetyllysine peptide (or protein) can be accommodated with 
movement of helix ηA2 and conformational change of L1 loop, although energetically less 
favorable.  
6.3.4 Structural basis for regioselectivity of HDAC10   
While the structural basis of HDAC10 selectivity for acetylpolyamine over acetyllysine-
containing peptide substrates appeared straightforward, the structural basis of its regioselectivity 
of N
8
-acetylspermidine over N
1
-acetylspermdine was more subtle. The protein surface becomes 
less anionic, and ultimately cationic at the base of the active site tunnel (Figure 6.16). The 
binding of N
8
-acetylspermidine would place the N4 amino group 8.5 Å away from the catalytic 
Zn
2+
 ion based on the crystal structure of the zHDAC10-AAT complex; the binding of N
1
-
acetylspermidine would place the N4 amino group 7.5 Å away from the catalytic Zn
2+
 ion. The 
positively charged N4 amino group from N
8
-acetylspermidine is stabilized by favorable 
electrostatic interaction with the dipole moment of the carbonyl group from the helix ηA2 A24 
residue, as well as electrostatic interaction and presumably also a water-mediated hydrogen bond 
with the gatekeeper residue E274. However, no apparent interaction can potentially stabilize the 
N4 amino group from N
1
-acetylspermidine based on current HDAC10 structure. 
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Figure 6.16: Comparison of the active site tunnel between zHDAC10 (left) and APAH (right, 
PDB entry 4ZUM). Electrostatic potential mapped onto the surface of protein (blue, -5 kT/e; 
white, 0 kT/e; red, 5 kT/e). The bound transition state analogue AAT is shown as stick model and 
Zn
2+
 ion is shown as white sphere.  
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(a) 
 
(b)       (c) 
Figure 6.17: Active site comparison between bacterial PDAC (APAH) and vertebrate PDAC 
(HDAC10). (a) Diagram of an “L”-shaped active site found in bacterial PDAC structure (Lombardi 
and Angell et al., 2011) and a straight active site found in vertebrate PDAC based on zHDAC10 
structure. Residue numbers in zHDAC10 are shown in parentheses. In hHDAC10, the side chain 
of E22 may interact with the terminal primary amino group from N
8
-acetylspermidine based on the 
current zHDAC10 structure. The positive charged N4 amino group from N
8
-acetylspermidine is 
stabilized through electrostatic interaction with E274, and the mainchain carbonyl group of E22 
(A24 in zHDAC10). In contrast, the positive charged N4 amino group from both N
8
-acetylspermi-
dine and N
1
-acetylspermidine/N
1
-acetylspermine can be stabilized by APAH through favorable 
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electrostatic interactions, as well as hydrogen bond networks (water-mediated or direct) with E17 
and E117. (b) Crystal structure of H159A APAH mutant complexed with substrate N
8
-acetyls-
permidine (PDB entry 3Q9C). The N4 amino group from N
8
-acetylspermidine is recognized by a 
water-mediated hydrogen bond with E17. Meanwhile, favorable electrostatic interaction is 
achieved with E117 (3.5 Å away). (c) Crystal structure of H159A APAH mutant complexed with 
substrate N
1
-acetylspermine (PDB entry 3Q9E). The N4 amino group from N
1
-acetylspermine/ 
N
1
-acetylspermidine is recognized by a direct hydrogen bond with E117 (3.2 Å).  
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In contrast to HDAC10, bacterial PDAC APAH, which can process a variety of 
acetylpolyamines including N
1
-acetylspermidine/N
1
-acetylspermine, bears a unique Glu residue 
from L2 loop (E117, structurally corresponding to D94 in zHDAC10 and A92 in hHDAC10) to 
stabilize the charged N4 amino group in N
1
-acetylspermidine/N
1
-acetylspermine through a direct 
salt bridge (Figure 6.17). Due to the lack of similar interaction in HDAC10 (even in zHDAC10, 
D94 is too far away from N4 amino group in either N
8
-acetylspermidine or N
1
-acetylspermidine), 
we suggest that the energetic cost of bringing the positively charged N4 amino group just 1 Å 
deeper into the HDAC10 active site tunnel disfavors N
1
-acetylspermidine binding and catalysis. 
Thus, the apparent “molecular ruler” mechanism summarized from HDAC10 substrate scope 
study (Figure 6.6) was achieved through an elaborate balance between favorable electrostatic 
interaction with surface acidic residues (both side chain and main chain) and the unfavorable 
electrostatic interaction with the cationic Zn
2+
 ion at the bottom of the active site tunnel.  
6.3.5 Evolutionary and functional implication of the ΨDAC domain   
The ΨDAC domain of HDAC10 has no known function and is an apparent evolutionary 
vestige. Neither the Zn
2+
 ligands nor the catalytic residues were conserved in the ΨDAC domain 
(Figure 6.11); indeed, the ΨDAC domain lacked an active site cleft. However, the ΨDAC domain 
was required for the solubilization and stabilization of the PDAC-ΨDAC HDAC10 construct, since 
we were unable to prepare a soluble stand-alone PDAC domain construct for biochemical study. 
PDAC-ΨDAC assembly is so tight that proteolyzed zHDAC10Δ did not dissociate into individual 
domains. 
The overall fold of the ΨDAC domain was most similar to that of PDAC as well as the 
catalytic domains of HDAC6 (~2.1 Å r.m.s.d. for ~196 Cα atoms with zHDAC6 CD1, zHDAC6 
CD2, and PDAC (calculated with DALI)), indicating that the ΨDAC domain resulted from gene 
duplication and fusion. In contrast with the PDAC domain, the ΨDAC domain exhibited low amino 
acid sequence identity across species (e.g., 28% sequence identity between zebrafish and 
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human proteins); however, α-helices αG and αH at the interdomain interface were highly 
conserved (Figure 6.14). The divergence of ΨDAC surface residues suggests that this domain 
evolved with no selective pressure for function following the gene duplication and fusion event; 
the conservation of interface residues may suggest that the ΨDAC domain evolved to play a 
structural role in the solubilization and stabilization of the PDAC domain.  
6.4 Discussion   
Our findings raise many intriguing questions. First, is HDAC10 a bifunctional deacetylase 
in vivo, involved in the regulation of polyamine metabolism as well as the lysine acetylome? If it 
is, then HDAC10 inhibition in vivo is likely to trigger changes in polyamine metabolism as well as 
lysine acetylation. Our data indicate that HDAC10 strongly prefers acetylpolyamine substrates in 
vitro. However, HDAC10 has also been implicated in the deacetylation of cytosolic proteins 
Hsc70/Hsp70 (Oehme et al., 2013) and MutS homolog 2 (MSH2) (Radhakrishnan et al., 2015). 
Dual PDAC/HDAC activity of HDAC10 would be consistent with HDAC10 domain architecture: 
the PDAC active site is oriented outward and could be readily available for the binding of large 
protein as well as small polyamine substrates. If the PDAC active site were packed against the 
ΨDAC domain, in a manner analogous to dimer formation in the bacterial polyamine deacetylase 
APAH, the active site would be exclusively accessible only to long, narrow polyamine substrates. 
Furthermore, dual PDAC/HDAC activity of HDAC10 would also be consistent with its canonical 
HDAC active site: the active site tunnel differs from other HDACs only by a 310 helix constriction 
and a gatekeeper Glu residue. Thus, it is possible that HDAC10 could deacetylate large protein 
substrates, which triggers a conformational change of the 310-helix ηA2.  
 The current work firmly establishes that E274 of zHDAC10 is conserved in HDAC10 
orthologues as a gatekeeper establishing specificity for cationic substrates, just as K353 of 
zHDAC6 CD1 is conserved at the corresponding position to serve as a gatekeeper for an anionic 
substrate (an acetyllysine substrate bearing a C-terminal carboxylate). However, the gatekeeper 
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residue of the HDAC active site is necessary but not sufficient for full activity and selectivity – 
zHDAC10 and zHDAC6 CD1 have additional steric bulk on the opposite side of the active site 
from the gatekeeper that serves to further constrict the active site tunnel. In zHDAC10, the 310-
helix ηA2 provides this steric bulk; in hHDAC6 CD1, F105 and Y225 provides this steric bulk. 
Regardless, the gatekeeper residue in HDAC10 and HDAC6 appears to be a hot spot for 
governing substrate specificity in the greater family of HDACs.  
 Comparison with bacterial PDAC APAH, it clearly shows that HDAC10 employs a 
different strategy to achieve the same function: accommodating polyamine substrates. However, 
this function is unforeseeable given that HDAC10 is both sequencely and structurally similar to 
HDACs rather than PDACs. The similar domain-domain architecture of HDAC6 and HDAC10 
indicates the conserved gene-duplication and fusion event among class IIb HDACs. Besides, the 
ancestral origin is now indicated to be yeast class II HDAC since the similar domain-domain 
architecture of HDAC6/10 indeed appears first but as a quaternary structure as shown in the 
crystal structure of S. pombe Clr3 HDAC domain. Therefore, HDAC10 is believed to share the 
last common ancestor with HDAC6, which is believed to evolve from a class II HDAC ancestor 
such as Clr3; Besides, the fact that HDAC10 does not share an immediate common ancestor with 
APAH but is very similar to APAH in terms of function, indicates that APAH-HDAC10 represents 
an intriguing case of convergent evolution (Figure 6.18). 
 In summary, we have presented compelling evidence suggesting that HDAC10 is the 
long-sought mammalian (or perhaps even vertebrate) cytosolic PDAC responsible for N
8
-
acetylspermidine processing in polyamine metabolism. Our studies further point to a gatekeeper 
residue that has diverged only in the cytosolic class IIb HDACs, HDAC6 CD1 and HDAC10, to 
confer specificity toward anionic and cationic substrates, respectively. Given the recently 
discovered importance of HDAC10 in promoting autophagy-mediated survival of neuroblastoma 
cells, and the indication that inhibition of HDAC10 may sensitize aggressive neuroblastomas to 
chemotherapy, our work similarly points to a possible role for polyamine metabolism in HDAC10- 
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Figure 6.18: Phylogenetic unrooted tree of Zn
2+
-dependent deacetylases. The phylogentic 
tree was calculated by Clustal Omega after multiple sequence alignment. The amino acid 
sequences include the catalytic domains of 11 human HDACs, the catalytic domains of Rpd3 and 
Hda1 from S. cerevisiae, the catalytic domain of Clr6 and Clr3 from S. pombe, the catalytic 
domain of histone deacetylase like protein (HDLP) from Aquifex aeolicus, the catalytic domain of 
bacterial HDAC like proteins (HDAH from Bordetella sp. (strain FB188) and 5JI5 from 
Burkholderia phymatumphymatum), and the catalytic domain of bacterial polyamine deacetylases 
(APAH from Mycoplana ramose and 3MEN from Burkholderia pseudomallei). 
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dependent autophagy. With the crystal structure of HDAC10 now in hand, the development of 
isozyme-specific inhibitors may enable chemotherapeutic approaches for the treatment of 
aggressive, otherwise untreatable neuroblastomas in children who presently have no hope of 
recovery. 
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Chapter 7: Future Directions 
Since the first structure determinations of arginase (rat liver arginase, Kanyo et al., 1996) 
and deacetylase (HDLP, Finnin et al., 1999), the arginase-deacetylase superfamily has been 
firmly established. Our understanding about their catalysis and inhibition binding modes has also 
been brought down to the molecular level, thanks to the elegant structural snapshots, biochemical 
studies, and computational studies reported in the past decade. These studies show that Nature 
has employed the same tertiary scaffold (α/β for arginase-deacetylase) and similar catalytic 
machineries (binuclear manganese cluster or mononuclear zinc ion) to achieve a diverse range of 
functions, from primary metabolism, to secondary metabolism, as well as protein posttranslational 
modification, by just varying the “specificity” loops flanking the active site mouth. Thus, it has 
been optimistically believed that the exact substrate specificity has been dictated in the amino 
acid sequences of these specificity loops (Shishova et al., 2009; Dowling and Di Costanzo et al., 
2008).  
However, there are a number of arginase-deacetylase proteins whose precise 
function/substrates remain unknown, such as acetoin utilization protein AcuC (Leipe and 
Landsman, 1997), and the proteins whose functions are simply annotated as arginase-like, 
agmatinase-like, and HDAC-like proteins. Due to the exponential growth of genome sequences, 
the number of “putative” or “orphan” proteins in the database is increasing significantly. For some 
of them, crystal structures are even available now in the Protein Data Bank thanks to the effort 
made by the Structural Genomics Initiative, but these structures provide only little information 
regarding their substrates/functions. For example, the substrates of some arginase/agmatinase-
like ureohydrolases involved in secondary metabolism can not be easily and precisely predicted 
even though they all probably contain a guanidinium group. And yet in the deacetylase family, 
although some bacterial HDAC-like proteins have been proved to be bona fide lysine 
deacetylases experimentally and their structures are shown to be highly homologous to 
eukaryotic HDACs, the biological substrates (proteins) for these bacterial HDACs remain unclear.  
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Moreover, the appearance of arginase-deacetylase superfamily proteins that evolved 
without a metal binding site, exemplified by TbARG-like proteins found in trypanosomatids and 
the ΨDAC domain found in HDAC10, makes it even more difficult to decipher their biological 
functions merely based on their sequence/structural homology with other arginase/deacetylases. 
The existence of TbARG/ΨDAC nonmetallo-arginase/deacetylase-like proteins suggests that the 
arginase-deacetylase fold perhaps has been evolved by Nature for purposes other than 
metallohydrolase. Thus, the arginase-deacetylase scaffold could be much more multifaceted and 
the corresponding functions could be much more versatile than those which have been 
appreciated so far. It is very likely that metallo-arginase-deacetylase proteins, such as 
Brag/ΨDAC-like proteins, are just beginning to emerge.  
Another intriguing case worthy mentioning is the uncharacterized UPF0489 family 
(PF12640) conserved from bacteria to human. This family is assigned as an extra independent 
member in the clan of arginase-deacetylase according to the Pram database 
(http://pfam.xfam.org/family/PF12640#tabview=tab2) (Finn et al., 2016). Although members of this 
UPF0489 family do not share significant sequence identity with either arginase or deacetylase 
(<20%), secondary structure prediction algorithms suggest that this protein adopts an α/β fold. 
Additionally, a DXHXD motif and a DXDXD motif are conserved in this family. Thus, members of 
the UPF0489 family are probably metalloproteins as well.   
In summary, the future goal in studying arginase/deacetylase family is to annotate 
currently identified proteins that have unknown function, or have been mistakenly annotated, and 
eventually to understand the underlying structure-function relationships, and to explore all the 
possible functions that could be built upon the arginase-deacetylase scaffold.   
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APPENDIX 
Protein Knockout phenotype 
Arginase 1 Animals die after 14 days due to hyperammonemia
a 
Arginase 2 No obvious phenotype in animal model
a 
Leishmania mexicana arginase L-Ornithine auxotrophic
b 
Schistosoma mansoni arginase Unreported 
T. brucei Arginase-like protein No influence on cell viability, growth, L-arginine and 
polyamine metabolism
c 
Formiminoglutamase (FIGase) Growth deficiency found in Bacillus subtilis FIGase
-
 strain 
when L-histidine used as the sole nitrogen source
d 
HDAC6 Mice lacking HDAC6 have hyperacetylated tubulin but are 
viable and develop normally
e 
HDAC6 deletion delays disease progression in the SOD1
G93A
 
mouse model of amyotrophic lateral sclerosis
f
  
HDAC6 knock-out increased tubulin acetylation but does not 
modify disease progression in the R6/2 mouse model of 
Huntington’s disease
g
 
HDAC10  HDAC10 knockdown widely suppressed cell proliferation by 
inhibiting premature entry into mitosis
h 
a 
From Ref. Deignan et al., 2006. 
b 
From Ref. Roberts et al., 2004. 
c 
From Ref. Hai et al., 2015. 
d 
From Ref. Chasin and Magasanik, 1968. 
e 
From Ref. Zhang and Kwon et al., 2008 
f
 From Ref. Taes et al., 2013 
g 
From Ref. Bobrowska et al., 2011 
h 
From Ref. Li et al., 2015 
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